<SEC-DOCUMENT>0001387131-16-005278.txt : 20160505
<SEC-HEADER>0001387131-16-005278.hdr.sgml : 20160505
<ACCEPTANCE-DATETIME>20160505163125
ACCESSION NUMBER:		0001387131-16-005278
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20160331
FILED AS OF DATE:		20160505
DATE AS OF CHANGE:		20160505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		161624302

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>txmd-10q_033116.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 12pt;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 14pt;"><b>UNITED STATES</b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 14pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;"><b>WASHINGTON, D.C. 20549</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 18pt;"><b>FORM 10-Q</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Mark One)</font></p>
<table style="margin-bottom: 0; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; font: bold 12pt Times New Roman, Times, Serif;">
<td style="width: 7%; font: bold 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;"><b><font style="font-family: Wingdings 2;">R</font></b></font></td>
<td style="width: 93%; text-align: justify; font: bold 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; text-indent: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">For the quarterly period ended March 31, 2016</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;<b>&#xA0;</b></font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" border="0" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; font: bold 12pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; width: 7%; text-align: justify; text-indent: -10pt; font: bold 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;"><b>&#x2610;</b></font></td>
<td style="padding: 0; width: 93%; text-align: justify; text-indent: 0; font: bold 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">For the transition period from________ to ___________</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Commission File No. <b><u>010-001000</u></b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 24pt;"><b><u>THERAPEUTICSMD, INC.</u></b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Exact Name of Registrant as Specified in Its Charter)</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<table style="margin-bottom: 6pt; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="border-bottom: Black 1pt solid; padding: 0px; width: 45%; text-align: center; text-indent: 0px;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Nevada</b></font></td>
<td style="padding: 0px; width: 10%; text-align: center; text-indent: 0px;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding: 0px; width: 45%; text-align: center; text-indent: 0px;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>87-0233535</b></font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding: 0px; text-align: center; text-indent: 0px;"><font style="font: 10pt Times New Roman, Times, Serif;">(State</font> <font style="font: 10pt Times New Roman, Times, Serif;">or Other Jurisdiction of Incorporation or Organization)</font></td>
<td style="padding: 0px; text-align: center; text-indent: 0px;"><font style="font: 10pt Times New Roman, Times, Serif;"> </font></td>
<td style="padding: 0px; text-align: center; text-indent: 0px;"><font style="font: 10pt Times New Roman, Times, Serif;">(I.R.S. Employer Identification No.)</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding: 0px; text-align: center; text-indent: 0px;">&#xA0;</td>
<td style="padding: 0px; text-align: center; text-indent: 0px;">&#xA0;</td>
<td style="padding: 0px; text-align: center; text-indent: 0px;">&#xA0;</td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td style="border-bottom: Black 1pt solid; padding: 0px; text-align: center; text-indent: 0px;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>6800 Broken Sound Parkway NW, Third Floor, Boca Raton, FL 33487</b></font></td>
<td style="padding: 0px; text-align: center; text-indent: 0px;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding: 0px; text-align: center; text-indent: 0px;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>(561) 961-1900</b></font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td style="padding: 0px; text-align: center; text-indent: 0px;">(Address of Principal Executive Offices)</td>
<td style="padding: 0px; text-align: center; text-indent: 0px;">&#xA0;</td>
<td style="padding: 0px; text-align: center; text-indent: 0px;"><font style="font: 10pt Times New Roman, Times, Serif;">(Issuer&#x2019;s Telephone Number)</font></td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>N/A</u></b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes&#xA0;&#xA0;<font style="font-family: Wingdings 2;">R</font>&#xA0;&#xA0;&#xA0;&#xA0;No&#xA0;&#xA0;&#x2610;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes&#xA0;&#xA0;<font style="font-family: Wingdings 2;">R</font>&#xA0;&#xA0;&#xA0;&#xA0;No&#xA0;&#xA0;&#x2610;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer&#x201D; and &#x201C;smaller reporting company&#x201D; in Rule 12b-2 of the Exchange Act (Check one):</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
<td style="width: 12%; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="width: 36%; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Large accelerated filer&#xA0;<font style="font-family: Wingdings 2;">R</font></font></td>
<td style="width: 14%; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="width: 38%; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Accelerated filer &#x2610;</font></td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Non-accelerated filer&#xA0;&#x2610;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Smaller reporting company&#xA0;&#x2610;</font></td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">(Do not check if a smaller reporting company)</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#xA0;&#xA0;&#x2610;&#xA0;&#xA0;&#xA0;&#xA0;No&#xA0;&#xA0;</font><font style="font-family: Wingdings 2; font-size: 10pt;">R</font></p>
<p style="margin-bottom: 0; margin-right: 0; margin-top: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The number of shares outstanding of the registrant&#x2019;s common stock, par value $0.001 per share, as of May 2, 2016 was 196,263,700.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<!-- Field: Page; Sequence: 1 -->
<div style="border-bottom: Black 2px solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;"><b><font style="font: 10pt Times New Roman, Times, Serif;"><b>INDEX</b></font></b></font></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; width: 2%; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; width: 10%; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; width: 76%; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; width: 5%; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding: 5pt 0 0; width: 7%; text-align: center; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;">Page</font></td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; text-decoration: underline; font: bold 10pt/107% Times New Roman, Times, Serif;" colspan="3" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b><u>PART I - FINANCIAL INFORMATION</u></b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; text-decoration: none; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Item 1.</b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; text-decoration: none; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Financial Statements</b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><a href="#a_001">Consolidated Balance Sheets as of March 31, 2016 (Unaudited) and December 31, 2015</a></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;">3</font></td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><a href="#a_002">Consolidated Statements of Operations for the Three Months Ended March 31, 2016 (Unaudited) and 2015 (Unaudited)</a></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;">4</font></td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><a href="#a_003">Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2016 (Unaudited) and 2015 (Unaudited)</a></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;">5</font></td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><a href="#a_004">Notes to Unaudited Interim Consolidated Financial Statements</a></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;">6</font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; vertical-align: bottom; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; vertical-align: top; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b>Item 2.</b></font></td>
<td style="padding: 5pt 0 0; vertical-align: bottom; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b><a href="#a_005">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</a></b></font></td>
<td style="padding: 5pt 0 0; vertical-align: bottom; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; vertical-align: bottom; text-align: right; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;">19</font></td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b>Item 3.</b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b><a href="#a_006">Quantitative and Qualitative Disclosures about Market Risks</a></b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;">28</font></td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b>Item 4.</b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b><a href="#a_007">Controls and Procedures</a></b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;">28</font></td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" colspan="3" nowrap><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>Part II - OTHER INFORMATION</u></b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b>Item 1.</b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b><a href="#a_009">Legal Proceedings</a></b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;">29</font></td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b>Item 1A.</b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b><a href="#a_010">Risk Factors</a></b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;">29</font></td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b>Item 2.</b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b><a href="#a_011">Unregistered Sales of Equity Securities and Use of Proceeds</a></b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;">29</font></td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b>Item 6.</b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: bold 10pt/107% Times New Roman, Times, Serif;" nowrap><font style="font: 10pt Times New Roman, Times, Serif;"><b><a href="#a_012">Exhibits</a></b></font></td>
<td style="padding: 5pt 0 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif;" nowrap>&#xA0;</td>
<td style="padding: 5pt 0 0; text-align: right; text-indent: 0; font: 10pt/107% Times New Roman, Times, Serif;" nowrap>30</td>
</tr>
</table>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt/normal Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></font><br> <b><a name="a_001"></a>CONSOLIDATED BALANCE SHEETS</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt/normal Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<table style="width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="3">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="3">December 31, 2015</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-indent: -10pt;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="2">(Unaudited)</td>
<td style="text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="4">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">ASSETS</td>
<td style="font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
<td style="text-align: center; font: 10pt Calibri, Helvetica, Sans-Serif;" colspan="3">&#xA0;</td>
<td style="font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
<td style="text-align: center; font: 10pt Calibri, Helvetica, Sans-Serif;" colspan="3">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Current Assets:</td>
<td>&#xA0;</td>
<td colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="3">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 20pt; width: 64%; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Cash</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif;">182,097,345</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif;">64,706,355</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Accounts receivable, net of allowance for doubtful accounts&#xA0;of $318,061 and $81,910, respectively</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">5,063,773</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">3,049,715</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 20pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Inventory</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">957,434</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">690,153</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Other current assets</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">1,718,069</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">2,233,897</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Total current assets</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">189,836,621</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">70,680,120</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Fixed assets, net</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">264,706</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">198,592</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-indent: -10pt;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Other Assets:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Intangible assets, net</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">1,694,546</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">1,615,251</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Prepaid expense</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">1,047,970</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">1,109,883</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Security deposit</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">125,000</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">125,000</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Total other assets</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">2,867,516</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">2,850,134</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 40pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Total assets</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">192,968,843</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">73,728,846</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-indent: -10pt;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</td>
<td style="font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
<td style="font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Current Liabilities:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Accounts payable</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">3,430,649</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">3,126,174</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Other current liabilities</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">6,165,764</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">7,539,526</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Total current liabilities</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">9,596,413</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">10,665,700</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 40pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Total liabilities</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">9,596,413</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">10,665,700</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-indent: -10pt;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Commitments and Contingencies (Note 15)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Stockholders&#x2019; Equity:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 20pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Preferred stock - par value $0.001; 10,000,000 shares authorized; &#xA0;no shares issued and outstanding</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#x2014;&#xA0;&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#x2014;&#xA0;&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Common stock - par value $0.001; 350,000,000 shares authorized; 196,253,700 and 177,928,041 issued and outstanding, respectively</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">196,254</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">177,928</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Additional paid-in capital</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">423,932,401</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">282,712,078</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Accumulated deficit</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">(240,756,225</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">(219,826,860</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Total stockholders&#x2019; equity</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">183,372,430</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">63,063,146</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 40pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Total liabilities and stockholders&#x2019; equity</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">192,968,843</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">73,728,846</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt/normal Times New Roman, Times, Serif;">The accompanying footnotes are an integral part of these consolidated financial statements.</p>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 3; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt/normal Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></font><br> <b><a name="a_002"></a>CONSOLIDATED STATEMENTS OF OPERATIONS</b><br> <b>(Unaudited)</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt/normal Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt/normal Times New Roman, Times, Serif;"><b></b></p>
<table style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="7"><font style="font: 10pt Times New Roman, Times, Serif;">Three Months Ended</font></td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="3"><font style="font: 10pt Times New Roman, Times, Serif;">March 31, 2016</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="3"><font style="font: 10pt Times New Roman, Times, Serif;">March 31, 2015</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; width: 68%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Revenues, net</font></td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">4,930,091</font></td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">4,475,049</font></td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Cost of goods sold</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">1,108,443</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">1,043,641</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Gross profit</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">3,821,648</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">3,431,408</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Operating expenses:</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Sales, general, and administrative</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">9,678,552</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">6,163,612</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Research and development</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">15,097,017</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">18,176,835</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Depreciation and amortization</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">19,597</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">13,572</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Total operating expense</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">24,795,166</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">24,354,019</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Operating loss</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(20,973,518</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(20,922,611</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Other income</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Interest income</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">41,617</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">18,513</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Accreted interest</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">2,536</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">9,842</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Total other income</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">44,153</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">28,355</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Loss before income taxes</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(20,929,365</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(20,894,256</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Provision for income taxes</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;&#xA0;&#xA0;</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;&#xA0;&#xA0;</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Net loss</font></td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(20,929,365</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(20,894,256</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Net loss per share, basic and diluted</font></td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(0.11</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(0.13</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 10pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Weighted average number of common</font> <font style="font: 10pt Times New Roman, Times, Serif;">shares outstanding-basic and diluted</font></td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">194,901,560</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">163,448,130</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
</table>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt/normal Times New Roman, Times, Serif;">The accompanying footnotes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 4; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt/normal Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></font><b><a name="a_003"></a><br> CONSOLIDATED STATEMENTS OF CASH FLOWS<br> (Unaudited)</b></p>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="7">Three Months Ended</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Calibri, Helvetica, Sans-Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="3">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif;" colspan="3">March 31, 2015</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-indent: -10pt; font: bold 10pt Times New Roman, Times, Serif;">CASH FLOWS FROM OPERATING ACTIVITIES</td>
<td>&#xA0;</td>
<td colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="3">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 20pt; width: 68%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Net loss</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif;">(20,929,365</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif;">(20,894,256</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Adjustments to reconcile net loss to net cash used in operating activities:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 40pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Depreciation of fixed assets</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">8,363</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">6,881</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 40pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Amortization of intangible assets</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">11,234</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">6,691</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 40pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Provision for doubtful accounts</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">236,151</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">13,004</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 40pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Share-based compensation</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">4,381,690</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">840,464</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 40pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Changes in operating assets and liabilities:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 50pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Accounts receivable</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">(2,250,209</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">(502,836</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 50pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Inventory</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">(267,281</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">222,925</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 50pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Other current assets</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">477,312</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">91,412</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 50pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Other assets</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">(2,536</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">(9,842</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 50pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Accounts payable</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">304,475</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">(91,946</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 50pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Deferred revenue</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#x2014;&#xA0;&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">(522,613</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 50pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Other current liabilities</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">(1,373,762</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">1,038,813</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 50pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Other long-term liabilities</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">&#x2014;&#xA0;&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">651,567</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Net cash used in operating activities</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">(19,403,928</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">(19,149,736</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 10pt; text-indent: -10pt;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: bold 10pt Times New Roman, Times, Serif;">CASH FLOWS FROM INVESTING ACTIVITIES</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Patent costs</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">(90,529</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">(36,853</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Purchase of fixed assets</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">(74,478</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">&#x2014;&#xA0;&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Net cash used in investing activities</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">(165,007</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">(36,853</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">)</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 10pt; text-indent: -10pt;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: bold 10pt Times New Roman, Times, Serif;">CASH FLOWS FROM FINANCING ACTIVITIES</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Proceeds from sale of common stock, net of costs</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">134,863,475</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">59,117,827</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 30pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Proceeds from exercise of options</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">786,450</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">7,208</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 30pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Proceeds from exercise of warrants</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">1,310,000</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">358,400</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Net cash provided by financing activities</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">136,959,925</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">59,483,435</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Increase in cash</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">117,390,990</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif;">40,296,846</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: White; vertical-align: bottom">
<td style="padding-left: 20pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Cash, beginning of period</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">64,706,355</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font: 10pt Times New Roman, Times, Serif;">51,361,607</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="background-color: rgb(204,238,255); vertical-align: bottom">
<td style="padding-left: 20pt; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif;">Cash, end of period</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">182,097,345</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left; font: 10pt Times New Roman, Times, Serif;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right; font: 10pt Times New Roman, Times, Serif;">91,658,453</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt/normal Times New Roman, Times, Serif;">The accompanying footnotes are an integral part of these consolidated financial statements.</p>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 5; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center;"></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b><br> <b><a name="a_004"></a>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center;"><b>&#xA0;</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center;"><b></b>&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 1 &#x2013; THE COMPANY</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &#x201C;our company,&#x201D; &#x201C;we,&#x201D; &#x201C;our,&#x201D; or &#x201C;us.&#x201D;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Nature of Business</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We are a women&#x2019;s health care product company focused on creating and commercializing products targeted exclusively for women. As of the date of these unaudited consolidated financial statements, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 2 &#x2013; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Interim Financial Statements</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="color: #252525;">The accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission, or the SEC, from which we derived the accompanying consolidated balance sheet as of December 31, 2015. The accompanying unaudited interim consolidated financial statements have been prepared in accordance </font>with accounting principles generally accepted in the United States of America, or GAAP<font style="color: #252525;">, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year or any other interim period in the future.</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><u>Recently Issued Accounting Pronouncements</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="color: #252525;">In March 2016, the Financial Accounting Standards Board, or FASB, issued ASU 2016-09, Compensation &#x2013; Stock Compensation: Improvements to Employee Share-Based Payment Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is effective for our company for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted in any annual or interim period for which financial statements have not been issued or made available for issuance, but all of the guidance must be adopted in the same period. If an entity early adopts the guidance in an interim period, any adjustments must be reflected as of the beginning of the fiscal year that includes that interim period.</font> We are currently evaluating the impact of this guidance on our consolidated financial statements and disclosures.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 6; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are currently evaluating the impact of this guidance on our consolidated financial statements and disclosures.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), simplifying the Measurement of Inventory. This guidance requires entities to measure inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM). The guidance applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does not change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM guidance. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Under the new guidance, however, entities will no longer need to calculate other measures of &#x201C;market.&#x201D; The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact of this guidance, if any, on our consolidated financial statements and disclosures.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#x2019;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB issued final <font style="color: #252525;">amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08) as well as accounting for licenses of intellectual property and identifying performance obligations in its new revenue standard (ASU 2016-10). We are currently evaluating the impact of this guidance on our consolidated financial statements and disclosures.</font></p>
<p style="color: #252525; margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="color: #252525; margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 7; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="color: #252525; margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="color: #252525; margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="color: #252525; margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="color: #252525; margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b></b>&#xA0;&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 3 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><u>Fair Value of Financial Instruments</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Our financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, <i>Fair Value Measurements. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left;">
<td style="width: 10%;">&#xA0;</td>
<td style="width: 7%;"><b>Level 1</b></td>
<td style="width: 3%;">&#xA0;</td>
<td style="width: 80%; text-align: justify;">unadjusted quoted prices in active markets for identical assets or liabilities;</td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td>&#xA0;</td>
<td><b>Level 2</b></td>
<td>&#xA0;</td>
<td style="text-align: justify;">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td>&#xA0;</td>
<td><b>Level 3</b></td>
<td>&#xA0;</td>
<td style="text-align: justify;">unobservable inputs for the asset or liability.</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">At March 31, 2016 and 2015, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company&#x2019;s impairment test. There was no impairment of intangible assets or long-lived assets during the three months ended March 31, 2016 and 2015.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Revenue Recognition</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note 14. There are no major external customers for our OTC prenatal vitamin or other products.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>OTC Products</u></i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 8; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i><u>Prescription Products</u></i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and customer rebates.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We accept returns of unsalable prescription products from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015, we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><u>Share-Based Compensation</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718 to value options. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, Equity - Based Payments to Non-Employees, or ASC 505. ASC 505 defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 9; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><u>Research and Development Expenses</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Research and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities are capitalized, and were $1,005,503 at March 31, 2016, of which $941,054 was included in other current assets and $64,449 was included in long-term prepaid expense on the accompanying consolidated balance sheets. Advance payments to be expensed in future research and development activities were $1,138,073 at December 31, 2015, of which $1,009,175 was included in other current assets and $128,898 was included in long term prepaid expense on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&#38;D expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><u>Segment Reporting</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 10; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 4 &#x2013; INVENTORY</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Inventory consists of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">March 31, 2016</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt;">Finished product</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">907,510</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">661,167</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt;">Raw material</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">49,924</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">28,986</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt;">TOTAL INVENTORY</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">957,434</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">690,153</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 5 &#x2013; OTHER CURRENT ASSETS</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Other current assets consist of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">March 31, 2016</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt;">Prepaid consulting</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">296,305</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">334,822</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Prepaid insurance</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">438,420</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">695,421</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Prepaid research and development costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">644,749</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">674,353</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Prepaid vendor deposits</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">107,300</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">159,489</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt;">Other prepaid costs</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">231,295</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">369,812</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt;">TOTAL OTHER CURRENT ASSETS</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">1,718,069</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">2,233,897</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 6 &#x2013; FIXED ASSETS, NET<br></u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Fixed assets consist of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">March 31, 2016</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt;">Equipment</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">156,502</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">132,150</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Accounting system in process</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">205,712</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">149,699</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt;">Furniture and fixtures</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">63,566</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">69,454</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">425,780</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">351,303</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt;">Accumulated depreciation</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(161,074</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(152,711</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt;">TOTAL FIXED ASSETS</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">264,706</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">198,592</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Depreciation expense for the three months ended March 31, 2016 and 2015 was $8,363 and $6,881, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 7 &#x2013; PREPAID EXPENSE</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Prepaid expense consists of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">March 31, 2016</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt;">Prepaid manufacturing costs</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">983,521</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">980,985</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt;">Prepaid research and development costs</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">64,449</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">128,898</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt;">TOTAL PREPAID EXPENSE</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">1,047,970</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">1,109,883</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 11; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 8 &#x2013; INTANGIBLE ASSETS, NET<br></u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2016 and December 31, 2015:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="15">March 31, 2016</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Gross<br> Carrying<br> Amount</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Accumulated Amortization</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Net Amount</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Weighted- Average Remaining Amortization Period (yrs.)</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Amortizing intangible assets:</td>
<td>&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 20pt; width: 46%; text-align: left; text-indent: -10pt;"><font style="font: 10pt Times New Roman, Times, Serif;">OPERA<sup>&#xAE; </sup>software patent</font></td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">31,951</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">(4,993</td>
<td style="width: 1%; text-align: left;">)</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">26,958</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">13.5</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt;">Development costs of corporate website</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">91,743</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(91,743</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt;">Approved hormone therapy drug candidate patents</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">779,777</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(60,579</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;"></td>
<td style="text-align: right;">719,198</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">16.75</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt;">Hormone therapy drug candidate patents&#xA0;(pending)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">787,149</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">787,149</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Non-amortizing intangible assets:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt;">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">161,241</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">161,241</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left; text-indent: -10pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">1,851,861</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">(157,315</td>
<td style="padding-bottom: 2.5pt; text-align: left;">)</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">1,694,546</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="15">December 31, 2015</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Gross<br> Carrying Amount</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Accumulated Amortization</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Net Amount</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Weighted- Average Remaining Amortization Period (yrs.)</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Amortizing intangible assets:</td>
<td>&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 20pt; width: 46%; text-align: left; text-indent: -10pt;"><font style="font: 10pt Times New Roman, Times, Serif;">OPERA<sup>&#xAE; </sup>software patent</font></td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">31,951</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">(4,493</td>
<td style="width: 1%; text-align: left;">)</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;">27,458</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 9%; text-align: right;">13.75</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt;">Development costs of corporate website</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">91,743</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(91,743</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt;">Approved hormone therapy drug candidate patents</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">705,752</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(49,845</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">655,907</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">17</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt;">Hormone therapy drug candidate patents (pending)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">774,165</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">774,165</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Non-amortizing intangible assets:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt;">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">157,721</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">157,721</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left; text-indent: -10pt;">Total</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">1,761,332</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">(146,081</td>
<td style="padding-bottom: 2.5pt; text-align: left;">)</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">1,615,251</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 12; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b></b>&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately 20 years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. As of March 31, 2016, the remaining life related to OPERA&#xAE; patent was approximately 14 years and the remaining life related to the approved hormone therapy drug candidate patents was approximately 17 years.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In addition to numerous pending patent applications, as of March 31, 2016, we had sixteen issued patents, including:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; width: 100%; font: 12pt Arial, Helvetica, Sans-Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 0.25in;">&#xA0;</td>
<td style="width: 0.25in;"><font style="font: 10pt Symbol;">&#xB7;</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif;">twelve utility patents that relate to our combination progesterone and estradiol product candidates, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="width: 0.25in;">&#xA0;</td>
<td style="width: 0.25in;"><font style="font: 10pt Symbol;">&#xB7;</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif;">two utility patents that relate to TX-004HR, our applicator-free vaginal estradiol softgel product candidate, which establish an important intellectual property foundation for TX-004HR, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2033. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="width: 0.25in;">&#xA0;</td>
<td style="width: 0.25in;"><font style="font: 10pt Symbol;">&#xB7;</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif;">one utility patent that relates to a pipeline transdermal patch technology, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2032. We have pending patent application with respect to this patent in Australia, Brazil, Canada, Europe, Mexico, and Japan; and<br></font></td>
</tr>
<tr style="vertical-align: top;">
<td style="width: 0.25in;">&#xA0;</td>
<td style="width: 0.25in;"><font style="font: 10pt Symbol;">&#xB7;</font></td>
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif;">one utility patent that relates to our OPERA&#xAE; information technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029.</font></td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Subsequent to March 31, 2016, one additional patent was issued relating to our progesterone and estradiol product candidates.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Amortization expense was $11,234 and $6,691 for the three months ended March 31, 2016 and 2015, respectively. Estimated amortization expense for the next five years is as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: Black 1pt solid; text-align: left;" colspan="2">Year Ending December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Estimated<br> Amortization</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 75%; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif;">2016 (9 months)</font></td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 20%; text-align: right;">33,701</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">2017</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">44,934</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">2018</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">44,934</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">2019</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">44,934</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">2020</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">44,934</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b></b></p>
<!-- Field: Page; Sequence: 13; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 9 &#x2013; OTHER CURRENT LIABILITIES</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Other current liabilities consist of the following:</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">March 31, 2016</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt;">Accrued clinical trial costs</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">3,042,956</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">3,725,377</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Accrued payroll, bonuses and commission costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1,396,234</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">2,108,143</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Accrued compensated absences</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">623,918</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">562,096</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Accrued legal and accounting expense</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">413,240</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">210,309</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Other accrued expenses</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">312,329</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">546,264</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Allowance for wholesale distributor fees</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">76,012</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">32,659</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Accrued royalties</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">35,773</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">46,851</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Allowance for coupons and returns</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">185,441</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">224,300</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt;">Accrued rent</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">79,861</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">83,527</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt;">TOTAL OTHER CURRENT LIABILITIES</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">6,165,764</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">7,539,526</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 10 &#x2013; NET LOSS PER SHARE</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We calculate basic and diluted net loss per share allocable to common stockholders using the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of our Common Stock outstanding subject to repurchase or forfeiture for the three months ended March 31, 2016 and 2015.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Since we are in a net loss position, we have excluded outstanding stock options, all of which are subject to forfeiture, as well as warrants for the purchase of our Common Stock from our calculation of diluted net loss per share.</p>
<p style="color: #252525; margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7">Three months ended</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">March 31, 2016</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">March 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt;">Stock options</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 14%; text-align: right;">20,569,655</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 14%; text-align: right;">17,586,109</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt;">Warrants</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">12,281,059</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">13,002,431</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;&#xA0; TOTAL</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">32,850,714</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">30,588,540</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 14; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 11 &#x2013; STOCKHOLDERS&#x2019; EQUITY</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><u>Preferred Stock</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">At March 31, 2016, we had 10,000,000 shares of Preferred Stock, par value $0.001, authorized for issuance, of which no shares of Preferred Stock were issued or outstanding.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><u>Common Stock</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">At March 31, 2016, we had 350,000,000 shares of Common Stock authorized, of which 196,253,700 shares of Common Stock were issued and outstanding.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">On January&#xA0;6, 2016, we entered into an underwriting agreement with Goldman Sachs &#38; Co. and Cowen and Company, LLC, as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of our Common Stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $134.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on January&#xA0;12, 2016 and we issued 17,424,242 shares of our Common Stock.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">On July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus&#xA0;&#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July&#xA0;15, 2015 and we issued 4,423,077 shares of our Common Stock.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our Common Stock.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">During the three months ended March 31, 2016, certain individuals exercised stock options to purchase 340,045 shares of Common Stock for $786,450 in cash. During the three months ended March 31, 2015, a certain individual exercised stock options to purchase 11,250 shares of Common Stock for $7,208 in cash.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><u>Warrants to Purchase Common Stock </u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">As of March 31, 2016, we had warrants outstanding to purchase an aggregate of 12,281,059 shares of Common Stock with a weighted-average contractual remaining life of 1.5 years, and exercise prices ranging from $0.24 to $7.59 per share, resulting in a weighted average exercise price of $1.97 per share.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The valuation methodology used to determine the fair value of our warrants is the Black-Scholes-Merton valuation model, or the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant. During the three months ended March 31, 2016, we granted warrants to purchase 120,000 shares of Common Stock to outside consultants at an exercise price of $7.59. The fair value for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; volatility of 74.15%; risk free rate of 1.28%; and dividend yield of 0%. The grant date fair value of the warrants was $4.60 per share. The warrants vest ratably over a 12-month period and have an expiration date of January 21, 2021. During the three months ended March 31, 2015, we did not grant any warrants. During the three months ended March 31, 2016 and 2015, we recorded $127,465 and $9,071, respectively, as share based compensation expense in the accompanying consolidated financial statements related to vested warrants. As of March 31, 2016, unamortized costs associated with these warrants totaled approximately $449,000.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 15; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In May 2013, we entered into a consulting agreement to develop drug platforms to be used in our hormone replacement drug candidates. As consideration under the agreement, we agreed to issue the consultant a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share, that has vested or will vest as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;">1.</td>
<td style="text-align: justify;">Warrants to purchase 283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the agreement, the shares did not vest until June 30, 2013;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;">2.</td>
<td style="text-align: justify;">Warrants to purchase 283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During both the three months ended March 31, 2016 and 2015, we recorded $38,517 as share based compensation expense in the accompanying consolidated financial statements related to these warrants. As of March 31, 2016, there was a remaining balance of $38,509 related to these warrants which was included in other current assets in the accompanying consolidated financial statements;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;">3.</td>
<td style="text-align: justify;">Warrants to purchase 283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate which the warrant holder helped us design. It is anticipated that this event will not occur before December 2016.</td>
</tr>
</table>
<p style="margin-top: 0; margin-right: 0; margin-bottom: 8pt; font: 10pt/107% Times New Roman, Times, Serif; padding-top: 9pt">As of March 31, 2016, unamortized costs associated with these warrants and warrants issued to the same holder in 2012 totaled approximately $361,000.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">During the three months ended March 31, 2016, certain
individuals exercised warrants to purchase 561,372 shares of our Common Stock for $1,310,000 in cash. During the three months
ended March 31, 2015, an outside service provider exercised warrants to purchase 925,485 shares of our Common Stock
for $358,400 in cash.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><u>Options to Purchase Common Stock</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. As of March 31, 2016, there were non-qualified stock options to purchase 17,701,181 shares of Common Stock outstanding under the 2009 Plan. As of March 31, 2016, there were 3,423,477 shares available to be issued under 2009 Plan.</p>
<p style="margin: 0 0 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-weight: normal;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of March 31, 2016, there were non-qualified stock options to purchase 2,868,474 shares of Common Stock outstanding under the 2012 Plan. As of March 31, 2016, there were 7,050,000 shares available to be issued under 2012 Plan.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model for options granted during the three months ended March 31, 2016 and 2015 are set forth in the table below.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Three Months Ended<br> March 31, 2016</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Three Months Ended<br> March 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt;">Risk-free interest rate</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 14%; text-align: right;">1.70</td>
<td style="width: 1%; text-align: left;">%</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 14%; text-align: right;">1.47</td>
<td style="width: 1%; text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Volatility</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">71.22</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">58.78-62.59</font></td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Term (in years)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">6.25</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">5.27-6.25</font></td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Dividend yield</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">0.00</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">0.00</td>
<td style="text-align: left;">%</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 16; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The expected term is based on the contractual terms of the stock option using the simplified method.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">A summary of activity under the 2009 and 2012 Plans and related information follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Number of Shares Underlying Stock Options</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Weighted<br> Average<br> Exercise<br> Price</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Weighted Average Remaining Contractual Life in Years</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Aggregate<br> Intrinsic<br> Value</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; width: 44%; text-align: left; text-indent: -10pt;">Balance at December 31, 2015</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">20,725,325</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">3.28</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">6.5</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">146,864,184</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt;">Granted</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">185,500</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">7.59</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt;">Exercised</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(340,045</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">2.31</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">2,051,619</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 20pt; text-align: left; text-indent: -10pt;">Expired/Forfeited</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(1,125</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3.59</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: -10pt;">Balance at March 31, 2016</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">20,569,655</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3.34</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">6.3</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">71,940,245</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Vested and Exercisable at March 31, 2016</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">15,988,578</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">2.17</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">5.5</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">69,261,183</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;">Unvested at March 31, 2016</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4,581,077</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">7.42</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">9.2</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">2,679,062</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">At March 31, 2016, our outstanding stock options had exercise prices ranging from $0.10 to $8.92 per share. The weighted average grant date fair value per share of options granted was $4.91 and $3.17 during the three months ended March 31, 2016 and 2015, respectively. Share-based compensation expense for options recognized in our results of operations for the three months ended March 31, 2016 and 2015 ($4,151,259 and $728,426, respectively) is based on vested awards. We estimate forfeitures at the time of grant and revise the forfeiture rate in subsequent periods if actual forfeitures differ from the estimates. At March 31, 2016, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $16,285,000 which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of 1.7 years. No tax benefit was realized due to a continued pattern of operating losses.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 12 &#x2013; INCOME TAXES</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2016 as a result of (i) the losses recorded during the three months ended March 31, 2016, (ii) additional losses expected for the remainder of 2016, and/or (iii) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#x201C;more likely than not&#x201D; that some component or all of the benefits of deferred tax assets will not be realized. As of March 31, 2016, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 17; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b></b>&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 13 &#x2013; RELATED PARTIES</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In July 2015, J. Martin Carroll, a director of our Company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc in the normal course of business. Agreements with Catalent Inc. have been reviewed by independent directors of our Company or a committee consisting of independent directors of our Company since July 2015. During the three months ended March 31, 2016, we were billed by Catalent, Inc. $1,464,858 for manufacturing activities related to our clinical trials. As of March 31, 2016, there were amounts due to Catalent, Inc. of $59,275.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 14 &#x2013; BUSINESS CONCENTRATIONS</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We purchase our products from several suppliers with approximately 95% of our purchases supplied from one vendor for both the three months ended March 31, 2016 and 2015.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the three months ended March 31, 2016, three customers each generated more than 10% of our total revenues and during the three months ended March 31, 2015 four customers each generated more than 10% of our total revenues. Revenue generated from three major customers accounted for approximately 61% of our recognized revenue for the three months ended March 31, 2016 and revenue generated from four customers accounted for approximately 70% of our recognized revenue for the three months ended March 31, 2015. Customers that generated more than 10% of our sales are designated as customers &#x201C;A&#x201D;, &#x201C;B&#x201D;, &#x201C;C&#x201D; and &#x201C;D&#x201D;. During the three months ended March 31, 2016, customers A, B and C generated $1,335,551, $1,104,344 and $680,096 in revenues, respectively. During the three months ended March 31, 2015 customers A, B, C and D generated $1,416,127, $626,731, $543,447 and $386,909 in sales, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 15 &#x2013; COMMITMENTS AND CONTINGENCIES</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We lease administrative office space in Boca Raton, Florida pursuant to a 63-month non-cancelable operating lease that commenced on July 1, 2013. The lease expires on September 30, 2018 and we have an option to extend the lease term for a period of five years. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum was effective beginning April 1, 2015 and will expire with the original lease term on September 30, 2018.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The rental expense related to our current lease during the three months ended March 31, 2016 and 2015 was $118,550 and $90,448, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">As of March 31, 2016, future minimum rental payments are as follows:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: Black 1pt solid; text-align: left;" colspan="2">Years Ending December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 75%; text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif;">2016 (9 months)</font></td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 20%; text-align: right;">418,130</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">2017</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">507,087</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">2018</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">388,976</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Total minimum lease payments</font></td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">1,314,193</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 16 &#x2013; SUBSEQUENT EVENTS</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">On April 26, 2016, we entered into an agreement to lease additional administrative office space in Boca Raton, Florida, pursuant to an addendum to our existing 63 month non-cancelable operating lease. This addendum was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<!-- Field: Page; Sequence: 18; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="a_005"></a>Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>General</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The following discussion and analysis provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read together with our consolidated financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form 10-Q. This information should also be read in conjunction with the information contained in our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission, or the Commission or the SEC, on February 26, 2016, or the Annual Report, including the audited financial statements and notes included therein. The reported results will not necessarily reflect future results of operations or financial condition.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, this Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &#x201C;believes,&#x201D; &#x201C;hopes,&#x201D; &#x201C;may,&#x201D; &#x201C;anticipates,&#x201D; &#x201C;should,&#x201D; &#x201C;intends,&#x201D; &#x201C;plans,&#x201D; &#x201C;will,&#x201D; &#x201C;expects,&#x201D; &#x201C;estimates,&#x201D; &#x201C;projects,&#x201D; &#x201C;positioned,&#x201D; &#x201C;strategy&#x201D; and similar expressions and are based on assumptions and assessments made in light of management&#x2019;s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are made as of the date of this Quarterly Report on Form 10-Q and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled &#x201C;Risk Factors&#x201D; in our Annual Report, and include the following: our ability to maintain or increase sales of our products; our ability to develop and commercialize our hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of our clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of our hormone therapy drug candidates; our reliance on third parties to conduct our clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;<font style="letter-spacing: -0.15pt;">&#xA0;</font></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Throughout this Quarterly Report on Form 10-Q, the terms &#x201C;we,&#x201D; &#x201C;us,&#x201D; &#x201C;our,&#x201D; &#x201C;TherapeuticsMD,&#x201D; or &#x201C;our company&#x201D; refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>Overview</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We are a women&#x2019;s health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created using our SYMBODA<sup>TM</sup> hormone technology, which enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins.</font></p>
<p style="margin: 0 0 0 1.1pt; text-align: justify; text-indent: 22pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0 0 0 1.1pt; text-align: justify; text-indent: 22pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<!-- Field: Page; Sequence: 19; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 0 1.1pt; text-align: justify; text-indent: 22pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our common stock, par value $0.001 per share, or Common Stock, is traded on the NYSE MKT under the symbol &#x201C;TXMD&#x201D;. We maintain websites at <i>www.therapeuticsmd.com</i>, <i>www.vitamedmd.com</i>, <i>www.vitamedmdrx.com</i>, and <i>www.bocagreenmd.com</i>. The information contained on our websites or that can be accessed through our websites does not constitute part of this Quarterly Report on Form 10-Q.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i><u>Research and Development</u></i></b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have obtained the U.S. Food and Drug Administration, or FDA, acceptance of our Investigational New Drug, or IND, applications to conduct clinical trials for four of our hormone therapy drug candidates: TX-001HR, our oral combination of progesterone and estradiol; TX-002HR, our oral progesterone alone; TX-003HR, our oral estradiol alone; and TX-004HR, our applicator-free vaginal estradiol softgel with estradiol alone.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">In December 2015, we completed a Phase 3 clinical trial of TX-004HR and we are currently conducting a Phase 3 clinical trial for TX-001HR. In July 2014, we temporarily suspended enrollment in the Phase 3 clinical trial for TX-002HR and, in October 2014, we temporarily stopped the trial in order to update the Phase 3 protocol based on discussions with the FDA. We have no current plans to conduct clinical trials for TX-003HR.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-001HR, our combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause, including hot flashes, night sweats, sleep disturbances, and vaginal discomfort for post-menopausal women with an intact uterus. The hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman&#x2019;s body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time a combination product of estradiol and progesterone bioidentical to &#x2013; or having the same chemical and molecular structure as &#x2013; the estradiol and progesterone produced by the ovaries would be approved for use in a single combined product.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On September 5, 2013, we began enrollment in the REPLENISH Trial, a multicenter, double-blind, placebo-controlled, Phase 3 study of TX-001HR in postmenopausal women with an intact uterus. The study is designed to evaluate the efficacy of TX-001HR for the treatment of moderate to severe vasomotor symptoms due to menopause and the endometrial safety of TX-001HR. Patients are assigned to one of five arms, four active and one placebo, and receive study medication for 12 months. The primary endpoint for the reduction of endometrial hyperplasia is an incidence of endometrial hyperplasia of less than 1% at 12 months, as determined by endometrial biopsy. The primary endpoint for the treatment of moderate to severe vasomotor symptoms is the mean change of frequency and severity of moderate to severe vasomotor symptoms at weeks four and 12 compared to placebo, as measured by the number and severity of hot flushes. Only subjects experiencing a minimum daily frequency of seven moderate to severe hot flushes at screening are included in the vasomotor symptoms analysis, while all subjects are included in the endometrial hyperplasia analysis. The secondary endpoints include reduction in sleep disturbances and improvement in quality of life measures, night sweats and vaginal dryness, measured at 12 weeks, six months and 12 months. The trial is designed to enroll approximately 1,750 patients at approximately 100 sites. We completed enrollment in the REPLENISH Trial in October 2015 and we currently anticipate that results of the trial will be reported late in the fourth quarter of 2016. Based on such timeline and assuming a successful trial, we would anticipate filing a New Drug Application, or NDA, for TX-001HR as soon as the first half of 2017 and assuming an FDA review period of ten months from the receipt date to the Prescription Drug User Fee Act, or PDUFA, date for a non-new molecular entity, the NDA for TX-001HR could be approved by the FDA as soon as the fourth quarter of 2017 or the first quarter of 2018. As of May 3, 2016, approximately 1,500 patients have exited the REPLENISH Trial and the incidence of endomentrial hyperplasia for these patients is less than 1%.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<!-- Field: Page; Sequence: 20; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy drug candidate is bioidentical to &#x2013; or having the same chemical and molecular structure as &#x2013; the hormones that naturally occur in a woman&#x2019;s body. We believe it will be similarly effective to traditional treatments, but may demonstrate efficacy at lower dosages. In January 2014, we began recruitment of patients in the SPRY Trial, a phase 3 clinical trial designed to measure the safety and effectiveness of TX-002HR in the treatment of secondary amenorrhea. During the first two quarters of 2014, the SPRY Trial encountered enrollment challenges because of Institutional Review Board approved clinical trial protocols and FDA inclusion and exclusion criteria. In July 2014, we temporarily suspended enrollment and in October 2014 we temporarily stopped the SPRY Trial in order to update the phase 3 protocol based on discussions with the FDA. We are considering updating the phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial. We believe that the updated phase 3 protocol, if proposed by us and approved by the FDA, would allow us to mitigate the enrollment challenges in, and shorten the duration of, the SPRY Trial. However, there can be no assurance that the FDA will approve the updated phase 3 protocol if we propose it.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">TX-004HR is a vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy, or VVA, in post-menopausal women with vaginal linings that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments for VVA because of an early onset of action with less systemic exposure, inferring a greater probability of dose administration to the target tissue, and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments. TX-004HR features our SYMBODA<sup>TM</sup> technology, which enables partial and complete solubilization of estradiol into medium-chain fatty acid oils often derived from coconut oil. This allows for the production of cohesive, stable formulations and provides content uniformity and accuracy of dosing strengths for TX-004HR. We initiated the REJOICE Trial, a randomized, multicenter, double-blind, placebo-controlled Phase 3 clinical trial during the third quarter of 2014 to assess the safety and efficacy of three doses &#x2013; 25 mcg, 10 mcg and 4 mcg (compared to placebo) &#x2013; of TX-004HR for the treatment of moderate to severe dyspareunia, or painful intercourse, as a symptom of VVA due to menopause.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On December 7, 2015, we announced positive top-line results from the REJOICE Trial. The pre-specified four co-primary efficacy endpoints were the changes from baseline to week 12 versus placebo in the percentage of vaginal superficial cells, percentage of vaginal parabasal cells, vaginal pH and severity of participants&#x2019; self-reported moderate to severe dyspareunia as the most bothersome symptom of VVA. The trial enrolled 764 postmenopausal women (40 to 75 years old) experiencing moderate to severe dyspareunia at approximately 89 sites across the United States and Canada. Trial participants were randomized to receive either TX-004HR at 25 mcg (n=190), 10 mcg (n=191), or 4 mcg (n=191) doses or placebo (n=192) for a total of 12 weeks, all administered once daily for two weeks and then twice weekly (approximately three to four days apart) for ten weeks.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 11pt Calibri, Helvetica, Sans-Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The 25 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 10 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 4 mcg dose of TX-004HR also demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoints of vaginal superficial cells, vaginal parabasal cells, and vaginal pH; the change from baseline compared to placebo in the severity of dyspareunia was statistically significant at the p = 0.0149 level. The FDA has previously indicated to us that in order to approve the drug based on a single trial, the trial would need to show statistical significance at the 0.01 level or lower for each endpoint, and that a trial that is merely statistically significant at a higher level may not provide sufficient evidence to support an NDA filing or approval of a drug candidate where the NDA relies on a single clinical trial. Statistical improvement over placebo was also observed for all three doses at the first assessment at week two and sustained through week 12. Vaginal dryness was a prespecified key secondary endpoint. The 25 mcg and 10 mcg doses of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoint of vaginal dryness. The 4 mcg dose of TX-004HR demonstrated statistically significant results at the p = 0.0014 level compared to placebo. The pharmacokinetic data for all three doses demonstrated negligible to very low systemic absorption of 17 beta estradiol, estrone and estrone conjugated, supporting the previous Phase 1 trial data. TX-004HR was well tolerated, and there were no clinically significant differences compared to placebo-treated participants with respect to adverse events. There were no drug-related serious adverse events reported.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">We currently intend to submit an NDA for the 25 mcg, 10 mcg and 4 mcg doses of TX-004HR to the FDA by the end of June 2016 and that such NDA could be approved by the FDA as soon as the first quarter of 2017, assuming an FDA review period of ten months from the receipt date to the PDUFA date for a non-new molecular entity. If approved, the 4 mcg formulation would represent a lower effective dose than the currently available VVA therapies approved by the FDA. We recently received conditional approval for the brand name Yuvvexy related to TX-004HR.</font></p>
<p style="margin: 0 0 0 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of March 31, 2016, we had 16 issued patents, which included 12 utility patents that relate to our combination progesterone and estradiol formulations, two utility patents that relate to TX-004HR, which establish an important intellectual property foundation for TX-004HR, one utility patent that relates to a pipeline transdermal patch technology, and one utility patent that relates to our OPERA<sup>&#xAE;</sup> information technology platform.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Subsequent to March 31, 2016, one additional patent was issued relating to our progesterone and estradiol product candidates.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<!-- Field: Page; Sequence: 21; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Research and Development Expenses</i></b></font></p>
<p style="margin: 0; text-indent: 24.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>&#xA0;</i></b></font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">A significant portion of our operating expenses to date have been incurred in research and development activities. Research and development expenses relate primarily to the discovery and development of our drug products. Our business model is dependent upon our company continuing to conduct a significant amount of research and development. Until one of our drug products receives IND approval from the FDA, products costs are listed as Other Research and Development costs in the accompanying consolidated financial statements. Our research and development expenses consist primarily of expenses incurred under agreements with contract research organizations, or CROs, investigative sites and consultants that conduct our clinical trials and a substantial portion of our preclinical studies; employee-related expenses, which include salaries and benefits, and non-cash share-based compensation; the cost of developing our chemistry, manufacturing and controls capabilities, and acquiring clinical trial materials; and costs associated with other research activities and regulatory approvals.</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> We make payments to the CROs based on agreed upon terms that may include payments in advance of a study starting date. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed in future research and development activities are capitalized, and were $1,005,503 at March 31, 2016, of which $941,054 was included in other current assets and $64,449 was included in long-term prepaid expense on our consolidated balance sheet. Advance payments to be expensed in future research and development activities were $1,138,073 at December 31, 2015, of which $1,009,175 was included in other current assets and $128,898 was included in long term prepaid expense on our consolidated balance sheet.</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The following table indicates our research and development expense by project/category for the periods indicated (in 000s):</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10; padding-right: 0; padding-top: 0; text-align: center; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7">Three months ended March 31,</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10; padding-right: 0; padding-top: 0; text-align: center; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">2016</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10; padding-right: 0; padding-top: 0; width: 64%; text-align: left; text-indent: -10;">TX 001-HR</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">9,026</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">8,611</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10; padding-right: 0; padding-top: 0; text-align: left; text-indent: -10;">TX 002-HR</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">3</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10; padding-right: 0; padding-top: 0; text-align: left; text-indent: -10;">TX 004-HR</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">2,437</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">5,047</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding: 0 0 1pt 10; text-align: left; text-indent: -10;">Other research and development</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">3,634</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">4,516</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding: 0 0 2.5pt 10; text-align: left; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">15,097</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">18,177</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Research and development expenditures will continue to be significant as we continue development of our drug candidates and advance the development of our proprietary pipeline of novel drug candidates. We expect to incur significant research and development costs as we develop our drug pipeline, complete the ongoing clinical trials of our drug candidates, conduct our planned phase 3 clinical trials, subject to receiving input from regulatory authorities, and prepare regulatory submissions.</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The costs of clinical trials may vary significantly over the life of a project owing to factors that include but are not limited to the following: per patient trial costs, the number of patients that participate in the trials; the number of sites included in the trials; the length of time each patient is enrolled in the trial; the number of doses that patients receive; the drop-out or discontinuation rates of patients; the amount of time required to recruit patients for the trial, the duration of patient follow-up; and the efficacy and safety profile of the drug candidate. We base our estimated expenses related to clinical trials on estimates that are based on our experience and estimates from CROs and other third parties.</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<!-- Field: Page; Sequence: 22; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="background-color: white; margin: 0; text-align: justify; text-indent: 24.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: 0pt; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>Results of Operations</u></b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: 0pt; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i><u>Three months ended March 31, 2016 compared with three months ended March 31, 2015</u></i></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>&#xA0;</i>&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10; text-align: center; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7">Three Months Ended March 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10; text-align: center; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">2016</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">2015</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">Change</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10; text-align: center; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="11">(000s)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10; width: 46%; text-align: left; text-indent: -10;">Revenues, net</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">4,930</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">4,475</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">455</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10; text-align: left; text-indent: -10;">Cost of goods sold</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1,108</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1,044</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">64</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10; text-align: left; text-indent: -10;">Operating expenses</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">24,795</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">24,354</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">441</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 20pt; text-align: left; text-indent: -10;">Operating loss</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(20,973</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(20,923</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(50</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10; text-align: left; text-indent: -10;">Other income, net</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">44</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">28</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">16</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 10; text-align: left; text-indent: -10;">Net loss</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">(20,929</td>
<td style="padding-bottom: 2.5pt; text-align: left;">)</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">(20,895</td>
<td style="padding-bottom: 2.5pt; text-align: left;">)</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">(34</td>
<td style="padding-bottom: 2.5pt; text-align: left;">)</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><u>Revenues and Cost of Goods Sold</u></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;<i>&#xA0;</i></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Revenues for the three months ended March 31, 2016 increased approximately $455,000, or 10%, to approximately $4,930,000, compared with approximately $4,475,000 for the three months ended March 31, 2015. Of this $455,000 increase, approximately 84% was attributable to an increase in the number of units sold and approximately 16% was attributable to product mix and an increase in the average net sales price of our products, partially offset by the impact of changes in insurance plans. Cost of goods sold increased approximately $64,000, or 6%, to approximately $1,108,000 for the three months ended March 31, 2016, compared with approximately $1,044,000 for the three months ended March 31, 2015. Cost of goods sold as a percentage of revenue was approximately 22% and 23% for the three months ended March 31, 2016 and 2015, respectively, which was primarily attributable to a favorable change in product mix.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Operating Expenses</u></font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our principal operating costs include the following items as a percentage of total operating expenses.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10; text-align: center; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7">Three Months Ended March 31,</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10; text-align: center; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">2016</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10; width: 64%; text-align: left; text-indent: -10;">Research and development costs</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 14%; text-align: right;">60.9</td>
<td style="width: 1%; text-align: left;">%</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 14%; text-align: right;">74.6</td>
<td style="width: 1%; text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10; text-align: left; text-indent: -10;">Human resource costs, including salaries, benefits and taxes</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">21.3</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">11.6</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10; text-align: left; text-indent: -10;">Sales and marketing costs, excluding human resource costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">6.5</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">5.9</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10; text-align: left; text-indent: -10;">Professional fees for legal, accounting and consulting</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">5.2</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">3.8</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10; text-align: left; text-indent: -10;">Other operating expenses</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">6.1</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4.1</td>
<td style="text-align: left;">%</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Operating expenses increased by approximately $441,000, or 2%, to approximately $24,795,000 for the three months ended March 31, 2016, from approximately $24,354,000 for the three months ended March 31, 2015 as a result of the following items:</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10; width: 82%; text-align: left; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 1pt; width: 2%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 14%; text-align: center;">(000s)</td>
<td style="padding-bottom: 1pt; width: 1%; text-align: center;"></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10; text-align: left; text-indent: -10;">Decrease in research and development costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(3,080</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10; text-align: left; text-indent: -10;">Increase in human resource costs, including salaries, benefits and taxes</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">2,448</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10; text-align: left; text-indent: -10;">Increase in other operating expenses</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">514</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10; text-align: left; text-indent: -10;">Increase in sales and marketing, excluding human resource costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">184</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 10; text-align: left; text-indent: -10;">Increase in professional fees for legal, accounting and consulting</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">375</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2.5pt; padding-left: 10; text-align: left; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 2.5pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">441</td>
<td style="padding-bottom: 2.5pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<!-- Field: Page; Sequence: 23; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Research and development costs for the three months ended March 31, 2016 decreased by approximately $3,080,000, or 17%, to approximately $15,097,000, compared with $18,177,000 for the three months ended March 31, 2015. Research and development costs include costs related to clinical trials as well as salaries, wages, non-cash compensation and benefits of personnel involved in research and development activities. Research and development costs decreased as a result of the completion of patient enrollment in the REPLENISH Trial for TX-001HR, our combination estradiol and progesterone drug candidate. Research and developments costs during the three months ended March 31, 2016 included the following research and development projects.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the three months ending March 31, 2016 and the period from February 2013 (project inception) through March 31, 2016, we have incurred approximately $9,026,000 and $73,185,000, respectively, in research and development costs with respect to TX-001HR, our combination estradiol and progesterone drug candidate.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the three months ended March 31, 2016 and the period April 2013 (project inception) through March 31, 2016, we have incurred approximately $0 and $2,525,000, respectively, in research and development costs with respect to TX-002HR, our progesterone only drug candidate.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the three months ended March 31, 2016 and the period from August 2014 (project inception) through March 31, 2016, we have incurred approximately $2,437,000 and $25,995,000, respectively, in research and development costs with respect to TX-004HR, our applicator-free vaginal estradiol softgel drug candidate.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">For a discussion of the nature of efforts and steps necessary to complete these projects, see &#x201C;Item 1. Business &#x2014; Research and Development.&#x201D; For a discussion of the risks and uncertainties associated with completing development of our products, see &#x201C;Item 1A. Risk Factors &#x2014; Risks Related to Our Business&#x201D; in our Annual Report. For a discussion of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see &#x201C;&#x2014; Liquidity and Capital Resources.&#x201D; For a discussion as to whether a future milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see &#x201C;Item 1. Business &#x2014; Our Hormone Therapy Drug Candidates,&#x201D; &#x201C;Item 1. Business &#x2014; Products in Development&#x201D; and &#x201C;Item 1. Business &#x2014; Pharmaceutical Regulation&#x201D; in our Annual Report. Future milestones, including NDA submission dates, are not easily determinable as such milestones are dependent on various factors related to our clinical trials, including the timing of ongoing patient recruitment efforts to find eligible subjects for the applicable trials.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Human resource costs, including salaries, benefits and taxes, for the three months ended March 31, 2016 increased by approximately $2,448,000, or 87%, to approximately $5,270,000, compared with approximately $2,822,000 for the three months ended March 31, 2015, primarily as a result of an increase of approximately $260,000 in personnel costs and approximately $2,188,000 in non-cash compensation related to stock option awards.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other operating expense for the three months ended March 31, 2016 increased by approximately $514,000, or 52%, to approximately $1,509,000, compared with approximately $995,000 for the three months ended March 31, 2015, primarily as a result of increased investor relations expenses and allowance for bad debt.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Sales and marketing costs for the three months ended March 31, 2016 increased by approximately $184,000, or 13%, to approximately $1,618,000, compared with approximately $1,434,000 for the three months ended March 31, 2015, primarily as a result of increased incentive expense and travel and related expenses associated with sales and marketing efforts.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 24; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Professional fees for the three months ended March 31, 2016 increased by approximately $375,000, or 41%, to approximately $1,300,000, compared with approximately $925,000 for the three months ended March 31, 2015, primarily as a result of increased legal fees.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Operating Loss</u></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As a result of the foregoing, our operating loss increased approximately $50,000 to approximately $20,973,000 for the three months ended March 31, 2016, compared with approximately $20,923,000 for the three months ended March 31, 2015, primarily as a result increased stock-based compensation expense and professional fees partially offset by decreased research and development costs and increased revenue from sales of our prenatal vitamin products.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As a result of the continued development of our hormone therapy drug candidates, we anticipate that we will continue to have operating losses for the near future until our hormone therapy drug candidates are approved by the FDA and brought to market, although there is no assurance that we will attain such approvals or that any marketing of our hormone therapy drug candidates, if approved, will be successful.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Other income </u></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;<i>&#xA0;</i></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other non-operating income increased by approximately $16,000 or 57%, to approximately $44,000 for the three months ended March 31, 2016 compared with approximately $28,000 for the comparable period in 2015, primarily as a result of increased interest income.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Net Loss</u></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As a result of the net effects of the foregoing, net loss increased approximately $34,000 to approximately $20,929,000 for the three months ended March 31, 2016, compared with approximately $20,895,000 for the three months ended March 31, 2015. Net loss per share of Common Stock, basic and diluted, was ($0.11) for the three months ended March 31, 2016, compared with ($0.13) per share of Common Stock for the three months ended March 31, 2015.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: 0pt; font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><u>Liquidity and Capital Resources</u></b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="color: windowtext; font-family: Times New Roman, Times, Serif; font-size: 10pt;">We have funded our operations primarily through public offerings of our Common Stock and private placements of equity and debt securities. For</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> the three months ended March 31, 2016 and the year ended December 31, 2015, we received approximately $134.9 million and $91.4 million in net proceeds, respectively, from the issuance of shares of our Common Stock. As of March 31, 2016, we had cash and cash equivalents totaling approximately $182.1 million, however, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On January 6, 2016, we entered into an underwriting agreement with Goldman, Sachs &#38; Co and Cowen and Company, LLC, as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of our Common Stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $134.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on January 12, 2016.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<!-- Field: Page; Sequence: 25; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus&#xA0;&#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July&#xA0;15, 2015 and we issued 4,423,077 shares of our Common Stock.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of our Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February&#xA0;17, 2015.</p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We believe that our existing cash will allow us to fund our operating plan through at least the next 12 months. If our available cash is insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or debt securities or obtain a credit facility. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our existing shareholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing shareholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products. Additionally, we may have to grant licenses on terms that may not be favorable to us.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We need substantial amounts of cash to complete the clinical development of our hormone therapy drug candidates. The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0 0.7pt 0 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Summary of (Uses) and Sources of Cash</u></font></p>
<p style="margin: 0 0.7pt 0 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 10; text-align: center; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7">Three Months Ended March 31,</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10; text-align: center; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">2016</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="3">2015</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 10; text-align: center; text-indent: -10;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="7">(000)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10; width: 64%; text-align: left; text-indent: -10;">Net cash used in operating activities</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">(19,404</td>
<td style="width: 1%; text-align: left;">)</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 14%; text-align: right;">(19,150</td>
<td style="width: 1%; text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 10; text-align: left; text-indent: -10;">Net cash used in investing activities</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(165</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(37</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 10; text-align: left; text-indent: -10;">Net cash provided by financing activities</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">136,960</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">59,483</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0 0 0 0.25pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0 0 0 0.25pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Operating Activities</i></font></p>
<p style="margin: 0 0 0 0.25pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The use of cash in both periods resulted primarily from our net loss adjusted for non-cash charges and changes in components of working capital. The increase of approximately $254,000 in cash used in operating activities for the three months ended March 31, 2016 compared with the comparable period in the prior year was due primarily to research and development, and sales, general, and administrative costs. These were partially offset by an increase of approximately $455,000 in revenue over the same periods.</font></p>
<p style="margin: 0 5.05pt 0 0; text-align: justify; text-indent: 38.45pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0 5.05pt 0 0; text-align: justify; text-indent: 38.45pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<!-- Field: Page; Sequence: 26; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 5.05pt 0 0; text-align: justify; text-indent: 38.45pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0 0.7pt 0 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Investing Activities</i></font></p>
<p style="margin: 0 0.7pt 0 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>&#xA0;</i></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">An increase in spending on patent and trademarks and fixed assets resulted in an increase in cash used in investing activities for the three months ended March 31, 2016 compared with the same period in 2015. </font></p>
<p style="margin: 0 5.05pt 0 0; text-align: justify; text-indent: 38.45pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;<i>&#xA0;</i></font></p>
<p style="margin: 0 0.7pt 0 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Financing Activities</i></font></p>
<p style="margin: 0 0.7pt 0 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>&#xA0;</i></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Financing activities represent the principal source of our cash flow. Our financing activities for the three months ended March 31, 2016 consisted of the proceeds from the January 2016 underwritten public offering of our Common Stock and stock option and warrant exercises.</font></p>
<p style="margin: 0 0.7pt 0 0.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Contractual Obligations</b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;&#xA0;</b></font></p>
<p style="color: #252525; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On April 26, 2016, we entered into an agreement to lease additional administrative office space in Boca Raton, Florida, pursuant to an addendum to our existing 63 month non-cancelable operating lease. This addendum was effective beginning May 1, 2016 and extended the expiration of the original lease term to October 31, 2021.</font></p>
<p style="color: #252525; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>New Accounting Pronouncements</b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;&#xA0;</b></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="color: #252525; font-family: Times New Roman, Times, Serif; font-size: 10pt;">In March 2016, the Financial Accounting Standards Board, or FASB, issued ASU 2016-09, Compensation &#x2013; Stock Compensation: Improvements to Employee Share-Based Payment Accounting. This guidance simplifies several aspects of the accounting for employee share-based payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted in any annual or interim period for which financial statements have not been issued or made available for issuance, but all of the guidance must be adopted in the same period. If an entity early adopts the guidance in an interim period, any adjustments must be reflected as of the beginning of the fiscal year that includes that interim period.</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> We are currently evaluating the impact of this guidance on our consolidated financial statements and disclosures.</font></p>
<p style="color: #252525; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are currently evaluating the impact of this guidance on our consolidated financial statements and disclosures.</font></p>
<p style="color: #252525; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), simplifying the Measurement of Inventory. This guidance requires entities to measure inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM). The guidance applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does not change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM guidance. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Under the new guidance, however, entities will no longer need to calculate other measures of &#x201C;market.&#x201D; The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact of this guidance, if any, on our consolidated financial statements and disclosures.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 27; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#x2019;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB issued final <font style="color: #252525;">amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08) as well as accounting for licenses of intellectual property and identifying performance obligations in its new revenue standard (ASU 2016-10). We are currently evaluating the impact of this guidance on our consolidated financial statements and disclosures.</font></font></p>
<p style="color: #252525; margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="a_006"></a>Item 3. Quantitative and Qualitative Disclosures about Market Risk</b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our market risk has not changed materially from the interest rate risk disclosed in Item 7A of our Annual Report.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;<b>&#xA0;</b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="a_007"></a>Item 4. Controls and Procedures</b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;&#xA0;</b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Disclosure Controls and Procedures</u></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time period specified in the SEC&#x2019;s rules and forms and is accumulated and communicated to our principal executive officer and principal financial officer, as appropriate, in order to allow timely decisions in connection with required disclosure.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 28; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Evaluation of Disclosure Controls and Procedures</u></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q were effective in providing reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration of the degree of compliance with policies or procedures.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><u>Changes in Internal Controls</u></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the three months ended March 31, 2016, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;<b>&#xA0;</b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="a_008"></a>PART II &#x2013; OTHER INFORMATION</b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="a_009"></a>Item 1. Legal Proceedings</b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;&#xA0;</b></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">From time to time, we are involved in litigation and proceedings in the ordinary course of our business. We are not currently involved in any legal proceeding that we believe would have a material adverse effect on our business or financial condition.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="a_010"></a>Item 1A. Risk Factors</b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">There have been no material changes to the risk factors previously disclosed in our Annual Report.</font></p>
<p style="margin: 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="a_011"></a>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</b></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On January 13, 2016, we issued 470,000 shares of our Common Stock upon the exercise of warrants previously issued to an outside service provider and received proceeds of $1,207,900 in connection with this exercise. On January 19, 2016, we issued 30,000 shares of our Common Stock upon the exercise of warrants previously issued to an outside service provider and received proceeds of $77,100 in connection with this exercise. On March 10, 2016, we issued 61,372 shares of our Common Stock upon the exercise of warrants previously issued in connection with a loan agreement and received proceeds of $25,000 in connection with this exercise. Proceeds from these transactions were used in working capital. The shares of Common Stock were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<!-- Field: Page; Sequence: 29; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><a name="a_012"></a>Item 6. Exhibits</b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; width: 10%; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Exhibit</b></font></td>
<td style="padding-bottom: 1pt; width: 3%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; width: 15%; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Date</b></font></td>
<td style="padding-bottom: 1pt; width: 3%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-left: 0; padding-right: 0; width: 69%; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Description</b></font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">10.1*</td>
<td>&#xA0;</td>
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">April 26, 2016</td>
<td>&#xA0;</td>
<td style="padding-left: 0; padding-right: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="ex10-1.htm">Second Amendment to Lease between the Company and 6800 Broken Sound, LLC.</a></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">31.1*</font></td>
<td>&#xA0;</td>
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">May 5, 2016</font></td>
<td>&#xA0;</td>
<td style="padding-left: 0; padding-right: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><a href="ex31-1.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</a></font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-right: 5.4pt; vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">31.2*</td>
<td>&#xA0;</td>
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">May 5, 2016</font></td>
<td>&#xA0;</td>
<td style="padding-left: 0; padding-right: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><a href="ex31-2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</a></font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">32.1*</font></td>
<td>&#xA0;</td>
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">May 5, 2016</font></td>
<td>&#xA0;</td>
<td style="padding-left: 0; padding-right: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><a href="ex32-1.htm">Section 1350 Certification of Chief Executive Officer</a></font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">32.2*</font></td>
<td>&#xA0;</td>
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">May 5, 2016</font></td>
<td>&#xA0;</td>
<td style="padding-left: 0; padding-right: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><a href="ex32-2.htm">Section 1350 Certification of Chief Financial Officer</a></font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">101.INS*</font></td>
<td>&#xA0;</td>
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td>&#xA0;</td>
<td style="padding-left: 0; padding-right: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">XBRL Instance Document</font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">101.SCH*</font></td>
<td>&#xA0;</td>
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td>&#xA0;</td>
<td style="padding-left: 0; padding-right: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">XBRL Taxonomy Extension Schema Document</font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">101.CAL*</font></td>
<td>&#xA0;</td>
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td>&#xA0;</td>
<td style="padding-left: 0; padding-right: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">XBRL Taxonomy Extension Calculation Linkbase Document</font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">101.DEF*</font></td>
<td>&#xA0;</td>
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td>&#xA0;</td>
<td style="padding-left: 0; padding-right: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">XBRL Taxonomy Extension Definition Linkbase Instance Document</font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">101.LAB*</font></td>
<td>&#xA0;</td>
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td>&#xA0;</td>
<td style="padding-left: 0; padding-right: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">XBRL Taxonomy Extension Label Linkbase Instance Document</font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">101.PRE*</font></td>
<td>&#xA0;</td>
<td style="padding-right: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td>&#xA0;</td>
<td style="padding-left: 0; padding-right: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">XBRL Taxonomy Extension Presentation Linkbase Instance Document</font></td>
</tr>
</table>
<p style="margin: 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
<div style="border-top: Black 1pt solid; width: 30%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"></font></p>
<p style="margin: 0 0 0 0.5in; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">* Filed herewith.</font></p>
<p style="margin: 0 0 0 0.5in; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 0 0.5in; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 30; Value: 2 -->
<div style="border-bottom: Black 2pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-bottom: 6pt; padding-top: 12pt; width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 0 0.5in; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>SIGNATURES</b></font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">DATE: May 5, 2016</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left;">
<td style="width: 50%;">&#xA0;</td>
<td style="width: 50%;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC.</b></font></td>
</tr>
</table>
<p style="margin: 0;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
<td style="width: 50%; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="width: 5%; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">By:</font></td>
<td style="border-bottom: Black 1pt solid; width: 45%; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>/s/ Robert G. Finizio </i></font></td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Robert G. Finizio</font></td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Chief Executive Officer</font></td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Principal Executive Officer)</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
<td style="width: 50%; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="width: 5%; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">By:</font></td>
<td style="border-bottom: Black 1pt solid; width: 45%; font: 10pt Times New Roman, Times, Serif;"><i>/s/ Daniel A. Cartwright</i></td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Daniel A. Cartwright</font></td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Chief Financial Officer</font></td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif;">
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(Principal Financial and Accounting Officer)</font></td>
</tr>
</table>
<p></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">31</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
<div style="border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<DESCRIPTION>SECOND AMENDMENT TO LEASE
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;"><a href="txmd-10q_033116.htm">TherapeuticsMD, Inc. 10-Q</a></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; text-align: right;"><b>Exhibit 10.1</b></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0 0 8pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif;"><u>SECOND AMENDMENT TO LEASE</u></p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">THIS SECOND AMENDMENT TO LEASE (the &#x201C;Second Amendment&#x201D;) is made and entered into as of the Effective Date hereof, by and between 6800 BROKEN SOUND LLC, a Florida limited liability company and its successors or assigns (&#x201C;Landlord&#x201D;), and THERAPEUTICSMD, INC., a Nevada corporation authorized to do business in Florida (&#x201C;Tenant&#x201D;).</p>
<p style="margin: 0 0 8pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif;">RECITALS:</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">A.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">Landlord and Tenant have entered into that certain Lease with the Effective Date of May 13, 2013 (the &#x201C;First Lease&#x201D;) for the Lease of that certain Premises described within the Lease as the entire third floor of the Building located at 6800 Broken Sound Parkway, Boca Raton, Florida (&#x201C;First Premises&#x201D;).</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">B.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">Subsequently, Landlord and Tenant entered into that certain First Amendment to Lease dated February 19, 2015 (&#x201C;First Amendment&#x201D; and together with the First Lease, the &#x201C;Original Lease&#x201D;; the Original Lease, as modified by this Second Amendment is referred to herein as the &#x201C;Lease&#x201D;), which, among other things, modified the Premises to also include Suite 100 of the Building (as defined in the Lease) (the &#x201C;Second Premises&#x201D; and together with the First Premises, the &#x201C;Original Premises&#x201D;).</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">C.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">Landlord and Tenant desire to modify and amend the Original Lease to expand the Premises to include Suite 125 of the Building, which suite consists of approximately 3,542 rentable square feet, and to modify such other terms and conditions of the Original Lease consistent with the addition of the additional rentable square footage.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">D.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">Landlord and Tenant desire to enter into such other terms, conditions, and amendments to the Lease as are more specifically set forth herein.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">NOW, THEREFORE, in consideration of the mutual terms, covenants and conditions contained herein, and for separate consideration, the receipt and sufficiency of which is hereby acknowledged and agreed to by the parties hereto, the Landlord and Tenant do hereby agree as follows:</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">1.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Recitals</u>. The above recitals are hereby ratified and confirmed as being true and correct and are incorporated herein in all respects.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">2.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Definitions</u>. All terms defined herein shall have the identical definitions as ascribed to within the Original Lease, except where such definition is expressly modified herein.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">3.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Effective Date</u>. The Effective Date of this Second Amendment to Lease shall be the date and time of the last party to fully execute this Second Amendment.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">4.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Premises</u>. Commencing on May 1, 2016 (&#x201C;Additional Premises Commencement Date&#x201D;), the Premises as defined in Article 1 BASIC PROVISIONS of the Original Lease shall be amended and restated in its entirety to read as follows:</p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#x201C;B. &#xA0;&#xA0;<u>Premises</u>: The entire third floor of the Building as outlined on the floor plan attached to the Lease as Exhibit &#x201C;A&#x201D;, that certain space designated as Suite 100 located at the Building, and that certain space designated as Suite 125 located at the Building.&#x201D;</i></p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">For all purposes of the Original Lease and this Second Amendment, commencing upon the Additional Premises Commencement Date, where the defined term &#x201C;Premises&#x201D; is used the same shall be defined as the entire third floor of the Building as outlined on Exhibit &#x2018;&#x2018;A&#x201D; to the Lease, Suite 100, and Suite 125. Where the defined term &#x201C;Additional Premises&#x201D; is used in this Second Amendment, the same shall be defined solely as Suite 125 at the Building, and where the defined term &#x201C;Original Premises&#x201D; is used herein the same shall be defined solely as the entire third floor of the Building together with Suite 100 of the Building.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">5.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Additional Premises Occupancy Date</u>. Landlord shall allow Tenant occupancy of the Additional Premises on the Additional Premises Commencement Date.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">6.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Term</u>. The Lease Term for the Additional Premises shall commence upon the Additional Premises Commencement Date and be coterminous with the Lease Term for the Original Premises. The definition of Expiration Date as set forth in Article I <font style="text-transform: uppercase;">Basic Provisions</font> is hereby amended and restated to read as follows:</p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><i>&#x201C;G. &#xA0;&#xA0;Expiration Date: October 31, 2021, or such earlier date in which the term of the Lease for the Premises shall expire or be terminated pursuant to the terms and conditions of the Lease.&#x201D;</i></p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">The Renewal Option set forth in Article 33 of the Lease shall also apply to the Additional Premises, and in the event Tenant should exercise the Renewal Option, it must be exercised for both the Original Premises and the Additional Premises.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">7.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Additional Premises Rentable Area</u>. The Additional Premises Rentable Area consists of approximately 3,542 rentable square feet and constitutes 6.97% percent of the gross rentable square footage of the Building, which is 50,809 rentable square feet. Commencing upon the Additional Premises Commencement Date, the Premises shall consist of approximately 24,761 rentable square feet and constitute collectively for both the Original Premises and Additional Premises 48.73% of the Gross Rentable square footage of the Building. The square footage and percentages set forth herein shall be deemed conclusive, with the Landlord and Tenant agreeing upon the square footage and percentages to be paid which may take into account any loss factor, area located between demising walls, and/or may include exterior wall structures. The parties acknowledge and agree that the Tenant is satisfied with the square footage calculation and the percentage calculation and accepts the same, thereby waiving any right to object to the square footage or percentage calculation in the future.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">8.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Tenant&#x2019;s Share of Taxes</u>. The Lease, Article 1: BASIC PROVISIONS (I) Tenant&#x2019;s Share of Taxes is hereby amended and restated in its entirety to read as follows:</p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#x201C;I. &#xA0;&#xA0;Tenant&#x2019;s Share of Taxes: Commencing on the Additional Premises Commencement Date, Tenant&#x2019;s Share of Taxes shall be 48.73% subject to Article 4 and Article 32 of the Lease. To the extent required for any calculation the Tenant&#x2019;s Share attributable to the Additional Premises shall be 6.97%.&#x201D;</i></p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">9.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Tenants Share of Expenses</u>. The Lease, Article 1: BASIC PROVISIONS (J) Tenant&#x2019;s Share of Expenses are hereby amended and restated in their entirety to read as follows:</p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#x201C;J. &#xA0;&#xA0;Tenant&#x2019;s Share of Expenses: Commencing on the Additional Premises Commencement Date, Tenants share of Expenses shall be 48.73% subject to Article 4 and Article 32 of the Lease. To the extent required for any calculation the Tenant&#x2019;s Share attributable to the Additional Premises shall be 6.97%.&#x201D;</i></p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i></i></p>
<!-- Field: Page; Sequence: 2 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">10.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Base Rent:</u> The Tenant shall pay the following Rent amounts:</p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">A.</p>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>First Premises</u>. Commencing on the Additional Premises Commencement Date, the Base Rent for the First Premises as defined in Article 1: BASIC PROVISIONS (K), and (i) as set forth in Exhibit E of the First Lease with respect to the First Premises, is hereby amended and restated in its entirety to reflect the Base Rent amounts set forth below:</p>
<p style="margin: 0 0 8pt; text-align: center; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><b><u>Schedule of Base Rent</u></b></p>
<p style="margin: 0 0 8pt; text-align: center; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"></p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="background-color: white; vertical-align: bottom;">
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; text-align: center; font-style: italic; font-weight: bold;">Lease Term</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Annual<br> Base Rent</i></b></font><br> <font style="font-size: 10pt;"><b><i>per Square<br> Foot</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Annual</i></b></font><br> <font style="font-size: 10pt;"><b><i>Base Rent</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Monthly</i></b></font><br> <font style="font-size: 10pt;"><b><i>Base Rent</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Monthly</i></b></font><br> <font style="font-size: 10pt;"><b><i>CAM</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Monthly</i></b></font><br> <font style="font-size: 10pt;"><b><i>Total</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 15%; text-align: center; font-style: italic;">5/1/16-6/31/16</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 13%; text-align: right; font-style: italic;">16.48</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 13%; text-align: right; font-style: italic;">291,465.28</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 13%; text-align: right; font-style: italic;">24,288.77</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 13%; text-align: right; font-style: italic;">19,159.83</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 13%; text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>$29,616.83*<sup>+</sup></i></font></td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">7/1/16-3/31/17</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">16.48</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">291,465.28</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">24,288.77</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">19,159.83</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>$30,503.33*<sup>+</sup></i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/17-6/31/17</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">16.97</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">300,131.42</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">25,010.95</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*<b><sup>+</sup></b></i>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">7/1/17-3/31/18</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">16.97</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">300,131.42</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">25,010.95</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*<sup>+</sup></i>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/18-6/31/18</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">17.48</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">309,151.28</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">25,762.61</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*<sup>+</sup></i>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">7/1/18-9/30/18</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">17.48</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">309,151.28</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">25,762.61</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*<sup>+</sup></i>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">10/1/18-3/31/19</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">17.48</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">309,151.28</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">25,762.61</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*</i></font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/19-3/31/20</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">18.00</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">318,348.00</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">26,529.00</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/20-3/31/21</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">18.54</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">327,898.44</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">27,324.00</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/21-10/31/21</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">19.10</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">337,802.60</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">28,150.22</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0 0 8pt; text-align: center; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><b><i>*Tenant shall pay all legally required sales tax together with each payment of Rent.</i></b></p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif;"><b><sup>+</sup><i>With respect to the First Premises, the installments of Rent qualified by this symbol are subject to the Rent Maximum Payment Ceiling set forth in the chart below. If the Monthly Base Rent plus the Monthly CAM (referred to as &#x201C;Expenses&#x201D; in the Original Lease) exceed the applicable monthly Rent Maximum Payment Ceiling set forth below, then the Rent due for the applicable month shall be the applicable monthly Rent Maximum Payment Ceiling set forth below.</i></b></font><b> <i>Notwithstanding any term or condition of the Lease, the Second Premises and/or Additional Premises Base Rent, Taxes, Expenses and/or other amounts due shall not be subject to, or used in any manner in calculating the Rent Maximum Payment Ceiling pursuant to the Lease; the Rent Maximum Payment Ceiling shall only apply to the Rent due with respect to the First Premises (and not the Second Premises or the Additional Premises).</i> <i>Further, the Rent Maximum Payment Ceiling shall cease to apply to the First Premises starting on October 1, 2018.</i></b></p>
<p style="margin-bottom: 8pt; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><i>&#xA0;</i><u>Rent Maximum Payment Ceiling Schedule</u></b></p>
<p style="margin-bottom: 8pt; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b></b></p>
<table align="CENTER" style="width: 70%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="background-color: white; vertical-align: bottom;">
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; text-align: center; font-style: italic; font-weight: bold;">Lease Term</td>
<td style="font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Rent Maximum Payment Ceiling (Annual)</i></b></font></td>
<td style="text-align: left; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Monthly Rent Maximum Payment Ceiling</i></b></font></td>
<td style="text-align: left; font-style: italic; font-weight: bold;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 37%; text-align: center; font-style: italic;">5/1/16-6/31/16</td>
<td style="width: 3%; font-style: italic;">&#xA0;</td>
<td style="width: 2%; text-align: left; font-style: italic;">$</td>
<td style="width: 17%; text-align: right; font-style: italic;">355,402.00</td>
<td style="width: 1%; text-align: left; font-style: italic;">*</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 2%; text-align: left; font-style: italic;">$</td>
<td style="width: 17%; text-align: right; font-style: italic;">29,616.83</td>
<td style="width: 1%; text-align: left; font-style: italic;">*</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">7/1/16-3/31/17</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">366,064.00</td>
<td style="text-align: left; font-style: italic;">*</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">30,505.33</td>
<td style="text-align: left; font-style: italic;">*</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/17-6/31/17</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">366,064.00</td>
<td style="text-align: left; font-style: italic;">*</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">25,010.95</td>
<td style="text-align: left; font-style: italic;">*</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">7/1/17-3/31/18</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">377,045.00</td>
<td style="text-align: left; font-style: italic;">*</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">31,420.42</td>
<td style="text-align: left; font-style: italic;">*</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/18-6/31/18</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">377,045.00</td>
<td style="text-align: left; font-style: italic;">*</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">31,420.42</td>
<td style="text-align: left; font-style: italic;">*</td>
</tr>
<tr style="background-color: white; vertical-align: top; text-align: left;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">7/1/18-9/30/18</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>$97,089.00 (for 3 months)</i></font></td>
<td style="font-style: italic;">*</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">32,363.00</td>
<td style="font-style: italic;">*</td>
</tr>
<tr style="background-color: white; vertical-align: top; text-align: left;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: top; text-align: left;">
<td style="padding-left: 5.4pt; text-align: left; text-indent: -10pt; font-style: italic;" colspan="8"><b>&#xA0;<i>*Tenant shall pay all legally required sales tax together with each payment of Rent.</i></b></td>
<td style="font-style: italic;">&#xA0;</td>
</tr>
</table>
<p style="margin-bottom: 8pt; margin-top: 0; text-align: center; text-indent: -280pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 8pt; margin-top: 0; text-align: center; text-indent: -280pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 3 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 8pt; margin-top: 0; text-align: center; text-indent: -280pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">B.</p>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Second Premises</u>. Commencing on the Additional Premises Commencement Date, the Base Rent for the Second Premises set forth in Section 12<b> </b>of the First Amendment is hereby amended and restated in its entirety to read as follows:</p>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"></p>
<table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="background-color: white; vertical-align: bottom;">
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; text-align: center; font-style: italic; font-weight: bold;">Lease Term</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Annual</i></b></font><br> <font style="font-size: 10pt;"><b><i>Base Rent</i></b></font><br> <font style="font-size: 10pt;"><b><i>per Square Foot</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Annual</i></b></font><br> <font style="font-size: 10pt;"><b><i>Base Rent</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Monthly</i></b></font><br> <font style="font-size: 10pt;"><b><i>Base Rent</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Monthly</i></b></font><br> <font style="font-size: 10pt;"><b><i>CAM</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Sales</i></b></font><br> <font style="font-size: 10pt;"><b><i>Tax</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Monthly</i></b></font><br> <font style="font-size: 10pt;"><b><i>Total</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 16%; text-align: center; font-style: italic;">5/1/16-3/31/17</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">16.48</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">58,223.84</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">4,851.98</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">3,827.42</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">520.76</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">9,200.16</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/17-3/31/18</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">16.97</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">59,955.01</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">4,998.25</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*</i></font>&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD</i></font>&#xA0;&#xA0;&#xA0;&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/18-3/31/19</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">17.48</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">61,756.84</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">5,146.40</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/19-3/31/20</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">18.00</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">63,594.00</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">5,299.50</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/20-3/31/21</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">18.54</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">65,501.82</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">5,458.49</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/21-10/31/21</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">19.10</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">67,480.30</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">5,623.36</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD&#xA0;&#xA0;&#xA0;&#xA0;</i></font></td>
<td style="text-align: left; font-style: italic;"></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left; font-style: italic;" colspan="24"><b><i>*Tenant shall pay all legally required sales tax together with each payment of Rent.</i></b></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">C.</p>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Additional Premises</u>. Commencing on the Additional Premises Commencement Date, the Base Rent for the Additional Premises shall be as follows:</p>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"></p>
<table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="background-color: white; vertical-align: bottom;">
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; text-align: center; font-style: italic; font-weight: bold;">Lease Term</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Annual</i></b></font><br> <font style="font-size: 10pt;"><b><i>Base Rent</i></b></font><br> <font style="font-size: 10pt;"><b><i>per Square Foot</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Annual</i></b></font><br> <font style="font-size: 10pt;"><b><i>Base Rent</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Monthly</i></b></font><br> <font style="font-size: 10pt;"><b><i>Base Rent</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Monthly</i></b></font><br> <font style="font-size: 10pt;"><b><i>CAM</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Sales</i></b></font><br> <font style="font-size: 10pt;"><b><i>Tax</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-style: italic; font-weight: bold;"><font style="font-size: 10pt;"><b><i>Monthly</i></b></font><br> <font style="font-size: 10pt;"><b><i>Total</i></b></font></td>
<td style="text-align: center; font-style: italic; font-weight: bold;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: right; font-weight: bold;">&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 16%; text-align: center; font-style: italic;">5/1/16-3/31/17</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">16.48</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">58,372.16</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">4,864.35</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">3,837.17</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">522.09</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
<td style="width: 2%; font-style: italic;">&#xA0;</td>
<td style="width: 1%; text-align: left; font-style: italic;">$</td>
<td style="width: 10%; text-align: right; font-style: italic;">9,223.61</td>
<td style="width: 1%; text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/17-3/31/18</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">16.97</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">60,107.74</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">5,008.98</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/18-3/31/19</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">17.48</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">61,914.16</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">5,159.51</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/19-3/31/20</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">18.00</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">63,756.00</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">5,313.00</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/20-3/31/21</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">18.54</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">65,668.68</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">5,472.39</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: center; font-style: italic;">4/1/21-10/31/21</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">19.10</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">67,652.20</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">$</td>
<td style="text-align: right; font-style: italic;">5,637.68</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD*</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="font-style: italic;">&#xA0;</td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
<td style="text-align: right; font-style: italic;"><font style="font-size: 10pt;"><i>TBD</i></font></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left; font-style: italic;" colspan="24"><b><i>*Tenant shall pay all legally required sales tax together with each payment of Rent.</i></b></td>
<td style="text-align: left; font-style: italic;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Except as expressly set forth herein, nothing contained in this Second Amendment shall diminish or reduce in any manner all amounts due and owing pursuant to the Original Lease for the Original Premises.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">11.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Additional Rent</u>. For all purposes as set forth within the Lease and for the Additional Premises, the Lease shall be deemed a triple net lease and Tenant shall be responsible for payment of Tenant&#x2019;s Share of all Expenses, Taxes and other amounts as defined and allowed pursuant to the Lease and Landlord shall be entitled to pass through Tenant&#x2019;s Share of all Expenses, Taxes and other amounts necessary to operate the Building, the Premises and Common Areas as set forth within the Original Lease, as amended by this Second Amendment.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">12.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Security Deposit</u>. Four Thousand Eight Hundred Sixty-Four Dollars and 35/100 ($4,864.35) Dollars shall be paid by Tenant to Landlord upon Tenant&#x2019;s execution of this Second Amendment to Lease. This amount shall be held as Security Deposit pursuant to all terms and conditions of the Lease in addition to all amounts previously received as a Security Deposit.</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 4 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">13.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Furniture</u>. Tenant shall have the right to use any office furniture located within the Additional Premises during the Term of the Lease at no additional cost to Tenant. The foregoing shall not grant any rights of ownership to any such office furniture to Tenant. All such furniture shall remain at the Additional Premises upon Tenant&#x2019;s vacating of the Additional Premises.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">14.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Additional Premises Tenant Improvements</u>. Tenant has performed such inspections of the Additional Premises as it deemed necessary in its sole and absolute discretion and understands the Tenant acceptance of the Additional Premises in accordance with the terms and conditions contained herein is a material inducement to Landlord entering into this Second Amendment. Tenant hereby accepts the Additional Premises in its &#x201C;AS IS, Where Is&#x201D; condition with any and all faults. Landlord shall have no responsibility or obligation whatsoever to perform any repairs, improvements or alterations to the Additional Premises in any manner and all alterations or improvements which Tenant may desire to the Additional Premises shall be at Tenants sole cost and expense and shall be performed in accordance with all other terms and conditions required pursuant to the Lease.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">15.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Lease Terms and Conditions</u>. Commencing upon the Additional Premises Commencement Date, other than as specifically provided for herein with respect to the Additional Premises, all the terms and conditions of the Original Lease shall also apply to and govern the Additional Premises. Tenant agrees that upon the Additional Premises Commencement Date, Tenant shall continue to be responsible for compliance with and satisfying all terms and conditions of the Original Lease, as amended by this Second Amendment, and specifically with those terms and conditions as are specifically set forth with respect to the Additional Premises herein which Tenant shall also be responsible for commencing upon the Additional Premises Commencement Date. Except to the extent any terms and conditions specifically provided for in this Second Amendment being specifically applicable to the Additional Premises, all terms and conditions of the Original Lease shall apply to and bind both the Additional Premises, in addition to the Original Premises. Notwithstanding the foregoing, this shall in no way diminish or reduce any responsibility, obligation or liability of Tenant pursuant to the Original Lease with respect to the Original Premises, but all such terms, conditions, obligations and responsibilities of Tenant with respect to the Original Premises shall continue for the full Term of the Lease.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">16.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Parking</u>. Commencing on the Additional Premises Commencement Date, Section 1(O) of the Lease is hereby amended and restated in its entirety to read as follows:</p>
<p style="margin: 0 0.5in 1pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#x201C;B. &#xA0;&#xA0;<u>Parking</u>: Up to seventy (70) total parking spaces, ten (10) of which shall be designated by Landlord for Tenant&#x2019;s use without additional charge, and the remainder of which will be non-exclusive unassigned spaces in the area show on the Site Plan.&#x201D;</i></p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">17.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Estoppel</u>. Tenant hereby represents and warrants that Tenant is not in default of any term or condition of the Lease and that the Lease is in full force and effect and is the binding obligation of the Tenant in accordance with all terms and conditions of the Original Lease, as supplemented or amended herein. Tenant further acknowledges and represents that the Landlord is not in default of any term or condition of the Lease, and the Lease is in full force and effect in accordance with its terms.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 5 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">18.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Notices</u>. All notices, communications and statements required or permitted under the Lease, as amended by this Second Amendment, shall be in writing, delivered in person or sent by United State Registered or Certified Mail, return receipt requested, with postage prepaid, or Express Mail or Federal Express (or other similar courier service having a delivery system which provides for or makes available a signed receipt of delivery) or by facsimile transmission (provided an original copy is thereafter provided by Express Mail or Federal Express overnight carrier service, addressed to the parties as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<table align="right" cellpadding="0" cellspacing="0" style="width: 95%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">AS TO TENANT:</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">AS TO LANDLORD:</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2">&#xA0;</td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2">&#xA0;</td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">TherapeuticsMD, Inc.</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">6800 Broken Sound, LLC</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">Attention: Mitchell Krassan</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">Attention: Marc Bell</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="border-bottom: Black 1pt solid; padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2">&#xA0;</td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">6800 Broken Sound Parkway</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="border-bottom: Black 1pt solid; padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2">&#xA0;</td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">Boca Raton, FL 33487</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; width: 9%; text-align: left"><font style="font-size: 10pt;">Phone: </font></td>
<td style="border-bottom: Black 1pt solid; padding-left: 0pt; padding-right: 5.75pt; width: 38%; text-align: left"><font style="font-size: 10pt;">&#xA0;</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; width: 2%; text-align: left">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; width: 51%; text-align: left"><font style="font-size: 10pt;">Phone: (561) 988-1700</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">&#xA0;</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">&#xA0;</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">&#xA0;</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">With Copy to:</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">With Copy to:</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">&#xA0;</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">&#xA0;</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">TherapeuticsMD, Inc.</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">Brenda J. Goerks, Esq.</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">Attention: Legal Dept.</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">Akerman LLP</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="border-bottom: Black 1pt solid; padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">&#xA0;</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">Three Brickell City Centre</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="border-bottom: Black 1pt solid; padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2"><font style="font-size: 10pt;">&#xA0;</font></td>
<td style="padding-left: 5.75pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">98 Southeast Seventh Street</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="border-bottom: Black 1pt solid; padding-left: 0pt; padding-right: 5.75pt; text-align: left;" colspan="2">&#xA0;</td>
<td style="padding-left: 0.1in; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">Suite 1100</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;"><font style="font-size: 10pt;">Phone:</font></td>
<td style="border-bottom: Black 1pt solid; padding-left: 0pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0.1in; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
<td style="padding-left: 0pt; padding-right: 5.75pt; text-align: left;">&#xA0;</td>
</tr>
</table><br style="clear: both">



<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>

<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif">Mail service shall be deemed effective upon the earlier of either seventy two (72) hours after deposit in the U.S. mail, in accordance herewith, or upon receipt or refusal to accept receipt by a reputable courier service. Notices sent by facsimile transmission which are received by 4:00 p.m. (in the addressees time zone), shall be deemed delivered as of the date of such transmission, provided that an original copy of such transmission is delivered to the addressee by a nationally utilized overnight courier service on the day following such transmission. Either party by written notice to the other may designate additional parties to receive copies of notices sent to it. Such designees may be changed by written notice. Either party may at any time, in the manner set forth for giving notice to the other, designate a different address to which notices, communication and statements to it shall be sent.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">19.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Duplicate Counterparts</u>. This Second Amendment may be executed by the parties in duplicate counterparts and when taken together the same shall make one complete and binding document. This Second Amendment may be executed in full via facsimile transfer or electronic transmission, which facsimile copy or electronic transfer shall be deemed as binding as an original. All parties hereto may rely upon such facsimile copy or electronic transfer as though it were an original.</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 6 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">20.0</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><u>Superseding Clause</u>. The terms and conditions of this Second Amendment shall supersede, amend and modify all terms and conditions of the Lease. In the event of any conflict between the terms and conditions contained herein and the terms and conditions contained in the Lease, all terms and conditions contained in this Second Amendment shall control. In all other respects, all terms and conditions of the Lease shall remain in full force and effect.</p>
<p style="margin: 0 0 8pt; text-align: center; font: bold 10pt Times New Roman, Times, Serif;"><i>[Signature Page to Follow]</i></p>
<!-- Field: Page; Sequence: 7 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 8pt; text-align: left; font: 10pt/115% Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><b>IN WITNESS WHEREOF,</b> the parties have executed this Lease as of the date first set forth above.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="vertical-align: top;">WITNESSES:</td>
<td>&#xA0;</td>
<td colspan="2"><b>LANDLORD:</b></td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2">&#xA0;</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2"><b>6800 Broken Sound LLC,</b> a Florida limited liability company</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2">&#xA0;</td>
</tr>
<tr>
<td style="border-bottom: Black 1pt solid; width: 46%; vertical-align: top;">/s/ Julie Candia</td>
<td style="width: 9%;">&#xA0;</td>
<td style="width: 8%;">By:</td>
<td style="width: 37%; vertical-align: top;">/s/ Marc Bell</td>
</tr>
<tr>
<td style="vertical-align: top;">Print Name: Julie Candia</td>
<td>&#xA0;</td>
<td>Print Name:</td>
<td style="border-top: #000000 1px solid; vertical-align: top;">Marc Bell</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td>Title:</td>
<td style="border-top: #000000 1px solid; vertical-align: top;">Managing Member</td>
</tr>
<tr>
<td style="border-bottom: Black 1pt solid; vertical-align: top;">/s/ Christine Antle</td>
<td>&#xA0;</td>
<td>Date:</td>
<td style="border-top: #000000 1px solid; vertical-align: top;">April 26, 2016</td>
</tr>
<tr>
<td style="vertical-align: top;">Print Name: Christine Antle</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="border-top: #000000 1px solid; vertical-align: top;">&#xA0;</td>
</tr>
</table>
<p style="margin-bottom: 6pt; margin-top: 0pt; text-align: left; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 6pt; margin-top: 0pt; text-align: left; text-indent: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0 0 8pt; text-align: center; text-transform: uppercase; font: bold 10pt Times New Roman, Times, Serif;">LANDLORD ACKNOWLEDGMENT</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="padding-bottom: 8pt; padding-left: 0pt; padding-right: 5.4pt; width: 21%; text-align: justify;"><font style="font-size: 10pt;">STATE OF FLORIDA</font></td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; width: 2%; text-align: justify;"><font style="font-size: 10pt;">)</font></td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; width: 77%; text-align: justify;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 8pt; padding-left: 0pt; padding-right: 5.4pt; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify;"><font style="font-size: 10pt;">)</font></td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify;"><font style="font-size: 10pt;">ss:</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 8pt; padding-left: 0pt; padding-right: 5.4pt; text-align: justify;"><font style="font-size: 10pt;">COUNTY OF PAM BEACH</font></td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify;"><font style="font-size: 10pt;">)</font></td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The foregoing instrument was acknowledged before me this 26th&#xA0;day of April, 2016 by Marc H. Bell as Managing Member of 6800 Broken Sound LLC, a Florida limited liability company, on behalf of the company. He/she personally appeared before me, is personally known to me or produced _______________________ as identification.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">IN WITNESS WHEREOF, I hereunto set my hand and official seal.</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid;" colspan="2">/s/ Robin J. Powers</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2">Notary Public</td>
</tr>
<tr>
<td style="width: 46%; vertical-align: top;">&#xA0;</td>
<td style="width: 9%;">&#xA0;</td>
<td style="width: 11%;">Print Name:</td>
<td style="border-bottom: Black 1pt solid; width: 34%; vertical-align: top;">Robin J. Powers</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2">My Comission Expires : &#xA0;&#xA0;July 19, 2017</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="border-top: Black 1pt solid; vertical-align: top;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 8pt; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;[Tenant Signature Page to Follow]</p>
<!-- Field: Page; Sequence: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 8pt; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2"><b>TENANT:</b></td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2">&#xA0;</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2"><b>TherapeuticsMD, Inc., </b>a Nevada corporation authorized to do business in Florida</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2">&#xA0;</td>
</tr>
<tr>
<td style="border-bottom: Black 1pt solid; width: 46%; vertical-align: top;">/s/ John Milligan</td>
<td style="width: 9%;">&#xA0;</td>
<td style="width: 8%;">By:</td>
<td style="width: 37%; vertical-align: top;">Robert Finizio</td>
</tr>
<tr>
<td style="vertical-align: top;">Print Name: John Milligan</td>
<td>&#xA0;</td>
<td>Print Name:</td>
<td style="border-top: #000000 1px solid; vertical-align: top;">Robert Finizio</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td>Title:</td>
<td style="border-top: #000000 1px solid; vertical-align: top;">Chief Executive Officer</td>
</tr>
<tr>
<td style="border-bottom: Black 1pt solid; vertical-align: top;">/s/ Brian Bernick</td>
<td>&#xA0;</td>
<td>Date:</td>
<td style="border-top: #000000 1px solid; vertical-align: top;">April 25, 2016</td>
</tr>
<tr>
<td style="vertical-align: top;">Print Name: Brian Bernick</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="border-top: #000000 1px solid; vertical-align: top;">&#xA0;</td>
</tr>
</table>
<p style="margin-bottom: 8pt; margin-top: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt; text-align: center; text-transform: uppercase; font: bold 10pt Times New Roman, Times, Serif;">TENANT ACKNOWLEDGMENT</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="padding-bottom: 8pt; padding-left: 0pt; padding-right: 5.4pt; width: 21%; text-align: justify;"><font style="font-size: 10pt;">STATE OF FLORIDA</font></td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; width: 2%; text-align: justify;"><font style="font-size: 10pt;">)</font></td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; width: 77%; text-align: justify;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 8pt; padding-left: 0pt; padding-right: 5.4pt; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify;"><font style="font-size: 10pt;">)</font></td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify;"><font style="font-size: 10pt;">ss:</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 8pt; padding-left: 0pt; padding-right: 5.4pt; text-align: justify;"><font style="font-size: 10pt;">COUNTY OF PAM BEACH</font></td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify;"><font style="font-size: 10pt;">)</font></td>
<td style="padding-bottom: 8pt; padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The foregoing instrument was acknowledged before me this 25<sup>th</sup> day of April, 2016 by Robert Finizio as Chief Executive Officer of TherapeuticsMD, Inc., a Nevada corporation authorized to do business in Florida, on behalf of said company. He/she personally appeared before me, is personally known to me or produced _______________________ as identification.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">IN WITNESS WHEREOF, I hereunto set my hand and official seal.</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid;" colspan="2">/s/ Giuseppina N. Gamby</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2">Notary Public</td>
</tr>
<tr>
<td style="width: 46%; vertical-align: top;">&#xA0;</td>
<td style="width: 9%;">&#xA0;</td>
<td style="width: 11%;">Print Name:</td>
<td style="border-bottom: Black 1pt solid; width: 34%; vertical-align: top;">Giuseppina N. Gamby</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="2">My Comission Expires : &#xA0;&#xA0;January 27, 2017</td>
</tr>
<tr>
<td style="vertical-align: top;">&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="border-top: Black 1pt solid; vertical-align: top;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 9; Options: Last -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 12pt;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;"><a href="txmd-10q_033116.htm">TherapeuticsMD, Inc. 10-Q</a></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>&nbsp;</b></font></p>

<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit 31.1</b></font></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">I, Robert G. Finizio, certify that:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(1)</font></td>
<td style="width: 96%; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">I have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.; </font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(2)</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(3)</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(4)</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 4%; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(a)</font></td>
<td style="width: 92%; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(b)</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(c)</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(d)</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(5)</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 4%; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(a)</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(b)</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 12pt; width: 50%; vertical-align: top; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">May 5, 2016</font></td>
<td style="width: 5%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; width: 45%; vertical-align: bottom; text-align: justify; text-decoration: none; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><i>/s/ Robert G. Finizio</i></font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Robert G. Finizio</font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Chief Executive Officer</font> <br> <font style="font: 10pt Times New Roman, Times, Serif;">(Principal Executive Officer)</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
<div style="border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 12pt;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><a href="txmd-10q_033116.htm">TherapeuticsMD, Inc. 10-Q</a>&#xA0;</p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&nbsp;</font></p>

<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit 31.2</b></font></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">I, Daniel A. Cartwright, certify that:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(1)</font></td>
<td style="width: 96%; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">I have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.; </font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(2)</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(3)</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(4)</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 4%; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(a)</font></td>
<td style="width: 92%; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(b)</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(c)</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(d)</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif;">
<td style="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(5)</font></td>
<td style="width: 96%; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="width: 4%; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 4%; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(a)</font></td>
<td style="width: 92%; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">(b)</font></td>
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="padding-left: 12pt; width: 50%; vertical-align: top; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">May 5, 2016</font></td>
<td style="width: 5%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; width: 45%; vertical-align: bottom; text-align: justify; text-decoration: underline; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><i><u style="text-decoration: none;">/s/ Daniel A. Cartwright</u></i></font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Daniel A. Cartwright</font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Chief Financial Officer<br> </font> <font style="font: 10pt Times New Roman, Times, Serif;">(Principal Financial and Accounting Officer)</font></td>
</tr>
</table>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
<div style="border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<table style="margin-bottom: 0; margin-top: 0; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 35pt; text-align: right;">&#xA0;</td>
<td style="width: 5pt;"></td>
<td style="text-align: justify;">&#xA0;</td>
</tr>
</table></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 12pt;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;">&#xA0;<a href="txmd-10q_033116.htm">TherapeuticsMD, Inc. 10-Q</a></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&nbsp;</b></font></p>

<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit 32.1</b></font></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">In connection with the quarterly report of TherapeuticsMD, Inc. (the &#x201C;Company&#x201D;) on Form 10-Q for the quarterly period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), I, Robert G. Finizio, Chief Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</font></p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 7%; text-align: right;"></td>
<td style="width: 5%;"><font style="font: 10pt Times New Roman, Times, Serif;">(1)</font></td>
<td style="width: 88%;"><font style="font: 10pt Times New Roman, Times, Serif;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</font></td>
</tr>
</table>
<p style="margin: 0 0 0 91.5pt; text-align: justify; text-indent: -55.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</font></p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 7%; text-align: right;"></td>
<td style="width: 5%;"><font style="font: 10pt Times New Roman, Times, Serif;">(2)</font></td>
<td style="width: 88%;"><font style="font: 10pt Times New Roman, Times, Serif;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></td>
</tr>
</table>
<p style="margin: 0 0 0 91.5pt; text-align: justify; text-indent: -55.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="width: 50%; vertical-align: top; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">May 5, 2016</font></td>
<td style="width: 5%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; width: 45%; vertical-align: bottom; text-align: justify; text-decoration: none; font: 10pt Times New Roman, Times, Serif;"><i>/s/ Robert G. Finizio</i></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Robert G. Finizio</font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Chief Executive Officer</font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">(Principal Executive Officer)</td>
</tr>
</table>
<p style="margin: 0 0 0 91.5pt; text-align: justify; text-indent: -55.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font>&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
<div style="border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 12pt;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;">&#xA0;<a href="txmd-10q_033116.htm">TherapeuticsMD, Inc. 10-Q</a></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>

<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Exhibit 32.2</b></font></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">In connection with the quarterly report of TherapeuticsMD, Inc. (the &#x201C;Company&#x201D;) on Form 10-Q for the quarterly period ended March 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the &#x201C;Report&#x201D;), I, Daniel A. Cartwright, Chief Financial Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 7%; text-align: right;"></td>
<td style="width: 5%;"><font style="font: 10pt Times New Roman, Times, Serif;">(1)</font></td>
<td style="width: 88%;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</td>
</tr>
</table>
<p></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 7%; text-align: right;"></td>
<td style="width: 5%;"><font style="font: 10pt Times New Roman, Times, Serif;">(2)</font></td>
<td style="width: 88%;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</td>
</tr>
</table>
<p></p>
<p style="margin-bottom: 0; margin-right: 0; margin-top: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0; margin-right: 0; margin-top: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</font></p>
<p style="margin-bottom: 0; margin-right: 0; margin-top: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="width: 50%; vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">May 5, 2016</font></td>
<td style="width: 5%; vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; width: 45%; vertical-align: bottom; text-align: justify; text-decoration: none; font: 10pt Times New Roman, Times, Serif;"><i>/s/ Daniel A. Cartwright</i></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Daniel A. Cartwright</font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">Chief Financial Officer</font></td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif;">
<td style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</td>
<td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif;">(Principal Financial and Accounting Officer)</td>
</tr>
</table>
<p></p>
<p style="margin: 0 0 0 91.5pt; text-align: justify; text-indent: -55.5pt; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
<div style="border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>txmd-20160331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20160331\txmd_033116.xfr; Date: 2016%2D05%2D04T21:54:35Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:txmd="http://therapeuticsmd.com/20160331">
    <link:schemaRef xlink:href="txmd-20160331.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_EmployeeStockOptionMember_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-08to2013-05-11_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-08</xbrli:startDate>
        <xbrli:endDate>2013-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-02-10_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-02-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-09</xbrli:startDate>
        <xbrli:endDate>2015-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-07-09_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-07-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-08</xbrli:startDate>
        <xbrli:endDate>2015-07-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-08to2015-07-15_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-08</xbrli:startDate>
        <xbrli:endDate>2015-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-09to2015-02-17_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-09</xbrli:startDate>
        <xbrli:endDate>2015-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-05to2016-01-06_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-05</xbrli:startDate>
        <xbrli:endDate>2016-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-01-06_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-11to2016-01-12_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-11</xbrli:startDate>
        <xbrli:endDate>2016-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_custom_OutsideConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_custom_Patents1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_WarrantMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_WarrantMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-05-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-05-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_custom_Patents2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_SubsequentEventMember_custom_Patents1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_custom_OutsideConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_custom_OutsideConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-01to2013-06-30_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-08to2016-03-31_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-08</xbrli:startDate>
        <xbrli:endDate>2016-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-11_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2016-01-01to2016-03-31">TherapeuticsMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2016-01-01to2016-03-31">0000025743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2016-01-01to2016-03-31">10-Q</dei:DocumentType>
    <dei:AmendmentFlag contextRef="From2016-01-01to2016-03-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2016-01-01to2016-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2016-01-01to2016-03-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2016-01-01to2016-03-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2016-01-01to2016-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2016-01-01to2016-03-31">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2016-01-01to2016-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2016-01-01to2016-03-31">2016</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2016-03-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2015-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2016-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2016-03-31" unitRef="Shares" decimals="INF">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">177928041</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2016-03-31" unitRef="Shares" decimals="INF">196253700</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">13580246</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">3846154</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-07-08to2015-07-15_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">4423077</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-02-09to2015-02-17_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">15617282</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">15151515</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-11to2016-01-12_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">17242242</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="AsOf2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="USDPShares" decimals="INF">4.05</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2015-07-09_custom_StifelUnderwritersMember" unitRef="USDPShares" decimals="INF">7.80</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2016-01-06_custom_GoldmanSachsMember" unitRef="USDPShares" decimals="INF">8.25</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">340045</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-03-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">340045</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-03-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">11250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="USD" decimals="0">59100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="USD" decimals="0">32200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember" unitRef="USD" decimals="0">134900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-03-31_us-gaap_OptionMember" unitRef="USD" decimals="0">786450</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-03-31_us-gaap_OptionMember" unitRef="USD" decimals="0">7208</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-03-31" unitRef="USDPShares" decimals="INF">1.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-03-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-03-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">7.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-03-31_custom_OutsideConsultantMember" unitRef="USDPShares" decimals="INF">7.59</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2013-05-11_custom_ConsultantMember" unitRef="USDPShares" decimals="INF">2.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2016-01-01to2016-03-31_custom_OutsideConsultantMember">2021-01-21</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-03-31_EmployeeStockOptionMember_MinimumMember">P5Y3M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-03-31_EmployeeStockOptionMember_MaximumMember">P6Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember">P6Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-03-31_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">.5878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-03-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">.6259</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">.7122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">.0170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">8.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">185500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">661167</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">907510</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">28986</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">49924</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryNet contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">690153</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">957434</us-gaap:InventoryNet>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">334822</txmd:PrepaidConsultingCurrent>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">296305</txmd:PrepaidConsultingCurrent>
    <us-gaap:PrepaidInsurance contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">695421</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">438420</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">369812</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">231295</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">2233897</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">1718069</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">351303</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-03-31_EquipmentMember" unitRef="USD" decimals="0">156502</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31_EquipmentMember" unitRef="USD" decimals="0">132150</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-03-31_FurnitureAndFixturesMember" unitRef="USD" decimals="0">63566</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31_FurnitureAndFixturesMember" unitRef="USD" decimals="0">69454</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">425780</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0">149699</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2016-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0">205712</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">152711</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">161074</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">198592</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">264706</us-gaap:PropertyPlantAndEquipmentNet>
    <txmd:PrepaidResearchDevelopmentCostsNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">128898</txmd:PrepaidResearchDevelopmentCostsNoncurrent>
    <txmd:PrepaidResearchDevelopmentCostsNoncurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">64449</txmd:PrepaidResearchDevelopmentCostsNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-03-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-03-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">774165</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-03-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">787149</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2016-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">779777</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">705752</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">27458</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-03-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">26958</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-03-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">774165</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-03-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">787149</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2016-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">719198</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">655907</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">7539526</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">6165764</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">73728846</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">192968843</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">-219826860</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">-240756225</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">282712078</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">423932401</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockValue contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">177928</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">196254</us-gaap:CommonStockValue>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">10665700</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">9596413</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">3126174</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">3430649</us-gaap:AccountsPayableCurrent>
    <us-gaap:Assets contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">73728846</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">192968843</us-gaap:Assets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">2850134</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">2867516</us-gaap:AssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">125000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">125000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">70680120</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">189836621</us-gaap:AssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">3049715</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">5063773</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:Cash contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">64706355</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">182097345</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2015-03-31" unitRef="USD" decimals="0">91658453</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">51361607</us-gaap:Cash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">81910</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">318061</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2015-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2016-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2016-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2016-03-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">4930091</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">4475049</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member" unitRef="USD" decimals="0">1335551</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member" unitRef="USD" decimals="0">1416127</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member" unitRef="USD" decimals="0">1104344</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member" unitRef="USD" decimals="0">626731</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2016-01-01to2016-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member" unitRef="USD" decimals="0">680906</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member" unitRef="USD" decimals="0">543447</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member" unitRef="USD" decimals="0">386909</us-gaap:SalesRevenueNet>
    <txmd:CapitalLeaseObligationsTerm contextRef="From2016-01-01to2016-03-31">P63M</txmd:CapitalLeaseObligationsTerm>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2016-03-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">59275</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-01-01to2016-03-31_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2015-01-01to2015-03-31_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-01-01to2016-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2016-01-01to2016-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">.61</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2015-01-01to2015-03-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">.70</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">157721</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2016-03-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">161241</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">157721</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2016-03-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">161241</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">1761332</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">1851861</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">674353</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">644749</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="AsOf2015-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">128898</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="AsOf2016-03-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">64449</us-gaap:PrepaidExpenseOtherNoncurrent>
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">980985</txmd:PrepaidManufacturingCostsNoncurrent>
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">983521</txmd:PrepaidManufacturingCostsNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">146081</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">157315</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">4493</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-03-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">4993</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-03-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2016-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">60579</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">49845</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2016-01-01to2016-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">561372</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">925485</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-01-01to2016-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">1310000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">358400</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">7.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">71940245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">146864184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:LeaseAndRentalExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">118550</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">90448</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-03-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">2868474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">20569655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">20725325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-03-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">17701181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2016-03-31" unitRef="Pure" decimals="INF">16</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2016-03-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="Pure" decimals="INF">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2016-03-31_us-gaap_PatentsMember" unitRef="Pure" decimals="INF">2</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2016-03-31_custom_Patents1Member" unitRef="Pure" decimals="INF">12</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2016-03-31_custom_Patents2Member" unitRef="Pure" decimals="INF">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2016-03-31_us-gaap_SubsequentEventMember_custom_Patents1Member" unitRef="Pure" decimals="INF">1</txmd:NumberOfIssuedPatents>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">2037036</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">576923</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2016-01-05to2016-01-06_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">2272727</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance contextRef="From2013-05-08to2013-05-11_custom_ConsultantMember" unitRef="Shares" decimals="INF">283333</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance contextRef="From2016-01-01to2016-03-31_custom_OutsideConsultantMember" unitRef="Shares" decimals="INF">120000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance contextRef="From2013-05-08to2016-03-31_custom_ConsultantMember" unitRef="Shares" decimals="INF">850000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2016-01-01to2016-03-31_custom_OutsideConsultantMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2013-06-01to2013-06-30_custom_ConsultantMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2016-01-01to2016-03-31_custom_OutsideConsultantMember" unitRef="Pure" decimals="INF">.7415</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2013-06-01to2013-06-30_custom_ConsultantMember" unitRef="Pure" decimals="INF">0.4584</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2016-01-01to2016-03-31_custom_OutsideConsultantMember" unitRef="Pure" decimals="INF">.0128</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2013-06-01to2013-06-30_custom_ConsultantMember" unitRef="Pure" decimals="INF">0.0141</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2016-01-01to2016-03-31_custom_OutsideConsultantMember" unitRef="Pure" decimals="INF">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2013-06-01to2013-06-30_custom_ConsultantMember" unitRef="Pure" decimals="INF">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2016-03-31" unitRef="USD" xsi:nil="true" />
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2016-01-01to2016-03-31_us-gaap_MinimumMember">P6M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2016-01-01to2016-03-31_us-gaap_MaximumMember">P12M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ShelfLifeOfPrescriptionProducts contextRef="From2016-01-01to2016-03-31">P24M</txmd:ShelfLifeOfPrescriptionProducts>
    <txmd:PrepaidVendorDeposits contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">159489</txmd:PrepaidVendorDeposits>
    <txmd:PrepaidVendorDeposits contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">107300</txmd:PrepaidVendorDeposits>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">1109883</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">1047970</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">1615251</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">1694546</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-01-01to2016-03-31_custom_OutsideConsultantMember" unitRef="USDPShares" decimals="INF">4.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2016-01-01to2016-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2016-01-01to2016-03-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P13Y6M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2016-01-01to2016-03-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P16Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2015-01-01to2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P13Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2015-01-01to2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P17Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2015-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">1009175</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2016-03-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">941054</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2015-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">1138073</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2016-03-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">1005503</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember">P6Y3M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-03-31_us-gaap_EmployeeStockOptionMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember">P9Y2M12D</txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm>
    <dei:DocumentPeriodEndDate contextRef="From2016-01-01to2016-03-31">2016-03-31</dei:DocumentPeriodEndDate>
    <us-gaap:PreferredStockValue contextRef="AsOf2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2016-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CostOfGoodsSold contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">1108443</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">1043641</us-gaap:CostOfGoodsSold>
    <us-gaap:GrossProfit contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">3821648</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">3431408</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">9678552</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">6163612</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">15097017</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">18176835</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">19597</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">13572</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">24795166</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">24354019</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-20973518</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-20922611</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-20929365</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-20894256</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2016-01-01to2016-03-31" unitRef="USDPShares" decimals="INF">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-01-01to2015-03-31" unitRef="USDPShares" decimals="INF">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2016-01-01to2016-03-31" unitRef="Shares" decimals="INF">194901560</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-01-01to2015-03-31" unitRef="Shares" decimals="INF">163448130</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">63063146</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">183372430</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-20929365</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-20894256</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">4381690</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-03-31_custom_ConsultantMember" unitRef="USD" decimals="0">38517</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">840464</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2016-01-01to2016-03-31_custom_OutsideConsultantMember" unitRef="USD" decimals="0">127465</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-03-31_custom_OutsideConsultantMember" unitRef="USD" decimals="0">9071</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-03-31_custom_ConsultantMember" unitRef="USD" decimals="0">38517</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">236151</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">13004</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">11234</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">6691</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">8363</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">6881</us-gaap:Depreciation>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-165007</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-36853</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">74478</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">90529</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">36853</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">117390990</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">40296846</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">136959925</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">59483435</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">1310000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">358400</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">786450</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">7208</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">134863475</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">59117827</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">651567</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-1373762</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">1038813</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-522613</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">304475</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-91946</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">2536</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">9842</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-477312</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-91412</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">267281</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-222925</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">2250209</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">502836</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">-19403928</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">-19149736</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">33701</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">44934</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">44934</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">44934</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">44934</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-03-31" unitRef="Shares" decimals="INF">32850714</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">12281059</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">20569655</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-03-31" unitRef="Shares" decimals="INF">30588540</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">17586109</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">13002431</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">12281059</us-gaap:WarrantsAndRightsOutstanding>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2016-01-01to2016-03-31">P1Y6M</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2016-01-01to2016-03-31_custom_OutsideConsultantMember">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2016-03-31_custom_OutsideConsultantMember" unitRef="USD" decimals="0">449000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2016-03-31_custom_ConsultantMember" unitRef="USD" decimals="0">361000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-1125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">15988578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">4581077</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">2051619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">69261183</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">2679062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">4.91</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2015-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.17</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockOptionPlanExpense contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">4151259</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense contextRef="From2015-01-01to2015-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">728426</us-gaap:StockOptionPlanExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">16285000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2016-01-01to2016-03-31_us-gaap_EmployeeStockOptionMember">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2016-03-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2016-03-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">25000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2016-03-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">7050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2016-03-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">3423477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="From2016-01-01to2016-03-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">1464858</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">418130</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">507087</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">388976</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">1314193</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:InvestmentIncomeInterest contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">41617</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">18513</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncome contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">2536</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">9842</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2016-01-01to2016-03-31" unitRef="USD" decimals="0">44153</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="0">28355</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Our financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, &lt;i&gt;Fair Value Measurements. &lt;/i&gt;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 7%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 80%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;unobservable inputs for the asset or liability.&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At March 31, 2016 and 2015, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company&amp;#x2019;s impairment test. There was no impairment of intangible assets or long-lived assets during the three months ended March 31, 2016 and 2015.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note 14. There are no major external customers for our OTC prenatal vitamin or other products.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;OTC Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin-bottom: 0; margin-top: 0; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Prescription Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and customer rebates.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We accept returns of unsalable prescription products from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015, we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Share-Based Compensation&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718 to value options. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, Equity - Based Payments to Non-Employees, or ASC 505. ASC 505 defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&amp;#x2019;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Segment Reporting&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 4 &amp;#x2013; INVENTORY&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Inventory consists of the following:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Finished product&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;907,510&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;661,167&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Raw material&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;49,924&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;28,986&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL INVENTORY&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;957,434&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;690,153&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Inventory consists of the following:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Finished product&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;907,510&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;661,167&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Raw material&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;49,924&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;28,986&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL INVENTORY&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;957,434&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;690,153&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 5 &amp;#x2013; OTHER CURRENT ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Other current assets consist of the following:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;296,305&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;334,822&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;438,420&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;695,421&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;644,749&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;674,353&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid vendor deposits&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;107,300&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;159,489&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;231,295&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;369,812&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,718,069&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,233,897&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Other current assets consist of the following:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;296,305&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;334,822&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;438,420&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;695,421&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;644,749&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;674,353&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid vendor deposits&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;107,300&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;159,489&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;231,295&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;369,812&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,718,069&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,233,897&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Fixed assets consist of the following:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;156,502&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accounting system in process&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;205,712&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;149,699&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,566&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;69,454&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;425,780&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;351,303&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(161,074&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(152,711&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL FIXED ASSETS&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;264,706&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;198,592&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <txmd:PrepaidExpensesDisclosureTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 7 &amp;#x2013; PREPAID EXPENSE&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid expense consists of the following:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;983,521&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;980,985&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;64,449&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;128,898&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL PREPAID EXPENSE&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,047,970&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,109,883&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;</txmd:PrepaidExpensesDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid expense consists of the following:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;983,521&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;980,985&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;64,449&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;128,898&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL PREPAID EXPENSE&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,047,970&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,109,883&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2016 and December 31, 2015:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Gross&lt;br /&gt; Carrying&lt;br /&gt; Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Net Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- Average Remaining Amortization Period (yrs.)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; width: 46%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#xAE; &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(4,993&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;26,958&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;13.5&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;779,777&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(60,579&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;719,198&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16.75&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents&amp;#xA0;(pending)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;787,149&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;787,149&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;161,241&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;161,241&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,851,861&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(157,315&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,694,546&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Gross&lt;br /&gt; Carrying Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Net Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- Average Remaining Amortization Period (yrs.)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; width: 46%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#xAE; &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(4,493&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;27,458&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;13.75&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;705,752&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(49,845&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;655,907&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;17&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;774,165&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;774,165&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157,721&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157,721&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,761,332&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(146,081&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,615,251&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Estimated amortization expense for the next five years is as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Year Ending December 31,&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Estimated&lt;br /&gt; Amortization&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 75%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016 (9 months)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 20%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;33,701&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;44,934&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;44,934&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;44,934&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;44,934&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 9 &amp;#x2013; OTHER CURRENT LIABILITIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Other current liabilities consist of the following:&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued clinical trial costs&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,042,956&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,725,377&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,396,234&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,108,143&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued compensated absences&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;623,918&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;562,096&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued legal and accounting expense&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;413,240&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;210,309&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;312,329&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;546,264&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,012&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;32,659&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued royalties&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;35,773&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;46,851&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for coupons and returns&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;185,441&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;224,300&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued rent&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;79,861&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;83,527&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,165,764&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,539,526&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Other current liabilities consist of the following:&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued clinical trial costs&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,042,956&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,725,377&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,396,234&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,108,143&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued compensated absences&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;623,918&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;562,096&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued legal and accounting expense&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;413,240&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;210,309&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;312,329&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;546,264&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;76,012&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;32,659&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued royalties&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;35,773&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;46,851&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for coupons and returns&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;185,441&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;224,300&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued rent&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;79,861&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;83,527&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,165,764&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,539,526&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three months ended&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;20,569,655&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;17,586,109&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,281,059&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,002,431&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0; TOTAL&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;32,850,714&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,588,540&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The assumptions used in the Black-Scholes Model for options granted during the three months ended March 31, 2016 and 2015 are set forth in the table below.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three Months Ended&lt;br /&gt; March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three Months Ended&lt;br /&gt; March 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.70&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.47&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;71.22&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;58.78-62.59&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.25&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.27-6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;A summary of activity under the 2009 and 2012 Plans and related information follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of Shares Underlying Stock Options&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate&lt;br /&gt; Intrinsic&lt;br /&gt; Value&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 44%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2015&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;20,725,325&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.28&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.5&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;146,864,184&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;185,500&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7.59&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(340,045&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.31&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,051,619&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Expired/Forfeited&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,125&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.59&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,569,655&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.34&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.3&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;71,940,245&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at March 31, 2016&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;15,988,578&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.17&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.5&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;69,261,183&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Unvested at March 31, 2016&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,581,077&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7.42&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;9.2&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,679,062&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 12 &amp;#x2013; INCOME TAXES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2016 as a result of (i) the losses recorded during the three months ended March 31, 2016, (ii) additional losses expected for the remainder of 2016, and/or (iii) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &amp;#x201C;more likely than not&amp;#x201D; that some component or all of the benefits of deferred tax assets will not be realized. As of March 31, 2016, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 15 &amp;#x2013; COMMITMENTS AND CONTINGENCIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We lease administrative office space in Boca Raton, Florida pursuant to a 63-month non-cancelable operating lease that commenced on July 1, 2013. The lease expires on September 30, 2018 and we have an option to extend the lease term for a period of five years. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum was effective beginning April 1, 2015 and will expire with the original lease term on September 30, 2018.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The rental expense related to our current lease during the three months ended March 31, 2016 and 2015 was $118,550 and $90,448, respectively.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;As of March 31, 2016, future minimum rental payments are as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Years Ending December 31,&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 75%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016 (9 months)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 20%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;418,130&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;507,087&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;388,976&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,314,193&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;As of March 31, 2016, future minimum rental payments are as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Years Ending December 31,&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 75%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016 (9 months)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 20%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;418,130&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;507,087&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;388,976&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,314,193&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-03-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">7.42</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2016-05-02" unitRef="Shares" decimals="INF">196263700</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 1 &amp;#x2013; THE COMPANY&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &amp;#x201C;our company,&amp;#x201D; &amp;#x201C;we,&amp;#x201D; &amp;#x201C;our,&amp;#x201D; or &amp;#x201C;us.&amp;#x201D;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Nature of Business&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We are a women&amp;#x2019;s health care product company focused on creating and commercializing products targeted exclusively for women. As of the date of these unaudited consolidated financial statements, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE&#13;2 &amp;#x2013; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS&lt;/u&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Interim&#13;Financial Statements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,&#13;should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report&#13;on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission, or the SEC, from which&#13;we derived the accompanying consolidated balance sheet as of December 31, 2015. The accompanying unaudited interim consolidated&#13;financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America,&#13;or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,&#13;since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of&#13;the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated&#13;financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management,&#13;necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative&#13;of results for a full year or any other interim period in the future.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Recently&#13;Issued Accounting Pronouncements&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;March 2016, the Financial Accounting Standards Board, or FASB, issued ASU 2016-09, Compensation &amp;#x2013; Stock Compensation: Improvements&#13;to Employee Share-Based Payment Accounting. This guidance simplifies several aspects of the accounting for employee share-based&#13;payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory&#13;tax withholding requirements, as well as classification in the statement of cash flows. The guidance is effective for our company&#13;for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted&#13;in any annual or interim period for which financial statements have not been issued or made available for issuance, but all of&#13;the guidance must be adopted in the same period. If an entity early adopts the guidance in an interim period, any adjustments&#13;must be reflected as of the beginning of the fiscal year that includes that interim period. We are currently evaluating the impact&#13;of this guidance on our consolidated financial statements and disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets&#13;but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current&#13;real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting&#13;for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning&#13;after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are currently&#13;evaluating the impact of this guidance on our consolidated financial statements and disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), simplifying the Measurement of Inventory. This guidance requires&#13;entities to measure inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM).&#13;The guidance applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail&#13;inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does not&#13;change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM guidance.&#13;Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion,&#13;disposal and transportation. Under the new guidance, however, entities will no longer need to calculate other measures of &amp;#x201C;market.&amp;#x201D;&#13;The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods&#13;within those fiscal years. Early adoption is permitted. We are currently evaluating the impact of this guidance, if any, on our&#13;consolidated financial statements and disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure&#13;of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate&#13;whether there are conditions and events that raise substantial doubt about the entity&amp;#x2019;s ability to continue as a going&#13;concern within one year after the financial statements are issued (or available to be issued when applicable) and, if so, disclose&#13;that fact. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods within annual periods&#13;beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial&#13;statements have not previously been issued. We do not expect the adoption of ASU 2014-15 to have a material effect on our consolidated&#13;financial statements and disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In&#13;May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with&#13;Customers (Topic 606). The standard&amp;#x2019;s core principle is that a company will recognize revenue when it transfers promised&#13;goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange&#13;for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous&#13;guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration&#13;to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015,&#13;the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after&#13;December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15,&#13;2017 and interim periods therein. In 2016, the FASB issued final amendments to clarify the implementation guidance for principal&#13;versus agent considerations (ASU 2016-08) as well as accounting for licenses of intellectual property and identifying performance&#13;obligations in its new revenue standard (ASU 2016-10). We are currently evaluating the impact of this guidance on our consolidated&#13;financial statements and disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;We&#13;do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently&#13;issued, but not yet effective, accounting standards been adopted in the current period.&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 8 &amp;#x2013; INTANGIBLE ASSETS, NET&lt;br /&gt;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2016 and December 31, 2015:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Gross&lt;br /&gt; Carrying&lt;br /&gt; Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Net Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- Average Remaining Amortization Period (yrs.)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; width: 46%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#xAE; &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(4,993&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;26,958&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;13.5&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;779,777&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(60,579&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;719,198&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16.75&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents&amp;#xA0;(pending)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;787,149&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;787,149&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;161,241&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;161,241&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,851,861&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(157,315&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,694,546&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Gross&lt;br /&gt; Carrying Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Net Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- Average Remaining Amortization Period (yrs.)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; width: 46%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#xAE; &lt;/sup&gt;software patent&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(4,493&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;27,458&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;13.75&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;705,752&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(49,845&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;655,907&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;17&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;774,165&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;774,165&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizing intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157,721&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157,721&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,761,332&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(146,081&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,615,251&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately 20 years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. As of March 31, 2016, the remaining life related to OPERA&amp;#xAE; patent was approximately 14 years and the remaining life related to the approved hormone therapy drug candidate patents was approximately 17 years.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In addition to numerous pending patent applications, as of March 31, 2016, we had sixteen issued patents, including:&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;twelve utility patents that relate to our combination progesterone and estradiol product candidates, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;two utility patents that relate to TX-004HR, our applicator-free vaginal estradiol softgel product candidate, which establish an important intellectual property foundation for TX-004HR, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2033. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;one utility patent that relates to a pipeline transdermal patch technology, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2032. We have pending patent application with respect to this patent in Australia, Brazil, Canada, Europe, Mexico, and Japan; and&lt;br /&gt;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;one utility patent that relates to our OPERA&amp;#xAE; information technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029.&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Subsequent to March 31, 2016, one additional patent was issued relating to our progesterone and estradiol product candidates.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Amortization expense was $11,234 and $6,691 for the three months ended March 31, 2016 and 2015, respectively. Estimated amortization expense for the next five years is as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Year Ending December 31,&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Estimated&lt;br /&gt; Amortization&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 75%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016 (9 months)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 20%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;33,701&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;44,934&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;44,934&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;44,934&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;44,934&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 10 &amp;#x2013; NET LOSS PER SHARE&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We calculate basic and diluted net loss per share allocable to common stockholders using the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of our Common Stock outstanding subject to repurchase or forfeiture for the three months ended March 31, 2016 and 2015.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Since we are in a net loss position, we have excluded outstanding stock options, all of which are subject to forfeiture, as well as warrants for the purchase of our Common Stock from our calculation of diluted net loss per share.&lt;/p&gt;&#13;&lt;p style="color: #252525; margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three months ended&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;20,569,655&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;17,586,109&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,281,059&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,002,431&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0; TOTAL&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;32,850,714&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,588,540&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2013-06-01to2013-06-30_custom_ConsultantMember" unitRef="Shares" decimals="INF">283333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2013-06-01to2013-06-30_custom_ConsultantMember" unitRef="USD" decimals="0">462196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <txmd:ExpectedToVestedWarrantsUponFdaApprovalShares contextRef="AsOf2016-03-31_custom_ConsultantMember" unitRef="Shares" decimals="INF">283334</txmd:ExpectedToVestedWarrantsUponFdaApprovalShares>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 13 &amp;#x2013; RELATED PARTIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In July 2015, J. Martin Carroll, a director of our Company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc in the normal course of business. Agreements with Catalent Inc. have been reviewed by independent directors of our Company or a committee consisting of independent directors of our Company since July 2015. During the three months ended March 31, 2016, we were billed by Catalent, Inc. $1,464,858 for manufacturing activities related to our clinical trials. As of March 31, 2016, there were amounts due to Catalent, Inc. of $59,275.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 16 &amp;#x2013; SUBSEQUENT EVENTS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On April 26, 2016, we entered into an agreement to lease additional administrative office space in Boca Raton, Florida, pursuant to an addendum to our existing 63 month non-cancelable operating lease. This addendum was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 6 &amp;#x2013; FIXED ASSETS, NET&lt;br /&gt;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Fixed assets consist of the following:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;156,502&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accounting system in process&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;205,712&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;149,699&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,566&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;69,454&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;425,780&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;351,303&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(161,074&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(152,711&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL FIXED ASSETS&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;264,706&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;198,592&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Depreciation expense for the three months ended March 31, 2016 and 2015 was $8,363 and $6,881, respectively.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 3 &amp;#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Our financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, &lt;i&gt;Fair Value Measurements. &lt;/i&gt;The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 7%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;&lt;td style="width: 3%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 80%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;unobservable inputs for the asset or liability.&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At March 31, 2016 and 2015, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company&amp;#x2019;s impairment test. There was no impairment of intangible assets or long-lived assets during the three months ended March 31, 2016 and 2015.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note 14. There are no major external customers for our OTC prenatal vitamin or other products.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;OTC Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin-bottom: 0; margin-top: 0; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Prescription Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and customer rebates.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We accept returns of unsalable prescription products from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015, we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Share-Based Compensation&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718 to value options. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, Equity - Based Payments to Non-Employees, or ASC 505. ASC 505 defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&amp;#x2019;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Research and Development Expenses&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="background-color: white; margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Research and development, or R&amp;#38;D, expenses include internal R&amp;#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities are capitalized, and were $1,005,503 at March 31, 2016, of which $941,054 was included in other current assets and $64,449 was included in long-term prepaid expense on the accompanying consolidated balance sheets. Advance payments to be expensed in future research and development activities were $1,138,073 at December 31, 2015, of which $1,009,175 was included in other current assets and $128,898 was included in long term prepaid expense on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&amp;#38;D expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding R&amp;#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Segment Reporting&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Research and Development Expenses&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="background-color: white; margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Research and development, or R&amp;#38;D, expenses include internal R&amp;#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities are capitalized, and were $1,005,503 at March 31, 2016, of which $941,054 was included in other current assets and $64,449 was included in long-term prepaid expense on the accompanying consolidated balance sheets. Advance payments to be expensed in future research and development activities were $1,138,073 at December 31, 2015, of which $1,009,175 was included in other current assets and $128,898 was included in long term prepaid expense on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&amp;#38;D expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding R&amp;#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 11 &amp;#x2013; STOCKHOLDERS&amp;#x2019; EQUITY&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Preferred Stock&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At March 31, 2016, we had 10,000,000 shares of Preferred Stock, par value $0.001, authorized for issuance, of which no shares of Preferred Stock were issued or outstanding.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Common Stock&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At March 31, 2016, we had 350,000,000 shares of Common Stock authorized, of which 196,253,700 shares of Common Stock were issued and outstanding.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On January&amp;#xA0;6, 2016, we entered into an underwriting agreement with Goldman Sachs &amp;#38; Co. and Cowen and Company, LLC, as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of our Common Stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $134.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on January&amp;#xA0;12, 2016 and we issued 17,424,242 shares of our Common Stock.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus&amp;#xA0;&amp;#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July&amp;#xA0;15, 2015 and we issued 4,423,077 shares of our Common Stock.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our Common Stock.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;During the three months ended March 31, 2016, certain individuals exercised stock options to purchase 340,045 shares of Common Stock for $786,450 in cash. During the three months ended March 31, 2015, a certain individual exercised stock options to purchase 11,250 shares of Common Stock for $7,208 in cash.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Warrants to Purchase Common Stock &lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;As of March 31, 2016, we had warrants outstanding to purchase an aggregate of 12,281,059 shares of Common Stock with a weighted-average contractual remaining life of 1.5 years, and exercise prices ranging from $0.24 to $7.59 per share, resulting in a weighted average exercise price of $1.97 per share.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The valuation methodology used to determine&#13;the fair value of our warrants is the Black-Scholes-Merton valuation model, or the Black-Scholes Model. The Black-Scholes Model&#13;requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term&#13;of the warrant. During the three months ended March 31, 2016, we granted warrants to purchase 120,000 shares of Common Stock to&#13;outside consultants at an exercise price of $7.59. The fair value for these shares was determined by using the Black-Scholes Model&#13;on the date of the vesting using a term of five years; volatility of 74.15%; risk free rate of 1.28%; and dividend yield of 0%.&#13;The grant date fair value of the warrants was $4.60 per share. The warrants vest ratably over a 12-month period and have an expiration&#13;date of January 21, 2021. During the three months ended March 31, 2015, we did not grant any warrants. During the three months&#13;ended March 31, 2016 and 2015, we recorded $127,465 and $9,071, respectively, as share based compensation expense in the accompanying&#13;consolidated financial statements related to vested warrants. As of March 31, 2016, unamortized costs associated with these warrants&#13;totaled approximately $449,000.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In May 2013, we entered into a consulting agreement to develop drug platforms to be used in our hormone replacement drug candidates. As consideration under the agreement, we agreed to issue the consultant a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share, that has vested or will vest as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Warrants to purchase 283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the agreement, the shares did not vest until June 30, 2013;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Warrants to purchase 283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During both the three months ended March 31, 2016 and 2015, we recorded $38,517 as share based compensation expense in the accompanying consolidated financial statements related to these warrants. As of March 31, 2016, there was a remaining balance of $38,509 related to these warrants which was included in other current assets in the accompanying consolidated financial statements;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;3.&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Warrants to purchase 283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate which the warrant holder helped us design. It is anticipated that this event will not occur before December 2016.&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0 0 8pt 0.5in; padding-top: 9pt; text-indent: -40pt; font: 10pt/107% Times New Roman, Times, Serif"&gt;&amp;#xA0; As of March 31, 2016, unamortized costs associated with these warrants and warrants issued to the same holder in 2012 totaled approximately $361,000.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;During the three months ended March 31, 2016, certain&#13;individuals exercised warrants to purchase 561,372 shares of our Common Stock for $1,310,000 in cash. During the three months&#13;ended March 31, 2015, an outside service provider exercised warrants to purchase 925,485 shares of our Common Stock&#13;for $358,400 in cash.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Options to Purchase Common Stock&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. As of March 31, 2016, there were non-qualified stock options to purchase 17,701,181 shares of Common Stock outstanding under the 2009 Plan. As of March 31, 2016, there were 3,423,477 shares available to be issued under 2009 Plan.&lt;/p&gt;&#13;&lt;p style="margin: 0 0 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of March 31, 2016, there were non-qualified stock options to purchase 2,868,474 shares of Common Stock outstanding under the 2012 Plan. As of March 31, 2016, there were 7,050,000 shares available to be issued under 2012 Plan.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model for options granted during the three months ended March 31, 2016 and 2015 are set forth in the table below.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three Months Ended&lt;br /&gt; March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Three Months Ended&lt;br /&gt; March 31, 2015&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.70&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.47&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;71.22&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;58.78-62.59&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.25&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.27-6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The expected term is based on the contractual terms of the stock option using the simplified method.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;A summary of activity under the 2009 and 2012 Plans and related information follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of Shares Underlying Stock Options&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted&lt;br /&gt; Average&lt;br /&gt; Exercise&lt;br /&gt; Price&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted Average Remaining Contractual Life in Years&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate&lt;br /&gt; Intrinsic&lt;br /&gt; Value&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; width: 44%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2015&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;20,725,325&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.28&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.5&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;146,864,184&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;185,500&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7.59&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(340,045&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.31&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,051,619&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Expired/Forfeited&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(1,125&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.59&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at March 31, 2016&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,569,655&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.34&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.3&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;71,940,245&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at March 31, 2016&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;15,988,578&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.17&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.5&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;69,261,183&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"&gt;Unvested at March 31, 2016&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,581,077&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7.42&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;9.2&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,679,062&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At March 31, 2016, our outstanding stock options had exercise prices ranging from $0.10 to $8.92 per share. The weighted average grant date fair value per share of options granted was $4.91 and $3.17 during the three months ended March 31, 2016 and 2015, respectively. Share-based compensation expense for options recognized in our results of operations for the three months ended March 31, 2016 and 2015 ($4,151,259 and $728,426, respectively) is based on vested awards. We estimate forfeitures at the time of grant and revise the forfeiture rate in subsequent periods if actual forfeitures differ from the estimates. At March 31, 2016, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $16,285,000 which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of 1.7 years. No tax benefit was realized due to a continued pattern of operating losses.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2016-01-01to2016-03-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 14 &amp;#x2013; BUSINESS CONCENTRATIONS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We purchase our products from several suppliers with approximately 95% of our purchases supplied from one vendor for both the three months ended March 31, 2016 and 2015.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the three months ended March 31, 2016, three customers each generated more than 10% of our total revenues and during the three months ended March 31, 2015 four customers each generated more than 10% of our total revenues. Revenue generated from three major customers accounted for approximately 61% of our recognized revenue for the three months ended March 31, 2016 and revenue generated from four customers accounted for approximately 70% of our recognized revenue for the three months ended March 31, 2015. Customers that generated more than 10% of our sales are designated as customers &amp;#x201C;A&amp;#x201D;, &amp;#x201C;B&amp;#x201D;, &amp;#x201C;C&amp;#x201D; and &amp;#x201C;D&amp;#x201D;. During the three months ended March 31, 2016, customers A, B and C generated $1,335,551, $1,104,344 and $680,096 in revenues, respectively. During the three months ended March 31, 2015 customers A, B, C and D generated $1,416,127, $626,731, $543,447 and $386,909 in sales, respectively.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">83527</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">79861</us-gaap:AccruedRentCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">224300</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">185441</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">46851</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">35773</us-gaap:AccruedRoyaltiesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">32659</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">76012</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">546264</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">312329</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">210309</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">413240</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">562096</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">623918</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">2108143</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">1396234</us-gaap:AccruedSalariesCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">3725377</txmd:AccruedClinicalTrialCostsCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2016-03-31" unitRef="USD" decimals="0">3042956</txmd:AccruedClinicalTrialCostsCurrent>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>txmd-20160331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20160331\txmd_033116.xfr; Date: 2016%2D05%2D04T21:54:35Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaaFWbP9w5dzSelBtm9zHTnqLysh40G0QyaUEirWAUsJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:txmd="http://therapeuticsmd.com/20160331" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20160331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Company" id="Company">
	  <link:definition>00000006 - Disclosure - THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" id="BasisOfPresentationAndRecentlyIssuedAccountingPronouncements">
	  <link:definition>00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Inventory" id="Inventory">
	  <link:definition>00000009 - Disclosure - INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
	  <link:definition>00000010 - Disclosure - OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" id="FixedAssetsNet">
	  <link:definition>00000011 - Disclosure - FIXED ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpense" id="PrepaidExpense">
	  <link:definition>00000012 - Disclosure - PREPAID EXPENSE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" id="IntangibleAssetsNet">
	  <link:definition>00000013 - Disclosure - INTANGIBLE ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000014 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShare" id="NetLossPerShare">
	  <link:definition>00000015 - Disclosure - NET LOSS PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000016 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000017 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000018 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" id="BusinessConcentrations">
	  <link:definition>00000019 - Disclosure - BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000021 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryTables" id="InventoryTables">
	  <link:definition>00000023 - Disclosure - INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
	  <link:definition>00000024 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" id="FixedAssetsNetTables">
	  <link:definition>00000025 - Disclosure - FIXED ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" id="PrepaidExpenseTables">
	  <link:definition>00000026 - Disclosure - PREPAID EXPENSE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" id="IntangibleAssetsNetTables">
	  <link:definition>00000027 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
	  <link:definition>00000029 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryDetails" id="InventoryDetails">
	  <link:definition>00000033 - Disclosure - INVENTORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" id="OtherCurrentAssetsDetails">
	  <link:definition>00000034 - Disclosure - OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" id="FixedAssetsNetDetailsNarrative">
	  <link:definition>00000035 - Disclosure - FIXED ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" id="FixedAssetsNetDetails">
	  <link:definition>00000036 - Disclosure - FIXED ASSETS, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" id="PrepaidExpenseDetails">
	  <link:definition>00000037 - Disclosure - PREPAID EXPENSE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" id="IntangibleAssetsNetDetailsNarrative">
	  <link:definition>00000038 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails" id="IntangibleAssetsNetDetails">
	  <link:definition>00000039 - Disclosure - INTANGIBLE ASSETS, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails1" id="IntangibleAssetsNetDetails1">
	  <link:definition>00000040 - Disclosure - INTANGIBLE ASSETS, NET (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
	  <link:definition>00000041 - Disclosure - OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" id="NetLossPerShareDetails">
	  <link:definition>00000042 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" id="StockholdersEquityDetailsNarrative1">
	  <link:definition>00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
	  <link:definition>00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
	  <link:definition>00000047 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" id="BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000048 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20160331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20160331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20160331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20160331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" name="ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidConsultingCurrent" name="PrepaidConsultingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchDevelopmentCostsNoncurrent" name="PrepaidResearchDevelopmentCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CapitalLeaseObligationsTerm" name="CapitalLeaseObligationsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchAndDevelopmentCostsCurrent" name="PrepaidResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidManufacturingCostsNoncurrent" name="PrepaidManufacturingCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatents" name="NumberOfIssuedPatents" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalPeriodForPurchaseShare" name="AdditionalPeriodForPurchaseShare" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" name="ReturnPeriodOfUnsalablePrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShelfLifeOfPrescriptionProducts" name="ShelfLifeOfPrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidVendorDeposits" name="PrepaidVendorDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidExpensesDisclosureTextBlock" name="PrepaidExpensesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ExpectedToVestedWarrantsUponFdaApprovalShares" name="ExpectedToVestedWarrantsUponFdaApprovalShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrantsMember" name="SancilioAndCompanyWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredRevenueConcentrationRiskMember" name="DeferredRevenueConcentrationRiskMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksForVitaminsSupplementsMember" name="MultipleTrademarksForVitaminsSupplementsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" name="ApprovedHormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk1Member" name="CustomerConcentrationRisk1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk2Member" name="CustomerConcentrationRisk2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk3Member" name="CustomerConcentrationRisk3Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk4Member" name="CustomerConcentrationRisk4Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CowenAndCompanyLLCMember" name="CowenAndCompanyLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StifelUnderwritersMember" name="StifelUnderwritersMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_GoldmanSachsMember" name="GoldmanSachsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OutsideConsultantMember" name="OutsideConsultantMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleAdvanceRevolvingCreditNoteMember" name="MultipleAdvanceRevolvingCreditNoteMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Patents1Member" name="Patents1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Patents2Member" name="Patents2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EntityCommonStockHeldByNonaffiliates" name="EntityCommonStockHeldByNonaffiliates" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" name="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidExpenseAbstract" name="PrepaidExpenseAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetLossPerShareAbstract" name="NetLossPerShareAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetLossPerShareTablesAbstract" name="NetLossPerShareTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CommitmentsAndContingenciesTablesAbstract" name="CommitmentsAndContingenciesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OtherCurrentAssetsAbstract" name="OtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAbstract" name="WarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" name="SummaryOfActivityUnder2009And2012PlansAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOptionsAbstract" name="NumberOptionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageExercisePriceAbstract" name="WeightedAverageExercisePriceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageRemainingContractualLifeAbstract" name="WeightedAverageRemainingContractualLifeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>txmd-20160331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20160331\txmd_033116.xfr; Date: 2016%2D05%2D04T21:54:35Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20160331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20160331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20160331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20160331.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20160331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20160331.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20160331.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20160331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20160331.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20160331.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20160331.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20160331.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:href="txmd-20160331.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20160331.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShare" xlink:href="txmd-20160331.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20160331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20160331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20160331.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20160331.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20160331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20160331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20160331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20160331.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20160331.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20160331.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20160331.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20160331.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:href="txmd-20160331.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20160331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20160331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20160331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20160331.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20160331.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20160331.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:href="txmd-20160331.xsd#FixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20160331.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails1" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20160331.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20160331.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20160331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20160331.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20160331.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20160331.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20160331.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20160331.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20160331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20160331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000006 - Disclosure - THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShare" xlink:title="00000015 - Disclosure - NET LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000023 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000024 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000025 - Disclosure - FIXED ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000026 - Disclosure - PREPAID EXPENSE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:title="00000027 - Disclosure - INTANGIBLE ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:title="00000029 - Disclosure - NET LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000033 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidVendorDeposits" xlink:label="loc_txmdPrepaidVendorDeposits" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidVendorDeposits" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000035 - Disclosure - FIXED ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:title="00000036 - Disclosure - FIXED ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000037 - Disclosure - PREPAID EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseNoncurrent" xlink:to="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="loc_txmdPrepaidManufacturingCostsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseNoncurrent" xlink:to="loc_txmdPrepaidManufacturingCostsNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000038 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails" xlink:title="00000039 - Disclosure - INTANGIBLE ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails1" xlink:title="00000040 - Disclosure - INTANGIBLE ASSETS, NET (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000041 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000042 - Disclosure - NET LOSS PER SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000047 - Disclosure - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000048 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
    </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>txmd-20160331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20160331\txmd_033116.xfr; Date: 2016%2D05%2D04T21:54:35Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20160331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20160331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20160331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20160331.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20160331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20160331.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20160331.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20160331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20160331.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20160331.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20160331.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20160331.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:href="txmd-20160331.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20160331.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShare" xlink:href="txmd-20160331.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20160331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20160331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20160331.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20160331.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20160331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20160331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20160331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20160331.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20160331.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20160331.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20160331.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20160331.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:href="txmd-20160331.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20160331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20160331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20160331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20160331.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20160331.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20160331.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:href="txmd-20160331.xsd#FixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20160331.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails1" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20160331.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20160331.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20160331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20160331.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20160331.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20160331.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20160331.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20160331.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20160331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20160331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000006 - Disclosure - THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShare" xlink:title="00000015 - Disclosure - NET LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000023 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000024 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000025 - Disclosure - FIXED ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000026 - Disclosure - PREPAID EXPENSE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:title="00000027 - Disclosure - INTANGIBLE ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:title="00000029 - Disclosure - NET LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsCurrent_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseOtherNoncurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseOtherNoncurrent_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000033 - Disclosure - INVENTORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000035 - Disclosure - FIXED ASSETS, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:title="00000036 - Disclosure - FIXED ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000037 - Disclosure - PREPAID EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000038 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_Patents1Member" xlink:label="loc_txmdPatents1Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents1Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_Patents2Member" xlink:label="loc_txmdPatents2Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents2Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfIssuedPatents_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails" xlink:title="00000039 - Disclosure - INTANGIBLE ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails1" xlink:title="00000040 - Disclosure - INTANGIBLE ASSETS, NET (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000041 - Disclosure - OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000042 - Disclosure - NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_StifelUnderwritersMember" xlink:label="loc_txmdStifelUnderwritersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdStifelUnderwritersMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="loc_txmdCowenAndCompanyLLCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdCowenAndCompanyLLCMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdGoldmanSachsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapOptionMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_190" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_OutsideConsultantMember" xlink:label="loc_txmdOutsideConsultantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ConsultantMember" xlink:label="loc_txmdConsultantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdConsultantMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapShareBasedCompensation_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsNoncurrentNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapDeferredFinanceCostsNoncurrentNet_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_170" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_170" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ExpectedToVestedWarrantsUponFdaApprovalShares" xlink:label="loc_txmdExpectedToVestedWarrantsUponFdaApprovalShares_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_txmdExpectedToVestedWarrantsUponFdaApprovalShares_170" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_170" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_170" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_170" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_170" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NumberOptionsAbstract" xlink:label="loc_txmdNumberOptionsAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOptionsAbstract_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_txmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_txmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_30" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000047 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000048 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="loc_txmdCustomerConcentrationRisk1Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk1Member_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmdCustomerConcentrationRisk2Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk2Member_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmdCustomerConcentrationRisk3Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk3Member_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmdCustomerConcentrationRisk4Member_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk4Member_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet_150" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>txmd-20160331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20160331\txmd_033116.xfr; Date: 2016%2D05%2D04T21:54:35Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="txmd_SancilioAndCompanyWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrantsMember_lbl" xml:lang="en-US">SCI - Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ConsultantMember" xlink:label="txmd_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ConsultantMember" xlink:to="txmd_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ConsultantMember_lbl" xml:lang="en-US">Consultant Agreement - Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_DeferredRevenueConcentrationRiskMember" xlink:label="txmd_DeferredRevenueConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredRevenueConcentrationRiskMember" xlink:to="txmd_DeferredRevenueConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredRevenueConcentrationRiskMember_lbl" xml:lang="en-US">Deferred revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US">Catalent Inc.[Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">OPERA software patent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="us-gaap_InternetDomainNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternetDomainNamesMember" xlink:to="us-gaap_InternetDomainNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternetDomainNamesMember_lbl" xml:lang="en-US">Development costs for corporate website [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone therapy drug candidate patents - (pending) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xml:lang="en-US">Multiple trademarks for vitamins/supplements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="txmd_CustomerConcentrationRisk1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk1Member" xlink:to="txmd_CustomerConcentrationRisk1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk1Member_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="txmd_CustomerConcentrationRisk2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk2Member" xlink:to="txmd_CustomerConcentrationRisk2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk2Member_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="txmd_CustomerConcentrationRisk3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk3Member" xlink:to="txmd_CustomerConcentrationRisk3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk3Member_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="txmd_CustomerConcentrationRisk4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk4Member" xlink:to="txmd_CustomerConcentrationRisk4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk4Member_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="us-gaap_WeightedAverageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageMember" xlink:to="us-gaap_WeightedAverageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageMember_lbl" xml:lang="en-US">Weighted Average [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="txmd_CowenAndCompanyLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CowenAndCompanyLLCMember" xlink:to="txmd_CowenAndCompanyLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CowenAndCompanyLLCMember_lbl" xml:lang="en-US">Cowen and Company, LLC (Underwriters) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options exercised [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_StifelUnderwritersMember" xlink:label="txmd_StifelUnderwritersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelUnderwritersMember" xlink:to="txmd_StifelUnderwritersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StifelUnderwritersMember_lbl" xml:lang="en-US">Stifel Underwriters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_GoldmanSachsMember" xlink:label="txmd_GoldmanSachsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_GoldmanSachsMember_lbl" xml:lang="en-US">Underwriting Agreement - Goldman And Cowen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_OutsideConsultantMember" xlink:label="txmd_OutsideConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultantMember" xlink:to="txmd_OutsideConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OutsideConsultantMember_lbl" xml:lang="en-US">Outside Consultant Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:to="txmd_MultipleAdvanceRevolvingCreditNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember_lbl" xml:lang="en-US">Multiple Advance Revolving Credit Note (Plato Warrant) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Accounting System in Process [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Utility Patent TX-004HR [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_Patents1Member" xlink:label="txmd_Patents1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents1Member" xlink:to="txmd_Patents1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Patents1Member_lbl" xml:lang="en-US">Utility Patent Progesterone and Estradiol Products [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US">Related to Research and Development Activities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_Patents2Member" xlink:label="txmd_Patents2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents2Member" xlink:to="txmd_Patents2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Patents2Member_lbl" xml:lang="en-US">Utility Patent Pipeline Transdermal Patch Technology [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long-term Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="txmd_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DocumentAndEntityInformationAbstract" xlink:to="txmd_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity a Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity a Voluntary Filer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity's Reporting Status Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xml:lang="en-US">Entity Common Stock, Shares held by Nonaffiliates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $318,061 and $81,910, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 15)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 350,000,000 and 250,000,000 shares authorized; 196,253,700 and 177,928,041 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Revenues, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="us-gaap_OtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAbstract_lbl" xml:lang="en-US">Other income:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Accreted Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Loss per share, basic and diluted:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Other long-term liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash flows used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash flows provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:to="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_lbl" xml:lang="en-US">Basis Of Presentation And Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsAbstract_2_lbl" xml:lang="en-US">Other Assets [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">FIXED ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidExpenseAbstract" xlink:label="txmd_PrepaidExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpenseAbstract" xlink:to="txmd_PrepaidExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidExpenseAbstract_lbl" xml:lang="en-US">Prepaid Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidExpensesDisclosureTextBlock" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpensesDisclosureTextBlock" xlink:to="txmd_PrepaidExpensesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NetLossPerShareAbstract" xlink:label="txmd_NetLossPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetLossPerShareAbstract" xlink:to="txmd_NetLossPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetLossPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpenseAbstract" xlink:to="txmd_PrepaidExpenseAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_PrepaidExpenseAbstract_2_lbl" xml:lang="en-US">Prepaid Expense Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NetLossPerShareTablesAbstract" xlink:label="txmd_NetLossPerShareTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetLossPerShareTablesAbstract" xlink:to="txmd_NetLossPerShareTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetLossPerShareTablesAbstract_lbl" xml:lang="en-US">Net Loss Per Share Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of potentially dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used in the Black-Scholes Model of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of plan activity</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CommitmentsAndContingenciesTablesAbstract" xlink:label="txmd_CommitmentsAndContingenciesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CommitmentsAndContingenciesTablesAbstract" xlink:to="txmd_CommitmentsAndContingenciesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CommitmentsAndContingenciesTablesAbstract_lbl" xml:lang="en-US">Commitments And Contingencies Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum rental payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Advance payments - total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Advance payments - other assets current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" xml:lang="en-US">Advance payments - long term prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in offerings, net of cost, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xml:lang="en-US">Return period of unsalable prescription products</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="txmd_ShelfLifeOfPrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_lbl" xml:lang="en-US">Shelf life of prescription products</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished product</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw material</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">TOTAL INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="txmd_OtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtherCurrentAssetsAbstract" xlink:to="txmd_OtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidConsultingCurrent" xlink:label="txmd_PrepaidConsultingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidConsultingCurrent_lbl" xml:lang="en-US">Prepaid consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xml:lang="en-US">Prepaid research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidVendorDeposits" xlink:label="txmd_PrepaidVendorDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidVendorDeposits" xlink:to="txmd_PrepaidVendorDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidVendorDeposits_lbl" xml:lang="en-US">Prepaid vendor deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Fixed assets, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">TOTAL FIXED ASSETS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpenseAbstract" xlink:to="txmd_PrepaidExpenseAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="txmd_PrepaidExpenseAbstract_3_lbl" xml:lang="en-US">Prepaid Expense Details</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsNoncurrent" xlink:to="txmd_PrepaidManufacturingCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent_lbl" xml:lang="en-US">Prepaid manufacturing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_lbl" xml:lang="en-US">Prepaid research and development costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xml:lang="en-US">TOTAL PREPAID EXPENSE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NumberOfIssuedPatents" xlink:label="txmd_NumberOfIssuedPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatents_lbl" xml:lang="en-US">Number of issued patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Weighted average remaining amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Estimated amortization expense for the year:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2016 (9 months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="txmd_AccruedClinicalTrialCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US">Accrued clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll, bonuses and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued compensated absences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Allowance for wholesale distributor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US">Accrued rent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares excluded from earnings per share calculation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued during the period (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Additional common stock issued under offering (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of common stock issued during period for stock options exercised (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Value of common stock issued during period for stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="txmd_AdditionalPeriodForPurchaseShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalPeriodForPurchaseShare_lbl" xml:lang="en-US">Number of days of the option to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise price of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Sharebased compensation - stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized estimated compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Recognized period for recognition - stock option compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of shares available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WarrantsAbstract" xlink:label="txmd_WarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAbstract" xlink:to="txmd_WarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAbstract_lbl" xml:lang="en-US">Warrants:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value of grant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xml:lang="en-US">Warrants granted to purchase common stock (shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Sharebased compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value (per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US">Unamortized costs of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares upon warrant exercise (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xml:lang="en-US">Expiration date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested warrants granted to purchase common stock (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ExpectedToVestedWarrantsUponFdaApprovalShares" xlink:label="txmd_ExpectedToVestedWarrantsUponFdaApprovalShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpectedToVestedWarrantsUponFdaApprovalShares" xlink:to="txmd_ExpectedToVestedWarrantsUponFdaApprovalShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ExpectedToVestedWarrantsUponFdaApprovalShares_lbl" xml:lang="en-US">Expected to vested warrants upon FDA approval (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unamortized noncash compensation associated with warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock issued for excercised warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Stock issued for excercised warrants, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:to="txmd_SummaryOfActivityUnder2009And2012PlansAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SummaryOfActivityUnder2009And2012PlansAbstract_lbl" xml:lang="en-US">Summary of Activity under 2009 and 2012 Plans:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NumberOptionsAbstract" xlink:label="txmd_NumberOptionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOptionsAbstract" xlink:to="txmd_NumberOptionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOptionsAbstract_lbl" xml:lang="en-US">Number Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Options Expired/Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="txmd_WeightedAverageExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageExercisePriceAbstract" xlink:to="txmd_WeightedAverageExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired/Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:to="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:to="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="txmd_AggregateIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AggregateIntrinsicValueAbstract" xlink:to="txmd_AggregateIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Options exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Manufacturing activities billed from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNet_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="txmd_CapitalLeaseObligationsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CapitalLeaseObligationsTerm_lbl" xml:lang="en-US">Non-cancelable operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rental Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xml:lang="en-US">Future minimum rental payments, year ending December 31,</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2016 (9 months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalPeriodForPurchaseShare_doc" xml:lang="en-US">Refers to additonal period for purchase of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CapitalLeaseObligationsTerm_doc" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are expired in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CowenAndCompanyLLCMember" xlink:to="txmd_CowenAndCompanyLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CowenAndCompanyLLCMember_doc" xml:lang="en-US">Refers to cowen and company llc member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk1Member" xlink:to="txmd_CustomerConcentrationRisk1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk1Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk2Member" xlink:to="txmd_CustomerConcentrationRisk2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk2Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk3Member" xlink:to="txmd_CustomerConcentrationRisk3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk3Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk4Member" xlink:to="txmd_CustomerConcentrationRisk4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk4Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredRevenueConcentrationRiskMember" xlink:to="txmd_DeferredRevenueConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredRevenueConcentrationRiskMember_doc" xml:lang="en-US">Deferred Revenue Concentration Risk Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_doc" xml:lang="en-US">Indicates the number pf common stock held by non-affiliates of the registrant as stated on cover of related periodic report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_GoldmanSachsMember_doc" xml:lang="en-US">Goldman Sachs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xml:lang="en-US">Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:to="txmd_MultipleAdvanceRevolvingCreditNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember_doc" xml:lang="en-US">Multiple Advance Revolving Credit Note Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xml:lang="en-US">Multiple Trademarks For Vitamins Supplements Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatents_doc" xml:lang="en-US">Number of issued patents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultantMember" xlink:to="txmd_OutsideConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OutsideConsultantMember_doc" xml:lang="en-US">Outside consultant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents1Member" xlink:to="txmd_Patents1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Patents1Member_doc" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidConsultingCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpensesDisclosureTextBlock" xlink:to="txmd_PrepaidExpensesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock_doc" xml:lang="en-US">Disclosure of prepaid expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsNoncurrent" xlink:to="txmd_PrepaidManufacturingCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of manufacturing contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; non-current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidVendorDeposits" xlink:to="txmd_PrepaidVendorDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidVendorDeposits_doc" xml:lang="en-US">It represents as a prepaid vendor deposits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xml:lang="en-US">Period the company accepts returns of unsalable prescription products from customers following product expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrantsMember_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:to="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_doc" xml:lang="en-US">Period shelf life of prescription products from date of manufacture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelUnderwritersMember" xlink:to="txmd_StifelUnderwritersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StifelUnderwritersMember_doc" xml:lang="en-US">Stifel Underwriters</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents2Member" xlink:to="txmd_Patents2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Patents2Member_doc" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ConsultantMember" xlink:to="txmd_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ConsultantMember_doc" xml:lang="en-US">A person who provides professional services to the Company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ExpectedToVestedWarrantsUponFdaApprovalShares" xlink:to="txmd_ExpectedToVestedWarrantsUponFdaApprovalShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ExpectedToVestedWarrantsUponFdaApprovalShares_doc" xml:lang="en-US">The number of shares expected to vest upon receiving FDA apporval.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire unvested shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_2_lbl" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_3_lbl" xml:lang="en-US">PrepaidResearchDevelopmentCostsNoncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>txmd-20160331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.13b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20160331\txmd_033116.xfr; Date: 2016%2D05%2D04T21:54:35Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20160331.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20160331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20160331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20160331.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20160331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20160331.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20160331.xsd#BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20160331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20160331.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20160331.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20160331.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20160331.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:href="txmd-20160331.xsd#IntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20160331.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShare" xlink:href="txmd-20160331.xsd#NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20160331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20160331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20160331.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20160331.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20160331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20160331.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20160331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20160331.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20160331.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20160331.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20160331.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20160331.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:href="txmd-20160331.xsd#NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20160331.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20160331.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20160331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20160331.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20160331.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20160331.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:href="txmd-20160331.xsd#FixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20160331.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails1" xlink:href="txmd-20160331.xsd#IntangibleAssetsNetDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20160331.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:href="txmd-20160331.xsd#NetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20160331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20160331.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20160331.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20160331.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20160331.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20160331.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20160331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20160331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="loc_txmdDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="loc_txmdEntityCommonStockHeldByNonaffiliates" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_txmdEntityCommonStockHeldByNonaffiliates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaapOtherIncomeAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOtherIncomeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000006 - Disclosure - THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS">
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:label="loc_txmdBasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaapBasisOfAccounting" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdBasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:to="loc_us-gaapBasisOfAccounting" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE">
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidExpenseAbstract" xlink:label="loc_txmdPrepaidExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidExpensesDisclosureTextBlock" xlink:label="loc_txmdPrepaidExpensesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdPrepaidExpenseAbstract" xlink:to="loc_txmdPrepaidExpensesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNet" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShare" xlink:title="00000015 - Disclosure - NET LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NetLossPerShareAbstract" xlink:label="loc_txmdNetLossPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNetLossPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000023 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000024 - Disclosure - OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000025 - Disclosure - FIXED ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000026 - Disclosure - PREPAID EXPENSE (Tables)">
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidExpenseAbstract" xlink:label="loc_txmdPrepaidExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdPrepaidExpenseAbstract" xlink:to="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetTables" xlink:title="00000027 - Disclosure - INTANGIBLE ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareTables" xlink:title="00000029 - Disclosure - NET LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NetLossPerShareTablesAbstract" xlink:label="loc_txmdNetLossPerShareTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNetLossPerShareTablesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CommitmentsAndContingenciesTablesAbstract" xlink:label="loc_txmdCommitmentsAndContingenciesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdCommitmentsAndContingenciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseOtherNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseOtherNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000033 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaapInventoryNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNetAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000034 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="loc_txmdOtherCurrentAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdOtherCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidVendorDeposits" xlink:label="loc_txmdPrepaidVendorDeposits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidVendorDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000035 - Disclosure - FIXED ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:title="00000036 - Disclosure - FIXED ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000037 - Disclosure - PREPAID EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidExpenseAbstract" xlink:label="loc_txmdPrepaidExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="loc_txmdPrepaidManufacturingCostsNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdPrepaidExpenseAbstract" xlink:to="loc_txmdPrepaidManufacturingCostsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdPrepaidExpenseAbstract" xlink:to="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdPrepaidExpenseAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative" xlink:title="00000038 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_Patents1Member" xlink:label="loc_txmdPatents1Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_Patents2Member" xlink:label="loc_txmdPatents2Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfIssuedPatents" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails" xlink:title="00000039 - Disclosure - INTANGIBLE ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsNetDetails1" xlink:title="00000040 - Disclosure - INTANGIBLE ASSETS, NET (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000041 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NetLossPerShareDetails" xlink:title="00000042 - Disclosure - NET LOSS PER SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaapCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCounterpartyNameAxis" xlink:to="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_StifelUnderwritersMember" xlink:label="loc_txmdStifelUnderwritersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdStifelUnderwritersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="loc_txmdCowenAndCompanyLLCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdCowenAndCompanyLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_txmdGoldmanSachsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockOptionPlanExpense" xlink:label="loc_us-gaapStockOptionPlanExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockOptionPlanExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_OutsideConsultantMember" xlink:label="loc_txmdOutsideConsultantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ConsultantMember" xlink:label="loc_txmdConsultantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsNoncurrentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsNoncurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ExpectedToVestedWarrantsUponFdaApprovalShares" xlink:label="loc_txmdExpectedToVestedWarrantsUponFdaApprovalShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdExpectedToVestedWarrantsUponFdaApprovalShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_NumberOptionsAbstract" xlink:label="loc_txmdNumberOptionsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOptionsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_txmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000047 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000048 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="loc_txmdCustomerConcentrationRisk1Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmdCustomerConcentrationRisk2Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmdCustomerConcentrationRisk3Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmdCustomerConcentrationRisk4Member" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20160331.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdCapitalLeaseObligationsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6783315760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>May. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TherapeuticsMD, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity a Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity a Voluntary Filer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity's Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,263,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6786389600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 182,097,345<span></span>
</td>
<td class="nump">$ 64,706,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $318,061 and $81,910, respectively</a></td>
<td class="nump">5,063,773<span></span>
</td>
<td class="nump">3,049,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">957,434<span></span>
</td>
<td class="nump">690,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,718,069<span></span>
</td>
<td class="nump">2,233,897<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">189,836,621<span></span>
</td>
<td class="nump">70,680,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">264,706<span></span>
</td>
<td class="nump">198,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,694,546<span></span>
</td>
<td class="nump">1,615,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expense</a></td>
<td class="nump">1,047,970<span></span>
</td>
<td class="nump">1,109,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">2,867,516<span></span>
</td>
<td class="nump">2,850,134<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">192,968,843<span></span>
</td>
<td class="nump">73,728,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,430,649<span></span>
</td>
<td class="nump">3,126,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">6,165,764<span></span>
</td>
<td class="nump">7,539,526<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">$ 9,596,413<span></span>
</td>
<td class="nump">$ 10,665,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 15)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 350,000,000 and 250,000,000 shares authorized; 196,253,700 and 177,928,041 issued and outstanding, respectively</a></td>
<td class="nump">$ 196,254<span></span>
</td>
<td class="nump">$ 177,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">423,932,401<span></span>
</td>
<td class="nump">282,712,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(240,756,225)<span></span>
</td>
<td class="num">(219,826,860)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">183,372,430<span></span>
</td>
<td class="nump">63,063,146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 192,968,843<span></span>
</td>
<td class="nump">$ 73,728,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6783403248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 318,061<span></span>
</td>
<td class="nump">$ 81,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">196,253,700<span></span>
</td>
<td class="nump">177,928,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6789153696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues, net</a></td>
<td class="nump">$ 4,930,091<span></span>
</td>
<td class="nump">$ 4,475,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">1,108,443<span></span>
</td>
<td class="nump">1,043,641<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">3,821,648<span></span>
</td>
<td class="nump">3,431,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administrative</a></td>
<td class="nump">9,678,552<span></span>
</td>
<td class="nump">6,163,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">15,097,017<span></span>
</td>
<td class="nump">18,176,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">19,597<span></span>
</td>
<td class="nump">13,572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">24,795,166<span></span>
</td>
<td class="nump">24,354,019<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(20,973,518)<span></span>
</td>
<td class="num">(20,922,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">41,617<span></span>
</td>
<td class="nump">18,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Accreted Interest</a></td>
<td class="nump">2,536<span></span>
</td>
<td class="nump">9,842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">44,153<span></span>
</td>
<td class="nump">28,355<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(20,929,365)<span></span>
</td>
<td class="num">(20,894,256)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,929,365)<span></span>
</td>
<td class="num">$ (20,894,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">194,901,560<span></span>
</td>
<td class="nump">163,448,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6783593104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,929,365)<span></span>
</td>
<td class="num">$ (20,894,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">8,363<span></span>
</td>
<td class="nump">6,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">11,234<span></span>
</td>
<td class="nump">6,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">236,151<span></span>
</td>
<td class="nump">13,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4,381,690<span></span>
</td>
<td class="nump">840,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,250,209)<span></span>
</td>
<td class="num">(502,836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(267,281)<span></span>
</td>
<td class="nump">222,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">477,312<span></span>
</td>
<td class="nump">91,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(2,536)<span></span>
</td>
<td class="num">(9,842)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">304,475<span></span>
</td>
<td class="num">(91,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(522,613)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(1,373,762)<span></span>
</td>
<td class="nump">1,038,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,567<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(19,403,928)<span></span>
</td>
<td class="num">(19,149,736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(90,529)<span></span>
</td>
<td class="num">(36,853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(74,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(165,007)<span></span>
</td>
<td class="num">(36,853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="nump">134,863,475<span></span>
</td>
<td class="nump">59,117,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">786,450<span></span>
</td>
<td class="nump">7,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">1,310,000<span></span>
</td>
<td class="nump">358,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">136,959,925<span></span>
</td>
<td class="nump">59,483,435<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Increase (decrease) in cash</a></td>
<td class="nump">117,390,990<span></span>
</td>
<td class="nump">40,296,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
<td class="nump">64,706,355<span></span>
</td>
<td class="nump">51,361,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
<td class="nump">$ 182,097,345<span></span>
</td>
<td class="nump">$ 91,658,453<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6584134240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">THE COMPANY</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 1 &#x2013; THE COMPANY</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &#x201C;our company,&#x201D; &#x201C;we,&#x201D; &#x201C;our,&#x201D; or &#x201C;us.&#x201D;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Nature of Business</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We are a women&#x2019;s health care product company focused on creating and commercializing products targeted exclusively for women. As of the date of these unaudited consolidated financial statements, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6770805392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract', window );"><strong>Basis Of Presentation And Recently Issued Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b><u>NOTE
2 &#x2013; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</u></b></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><u>Interim
Financial Statements</u></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">The
accompanying unaudited interim consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries,
should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report
on Form 10-K for the year ended December 31, 2015, as filed with the Securities and Exchange Commission, or the SEC, from which
we derived the accompanying consolidated balance sheet as of December 31, 2015. The accompanying unaudited interim consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America,
or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly,
since they are interim statements, the accompanying unaudited interim consolidated financial statements do not include all of
the information and notes required by GAAP for complete financial statements. The accompanying unaudited interim consolidated
financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management,
necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative
of results for a full year or any other interim period in the future.</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><u>Recently
Issued Accounting Pronouncements</u></font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">In
March 2016, the Financial Accounting Standards Board, or FASB, issued ASU 2016-09, Compensation &#x2013; Stock Compensation: Improvements
to Employee Share-Based Payment Accounting. This guidance simplifies several aspects of the accounting for employee share-based
payment transactions for both public and nonpublic entities, including the accounting for income taxes, forfeitures, and statutory
tax withholding requirements, as well as classification in the statement of cash flows. The guidance is effective for our company
for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted
in any annual or interim period for which financial statements have not been issued or made available for issuance, but all of
the guidance must be adopted in the same period. If an entity early adopts the guidance in an interim period, any adjustments
must be reflected as of the beginning of the fiscal year that includes that interim period. We are currently evaluating the impact
of this guidance on our consolidated financial statements and disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">In
February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets
but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current
real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting
for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning
after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. We are currently
evaluating the impact of this guidance on our consolidated financial statements and disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">In
July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), simplifying the Measurement of Inventory. This guidance requires
entities to measure inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM).
The guidance applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail
inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does not
change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM guidance.
Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion,
disposal and transportation. Under the new guidance, however, entities will no longer need to calculate other measures of &#x201C;market.&#x201D;
The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods
within those fiscal years. Early adoption is permitted. We are currently evaluating the impact of this guidance, if any, on our
consolidated financial statements and disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">In
August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure
of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate
whether there are conditions and events that raise substantial doubt about the entity&#x2019;s ability to continue as a going
concern within one year after the financial statements are issued (or available to be issued when applicable) and, if so, disclose
that fact. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods within annual periods
beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial
statements have not previously been issued. We do not expect the adoption of ASU 2014-15 to have a material effect on our consolidated
financial statements and disclosures.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with
Customers (Topic 606). The standard&#x2019;s core principle is that a company will recognize revenue when it transfers promised
goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange
for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous
guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration
to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015,
the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after
December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15,
2017 and interim periods therein. In 2016, the FASB issued final amendments to clarify the implementation guidance for principal
versus agent considerations (ASU 2016-08) as well as accounting for licenses of intellectual property and identifying performance
obligations in its new revenue standard (ASU 2016-10). We are currently evaluating the impact of this guidance on our consolidated
financial statements and disclosures.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">We
do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently
issued, but not yet effective, accounting standards been adopted in the current period.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779172288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 3 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Fair Value of Financial Instruments</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Our financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, <i>Fair Value Measurements. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
<td style="width: 10%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 7%; font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 80%; text-align: justify; font: 10pt Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or liabilities;</td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">unobservable inputs for the asset or liability.</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At March 31, 2016 and 2015, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company&#x2019;s impairment test. There was no impairment of intangible assets or long-lived assets during the three months ended March 31, 2016 and 2015.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Revenue Recognition</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note 14. There are no major external customers for our OTC prenatal vitamin or other products.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i><u>OTC Products</u></i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin-bottom: 0; margin-top: 0; text-align: left; font: 10pt Times New Roman, Times, Serif"><i><u>Prescription Products</u></i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and customer rebates.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We accept returns of unsalable prescription products from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015, we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Share-Based Compensation</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718 to value options. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, Equity - Based Payments to Non-Employees, or ASC 505. ASC 505 defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Research and Development Expenses</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="background-color: white; margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Research and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities are capitalized, and were $1,005,503 at March 31, 2016, of which $941,054 was included in other current assets and $64,449 was included in long-term prepaid expense on the accompanying consolidated balance sheets. Advance payments to be expensed in future research and development activities were $1,138,073 at December 31, 2015, of which $1,009,175 was included in other current assets and $128,898 was included in long term prepaid expense on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&#38;D expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Segment Reporting</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6770491248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 4 &#x2013; INVENTORY</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Inventory consists of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Finished product</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">907,510</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">661,167</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Raw material</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">49,924</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28,986</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">TOTAL INVENTORY</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">957,434</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">690,153</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779197920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 5 &#x2013; OTHER CURRENT ASSETS</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Other current assets consist of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid consulting</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">296,305</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">334,822</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid insurance</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">438,420</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">695,421</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">644,749</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">674,353</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid vendor deposits</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">107,300</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">159,489</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Other prepaid costs</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">231,295</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">369,812</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT ASSETS</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,718,069</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,233,897</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6584134240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS, NET</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 6 &#x2013; FIXED ASSETS, NET<br /></u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Fixed assets consist of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Equipment</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">156,502</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">132,150</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accounting system in process</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">205,712</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">149,699</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">63,566</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">69,454</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">425,780</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">351,303</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accumulated depreciation</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(161,074</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(152,711</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">TOTAL FIXED ASSETS</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">264,706</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">198,592</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Depreciation expense for the three months ended March 31, 2016 and 2015 was $8,363 and $6,881, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779172288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidExpenseAbstract', window );"><strong>Prepaid Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidExpensesDisclosureTextBlock', window );">PREPAID EXPENSE</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 7 &#x2013; PREPAID EXPENSE</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Prepaid expense consists of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid manufacturing costs</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">983,521</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">980,985</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">64,449</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">128,898</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">TOTAL PREPAID EXPENSE</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,047,970</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,109,883</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidExpensesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidExpensesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779152736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS, NET</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 8 &#x2013; INTANGIBLE ASSETS, NET<br /></u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2016 and December 31, 2015:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Gross<br /> Carrying<br /> Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Accumulated Amortization</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- Average Remaining Amortization Period (yrs.)</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; width: 46%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#xAE; </sup>software patent</font></td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(4,993</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">26,958</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">13.5</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">779,777</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(60,579</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif"></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">719,198</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">16.75</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents&#xA0;(pending)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">787,149</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">787,149</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">n/a</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Non-amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">161,241</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">161,241</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Total</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,851,861</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(157,315</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,694,546</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Gross<br /> Carrying Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Accumulated Amortization</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- Average Remaining Amortization Period (yrs.)</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; width: 46%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#xAE; </sup>software patent</font></td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(4,493</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif">27,458</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif">13.75</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">705,752</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(49,845</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">655,907</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">17</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">774,165</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">774,165</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Non-amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">157,721</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">157,721</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Total</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,761,332</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(146,081</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,615,251</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately 20 years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. As of March 31, 2016, the remaining life related to OPERA&#xAE; patent was approximately 14 years and the remaining life related to the approved hormone therapy drug candidate patents was approximately 17 years.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In addition to numerous pending patent applications, as of March 31, 2016, we had sixteen issued patents, including:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#xB7;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">twelve utility patents that relate to our combination progesterone and estradiol product candidates, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#xB7;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">two utility patents that relate to TX-004HR, our applicator-free vaginal estradiol softgel product candidate, which establish an important intellectual property foundation for TX-004HR, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2033. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#xB7;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">one utility patent that relates to a pipeline transdermal patch technology, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2032. We have pending patent application with respect to this patent in Australia, Brazil, Canada, Europe, Mexico, and Japan; and<br /></font></td>
</tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#xB7;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">one utility patent that relates to our OPERA&#xAE; information technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029.</font></td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Subsequent to March 31, 2016, one additional patent was issued relating to our progesterone and estradiol product candidates.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Amortization expense was $11,234 and $6,691 for the three months ended March 31, 2016 and 2015, respectively. Estimated amortization expense for the next five years is as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Year Ending December 31,</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Estimated<br /> Amortization</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="width: 75%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2016 (9 months)</font></td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 20%; text-align: right; font: 10pt Times New Roman, Times, Serif">33,701</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2017</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">44,934</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">44,934</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2019</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">44,934</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2020</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">44,934</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779193872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 9 &#x2013; OTHER CURRENT LIABILITIES</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Other current liabilities consist of the following:</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued clinical trial costs</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">3,042,956</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">3,725,377</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued payroll, bonuses and commission costs</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,396,234</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,108,143</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued compensated absences</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">623,918</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">562,096</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued legal and accounting expense</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">413,240</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">210,309</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Other accrued expenses</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">312,329</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">546,264</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Allowance for wholesale distributor fees</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,012</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">32,659</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued royalties</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">35,773</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">46,851</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Allowance for coupons and returns</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">185,441</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">224,300</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued rent</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">79,861</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">83,527</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT LIABILITIES</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,165,764</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,539,526</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779128992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetLossPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 10 &#x2013; NET LOSS PER SHARE</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We calculate basic and diluted net loss per share allocable to common stockholders using the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of our Common Stock outstanding subject to repurchase or forfeiture for the three months ended March 31, 2016 and 2015.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Since we are in a net loss position, we have excluded outstanding stock options, all of which are subject to forfeiture, as well as warrants for the purchase of our Common Stock from our calculation of diluted net loss per share.</p>
<p style="color: #252525; margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three months ended</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Stock options</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">20,569,655</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">17,586,109</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Warrants</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,281,059</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,002,431</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0; TOTAL</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,850,714</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,588,540</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779174352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 11 &#x2013; STOCKHOLDERS&#x2019; EQUITY</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Preferred Stock</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At March 31, 2016, we had 10,000,000 shares of Preferred Stock, par value $0.001, authorized for issuance, of which no shares of Preferred Stock were issued or outstanding.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Common Stock</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At March 31, 2016, we had 350,000,000 shares of Common Stock authorized, of which 196,253,700 shares of Common Stock were issued and outstanding.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On January&#xA0;6, 2016, we entered into an underwriting agreement with Goldman Sachs &#38; Co. and Cowen and Company, LLC, as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of our Common Stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $134.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on January&#xA0;12, 2016 and we issued 17,424,242 shares of our Common Stock.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus&#xA0;&#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July&#xA0;15, 2015 and we issued 4,423,077 shares of our Common Stock.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our Common Stock.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the three months ended March 31, 2016, certain individuals exercised stock options to purchase 340,045 shares of Common Stock for $786,450 in cash. During the three months ended March 31, 2015, a certain individual exercised stock options to purchase 11,250 shares of Common Stock for $7,208 in cash.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Warrants to Purchase Common Stock </u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of March 31, 2016, we had warrants outstanding to purchase an aggregate of 12,281,059 shares of Common Stock with a weighted-average contractual remaining life of 1.5 years, and exercise prices ranging from $0.24 to $7.59 per share, resulting in a weighted average exercise price of $1.97 per share.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The valuation methodology used to determine
the fair value of our warrants is the Black-Scholes-Merton valuation model, or the Black-Scholes Model. The Black-Scholes Model
requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term
of the warrant. During the three months ended March 31, 2016, we granted warrants to purchase 120,000 shares of Common Stock to
outside consultants at an exercise price of $7.59. The fair value for these shares was determined by using the Black-Scholes Model
on the date of the vesting using a term of five years; volatility of 74.15%; risk free rate of 1.28%; and dividend yield of 0%.
The grant date fair value of the warrants was $4.60 per share. The warrants vest ratably over a 12-month period and have an expiration
date of January 21, 2021. During the three months ended March 31, 2015, we did not grant any warrants. During the three months
ended March 31, 2016 and 2015, we recorded $127,465 and $9,071, respectively, as share based compensation expense in the accompanying
consolidated financial statements related to vested warrants. As of March 31, 2016, unamortized costs associated with these warrants
totaled approximately $449,000.</p>

<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In May 2013, we entered into a consulting agreement to develop drug platforms to be used in our hormone replacement drug candidates. As consideration under the agreement, we agreed to issue the consultant a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share, that has vested or will vest as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">1.</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Warrants to purchase 283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the agreement, the shares did not vest until June 30, 2013;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">2.</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Warrants to purchase 283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of five years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During both the three months ended March 31, 2016 and 2015, we recorded $38,517 as share based compensation expense in the accompanying consolidated financial statements related to these warrants. As of March 31, 2016, there was a remaining balance of $38,509 related to these warrants which was included in other current assets in the accompanying consolidated financial statements;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">3.</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">Warrants to purchase 283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate which the warrant holder helped us design. It is anticipated that this event will not occur before December 2016.</td>
</tr>
</table>
<p style="margin: 0 0 8pt 0.5in; padding-top: 9pt; text-indent: -40pt; font: 10pt/107% Times New Roman, Times, Serif">&#xA0; As of March 31, 2016, unamortized costs associated with these warrants and warrants issued to the same holder in 2012 totaled approximately $361,000.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">During the three months ended March 31, 2016, certain
individuals exercised warrants to purchase 561,372 shares of our Common Stock for $1,310,000 in cash. During the three months
ended March 31, 2015, an outside service provider exercised warrants to purchase 925,485 shares of our Common Stock
for $358,400 in cash.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Options to Purchase Common Stock</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. As of March 31, 2016, there were non-qualified stock options to purchase 17,701,181 shares of Common Stock outstanding under the 2009 Plan. As of March 31, 2016, there were 3,423,477 shares available to be issued under 2009 Plan.</p>
<p style="margin: 0 0 6pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of March 31, 2016, there were non-qualified stock options to purchase 2,868,474 shares of Common Stock outstanding under the 2012 Plan. As of March 31, 2016, there were 7,050,000 shares available to be issued under 2012 Plan.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model for options granted during the three months ended March 31, 2016 and 2015 are set forth in the table below.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended<br /> March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended<br /> March 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.70</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.47</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Volatility</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">71.22</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">58.78-62.59</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Term (in years)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.25</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5.27-6.25</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Dividend yield</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The expected term is based on the contractual terms of the stock option using the simplified method.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">A summary of activity under the 2009 and 2012 Plans and related information follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares Underlying Stock Options</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Contractual Life in Years</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate<br /> Intrinsic<br /> Value</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 44%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2015</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">20,725,325</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">3.28</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.5</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">146,864,184</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Granted</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">185,500</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">7.59</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Exercised</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(340,045</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.31</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,051,619</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Expired/Forfeited</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,125</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.59</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Balance at March 31, 2016</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">20,569,655</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.34</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.3</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">71,940,245</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at March 31, 2016</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">15,988,578</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.17</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.5</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">69,261,183</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Unvested at March 31, 2016</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,581,077</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">7.42</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">9.2</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,679,062</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At March 31, 2016, our outstanding stock options had exercise prices ranging from $0.10 to $8.92 per share. The weighted average grant date fair value per share of options granted was $4.91 and $3.17 during the three months ended March 31, 2016 and 2015, respectively. Share-based compensation expense for options recognized in our results of operations for the three months ended March 31, 2016 and 2015 ($4,151,259 and $728,426, respectively) is based on vested awards. We estimate forfeitures at the time of grant and revise the forfeiture rate in subsequent periods if actual forfeitures differ from the estimates. At March 31, 2016, total unrecognized estimated compensation expense related to unvested options granted prior to that date was approximately $16,285,000 which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of 1.7 years. No tax benefit was realized due to a continued pattern of operating losses.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779162576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 12 &#x2013; INCOME TAXES</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2016 as a result of (i) the losses recorded during the three months ended March 31, 2016, (ii) additional losses expected for the remainder of 2016, and/or (iii) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#x201C;more likely than not&#x201D; that some component or all of the benefits of deferred tax assets will not be realized. As of March 31, 2016, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779174352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 13 &#x2013; RELATED PARTIES</u></b></p>


<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p>


<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In July 2015, J. Martin Carroll, a director of our Company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc in the normal course of business. Agreements with Catalent Inc. have been reviewed by independent directors of our Company or a committee consisting of independent directors of our Company since July 2015. During the three months ended March 31, 2016, we were billed by Catalent, Inc. $1,464,858 for manufacturing activities related to our clinical trials. As of March 31, 2016, there were amounts due to Catalent, Inc. of $59,275.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6770984128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">BUSINESS CONCENTRATIONS</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 14 &#x2013; BUSINESS CONCENTRATIONS</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We purchase our products from several suppliers with approximately 95% of our purchases supplied from one vendor for both the three months ended March 31, 2016 and 2015.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the three months ended March 31, 2016, three customers each generated more than 10% of our total revenues and during the three months ended March 31, 2015 four customers each generated more than 10% of our total revenues. Revenue generated from three major customers accounted for approximately 61% of our recognized revenue for the three months ended March 31, 2016 and revenue generated from four customers accounted for approximately 70% of our recognized revenue for the three months ended March 31, 2015. Customers that generated more than 10% of our sales are designated as customers &#x201C;A&#x201D;, &#x201C;B&#x201D;, &#x201C;C&#x201D; and &#x201C;D&#x201D;. During the three months ended March 31, 2016, customers A, B and C generated $1,335,551, $1,104,344 and $680,096 in revenues, respectively. During the three months ended March 31, 2015 customers A, B, C and D generated $1,416,127, $626,731, $543,447 and $386,909 in sales, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6327-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779174352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 15 &#x2013; COMMITMENTS AND CONTINGENCIES</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We lease administrative office space in Boca Raton, Florida pursuant to a 63-month non-cancelable operating lease that commenced on July 1, 2013. The lease expires on September 30, 2018 and we have an option to extend the lease term for a period of five years. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum was effective beginning April 1, 2015 and will expire with the original lease term on September 30, 2018.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The rental expense related to our current lease during the three months ended March 31, 2016 and 2015 was $118,550 and $90,448, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of March 31, 2016, future minimum rental payments are as follows:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Years Ending December 31,</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="width: 75%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2016 (9 months)</font></td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 20%; text-align: right; font: 10pt Times New Roman, Times, Serif">418,130</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2017</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">507,087</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">388,976</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,314,193</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779110752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 16 &#x2013; SUBSEQUENT EVENTS</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On April 26, 2016, we entered into an agreement to lease additional administrative office space in Boca Raton, Florida, pursuant to an addendum to our existing 63 month non-cancelable operating lease. This addendum was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">&#xA0;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6775319888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Fair Value of Financial Instruments</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Our financial instruments consist primarily of accounts receivable, accounts payable and accrued expenses. The carrying amount of accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, <i>Fair Value Measurements. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
<td style="width: 10%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 7%; font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></td>
<td style="width: 3%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 80%; text-align: justify; font: 10pt Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or liabilities;</td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td>
</tr>
<tr style="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">unobservable inputs for the asset or liability.</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At March 31, 2016 and 2015, we had no assets or liabilities that were valued at fair value on a recurring basis. The fair value of indefinite-lived assets or long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the Company&#x2019;s impairment test. There was no impairment of intangible assets or long-lived assets during the three months ended March 31, 2016 and 2015.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Revenue Recognition</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note 14. There are no major external customers for our OTC prenatal vitamin or other products.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i><u>OTC Products</u></i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>

<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin-bottom: 0; margin-top: 0; text-align: left; font: 10pt Times New Roman, Times, Serif"><i><u>Prescription Products</u></i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and customer rebates.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We accept returns of unsalable prescription products from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015, we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Share-Based Compensation</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718 to value options. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Equity instruments issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, Equity - Based Payments to Non-Employees, or ASC 505. ASC 505 defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Research and Development Expenses</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="background-color: white; margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Research and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities are capitalized, and were $1,005,503 at March 31, 2016, of which $941,054 was included in other current assets and $64,449 was included in long-term prepaid expense on the accompanying consolidated balance sheets. Advance payments to be expensed in future research and development activities were $1,138,073 at December 31, 2015, of which $1,009,175 was included in other current assets and $128,898 was included in long term prepaid expense on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&#38;D expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Segment Reporting</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779095168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Inventory consists of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Finished product</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">907,510</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">661,167</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Raw material</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">49,924</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">28,986</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">TOTAL INVENTORY</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">957,434</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">690,153</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6770916992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of other current assets</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Other current assets consist of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid consulting</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">296,305</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">334,822</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid insurance</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">438,420</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">695,421</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">644,749</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">674,353</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid vendor deposits</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">107,300</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">159,489</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Other prepaid costs</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">231,295</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">369,812</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT ASSETS</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,718,069</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,233,897</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6615680112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Fixed assets consist of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Equipment</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">156,502</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">132,150</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accounting system in process</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">205,712</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">149,699</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">63,566</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">69,454</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">425,780</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">351,303</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accumulated depreciation</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(161,074</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(152,711</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">TOTAL FIXED ASSETS</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">264,706</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">198,592</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779046496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidExpenseAbstract', window );"><strong>Prepaid Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of prepaid expense</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Prepaid expense consists of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: center; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid manufacturing costs</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">983,521</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">980,985</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">64,449</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">128,898</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">TOTAL PREPAID EXPENSE</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,047,970</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,109,883</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6783642464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2016 and December 31, 2015:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Gross<br /> Carrying<br /> Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Accumulated Amortization</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- Average Remaining Amortization Period (yrs.)</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; width: 46%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#xAE; </sup>software patent</font></td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(4,993</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">26,958</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">13.5</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">779,777</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(60,579</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif"></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">719,198</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">16.75</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents&#xA0;(pending)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">787,149</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">787,149</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">n/a</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Non-amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">161,241</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">161,241</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Total</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,851,861</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(157,315</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,694,546</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="15" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Gross<br /> Carrying Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Accumulated Amortization</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- Average Remaining Amortization Period (yrs.)</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; width: 46%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#xAE; </sup>software patent</font></td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(4,493</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif">27,458</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif">13.75</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">705,752</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(49,845</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">655,907</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">17</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents (pending)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">774,165</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">774,165</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Non-amortizing intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">157,721</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">157,721</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 30pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Total</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,761,332</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(146,081</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,615,251</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated amortization expense</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Estimated amortization expense for the next five years is as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Year Ending December 31,</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Estimated<br /> Amortization</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="width: 75%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2016 (9 months)</font></td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 20%; text-align: right; font: 10pt Times New Roman, Times, Serif">33,701</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2017</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">44,934</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">44,934</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2019</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">44,934</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2020</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">44,934</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b>&#xA0;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6770676336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of other current liabilities</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Other current liabilities consist of the following:</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued clinical trial costs</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">3,042,956</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">3,725,377</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued payroll, bonuses and commission costs</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1,396,234</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,108,143</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued compensated absences</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">623,918</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">562,096</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued legal and accounting expense</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">413,240</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">210,309</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Other accrued expenses</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">312,329</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">546,264</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Allowance for wholesale distributor fees</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">76,012</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">32,659</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued royalties</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">35,773</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">46,851</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Allowance for coupons and returns</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">185,441</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">224,300</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Accrued rent</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">79,861</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">83,527</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT LIABILITIES</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,165,764</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,539,526</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6770677728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetLossPerShareTablesAbstract', window );"><strong>Net Loss Per Share Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three months ended</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Stock options</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">20,569,655</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">17,586,109</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Warrants</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,281,059</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,002,431</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0; TOTAL</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">32,850,714</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,588,540</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetLossPerShareTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetLossPerShareTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6772658896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes Model of stock options</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The assumptions used in the Black-Scholes Model for options granted during the three months ended March 31, 2016 and 2015 are set forth in the table below.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended<br /> March 31, 2016</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Three Months Ended<br /> March 31, 2015</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 64%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.70</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 14%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.47</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Volatility</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">71.22</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">58.78-62.59</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Term (in years)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.25</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5.27-6.25</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Dividend yield</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.00</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of plan activity</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">A summary of activity under the 2009 and 2012 Plans and related information follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares Underlying Stock Options</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted<br /> Average<br /> Exercise<br /> Price</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted Average Remaining Contractual Life in Years</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate<br /> Intrinsic<br /> Value</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; width: 44%; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2015</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">20,725,325</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">3.28</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.5</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">146,864,184</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Granted</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">185,500</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">7.59</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Exercised</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(340,045</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.31</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,051,619</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 20pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Expired/Forfeited</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,125</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.59</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Balance at March 31, 2016</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">20,569,655</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.34</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.3</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">71,940,245</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at March 31, 2016</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">15,988,578</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.17</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.5</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">69,261,183</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif">Unvested at March 31, 2016</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,581,077</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">7.42</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">9.2</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,679,062</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6772248144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CommitmentsAndContingenciesTablesAbstract', window );"><strong>Commitments And Contingencies Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum rental payments</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of March 31, 2016, future minimum rental payments are as follows:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 60%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">Years Ending December 31,</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="3" style="text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="width: 75%; text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">2016 (9 months)</font></td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 20%; text-align: right; font: 10pt Times New Roman, Times, Serif">418,130</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2017</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">507,087</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">388,976</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 10pt; text-align: left; text-indent: -10pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</font></td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,314,193</td>
<td style="padding-bottom: 2.5pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CommitmentsAndContingenciesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CommitmentsAndContingenciesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6775437424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Related to Research and Development Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Advance payments - total</a></td>
<td class="nump">$ 1,005,503<span></span>
</td>
<td class="nump">$ 1,138,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Advance payments - other assets current</a></td>
<td class="nump">941,054<span></span>
</td>
<td class="nump">1,009,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Advance payments - long term prepaid expense</a></td>
<td class="nump">$ 64,449<span></span>
</td>
<td class="nump">$ 128,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the company accepts returns of unsalable prescription products from customers following product expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ReturnPeriodOfUnsalablePrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShelfLifeOfPrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period shelf life of prescription products from date of manufacture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShelfLifeOfPrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6769776144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished product</a></td>
<td class="nump">$ 907,510<span></span>
</td>
<td class="nump">$ 661,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw material</a></td>
<td class="nump">49,924<span></span>
</td>
<td class="nump">28,986<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY</a></td>
<td class="nump">$ 957,434<span></span>
</td>
<td class="nump">$ 690,153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6775379408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidConsultingCurrent', window );">Prepaid consulting</a></td>
<td class="nump">$ 296,305<span></span>
</td>
<td class="nump">$ 334,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">438,420<span></span>
</td>
<td class="nump">695,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent', window );">Prepaid research and development costs</a></td>
<td class="nump">644,749<span></span>
</td>
<td class="nump">674,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidVendorDeposits', window );">Prepaid vendor deposits</a></td>
<td class="nump">107,300<span></span>
</td>
<td class="nump">159,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
<td class="nump">231,295<span></span>
</td>
<td class="nump">369,812<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
<td class="nump">$ 1,718,069<span></span>
</td>
<td class="nump">$ 2,233,897<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidConsultingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidConsultingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidVendorDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a prepaid vendor deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidVendorDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6772141216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">$ 8,363<span></span>
</td>
<td class="nump">$ 6,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6775026640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 425,780<span></span>
</td>
<td class="nump">$ 351,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(161,074)<span></span>
</td>
<td class="num">(152,711)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">264,706<span></span>
</td>
<td class="nump">198,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">156,502<span></span>
</td>
<td class="nump">132,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Accounting System in Process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">205,712<span></span>
</td>
<td class="nump">149,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 63,566<span></span>
</td>
<td class="nump">$ 69,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6783348144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidExpenseAbstract', window );"><strong>Prepaid Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidManufacturingCostsNoncurrent', window );">Prepaid manufacturing costs</a></td>
<td class="nump">$ 983,521<span></span>
</td>
<td class="nump">$ 980,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchDevelopmentCostsNoncurrent', window );">Prepaid research and development costs</a></td>
<td class="nump">64,449<span></span>
</td>
<td class="nump">128,898<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">TOTAL PREPAID EXPENSE</a></td>
<td class="nump">$ 1,047,970<span></span>
</td>
<td class="nump">$ 1,109,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidManufacturingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of manufacturing contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidManufacturingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchDevelopmentCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; non-current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidResearchDevelopmentCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6786264960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 11,234<span></span>
</td>
<td class="nump">$ 6,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">OPERA software patent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member', window );">Utility Patent Progesterone and Estradiol Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member', window );">Utility Patent Progesterone and Estradiol Products [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Utility Patent TX-004HR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member', window );">Utility Patent Pipeline Transdermal Patch Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6789149392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (157,315)<span></span>
</td>
<td class="num">$ (146,081)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">1,851,861<span></span>
</td>
<td class="nump">1,761,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Amount</a></td>
<td class="nump">1,694,546<span></span>
</td>
<td class="nump">1,615,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone therapy drug candidate patents - (pending) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">787,149<span></span>
</td>
<td class="nump">774,165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">787,149<span></span>
</td>
<td class="nump">774,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember', window );">Multiple trademarks for vitamins/supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">161,241<span></span>
</td>
<td class="nump">157,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
<td class="nump">161,241<span></span>
</td>
<td class="nump">157,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">OPERA software patent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">31,951<span></span>
</td>
<td class="nump">31,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,993)<span></span>
</td>
<td class="num">(4,493)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 26,958<span></span>
</td>
<td class="nump">$ 27,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining amortization period</a></td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">13 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Development costs for corporate website [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 91,743<span></span>
</td>
<td class="nump">$ 91,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (91,743)<span></span>
</td>
<td class="num">$ (91,743)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 779,777<span></span>
</td>
<td class="nump">$ 705,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(60,579)<span></span>
</td>
<td class="num">(49,845)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 719,198<span></span>
</td>
<td class="nump">$ 655,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining amortization period</a></td>
<td class="text">16 years 9 months<span></span>
</td>
<td class="text">17 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6772689024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, NET (Details 1)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated amortization expense for the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2016 (9 months)</a></td>
<td class="nump">$ 33,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2017</a></td>
<td class="nump">44,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2018</a></td>
<td class="nump">44,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2019</a></td>
<td class="nump">44,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2020</a></td>
<td class="nump">$ 44,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6775377488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedClinicalTrialCostsCurrent', window );">Accrued clinical trial costs</a></td>
<td class="nump">$ 3,042,956<span></span>
</td>
<td class="nump">$ 3,725,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
<td class="nump">1,396,234<span></span>
</td>
<td class="nump">2,108,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued compensated absences</a></td>
<td class="nump">623,918<span></span>
</td>
<td class="nump">562,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
<td class="nump">413,240<span></span>
</td>
<td class="nump">210,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">312,329<span></span>
</td>
<td class="nump">546,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
<td class="nump">76,012<span></span>
</td>
<td class="nump">32,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">35,773<span></span>
</td>
<td class="nump">46,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
<td class="nump">185,441<span></span>
</td>
<td class="nump">224,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
<td class="nump">79,861<span></span>
</td>
<td class="nump">83,527<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
<td class="nump">$ 6,165,764<span></span>
</td>
<td class="nump">$ 7,539,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6770752496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">32,850,714<span></span>
</td>
<td class="nump">30,588,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">12,281,059<span></span>
</td>
<td class="nump">13,002,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">20,569,655<span></span>
</td>
<td class="nump">17,586,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6790713536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Jan. 06, 2016</div></th>
<th class="th"><div>Jul. 15, 2015</div></th>
<th class="th"><div>Jul. 09, 2015</div></th>
<th class="th"><div>Feb. 17, 2015</div></th>
<th class="th"><div>Feb. 10, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long-term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,701,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,423,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,868,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.91<span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Sharebased compensation - stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,151,259<span></span>
</td>
<td class="nump">$ 728,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized estimated compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized period for recognition - stock option compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,569,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ .10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember', window );">Options exercised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,045<span></span>
</td>
<td class="nump">11,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 786,450<span></span>
</td>
<td class="nump">$ 7,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=txmd_StifelUnderwritersMember', window );">Stifel Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,423,077<span></span>
</td>
<td class="nump">3,846,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=txmd_CowenAndCompanyLLCMember', window );">Cowen and Company, LLC (Underwriters) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,617,282<span></span>
</td>
<td class="nump">13,580,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,037,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=txmd_GoldmanSachsMember', window );">Underwriting Agreement - Goldman And Cowen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period (shares)</a></td>
<td class="nump">17,242,242<span></span>
</td>
<td class="nump">15,151,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,272,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalPeriodForPurchaseShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to additonal period for purchase of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalPeriodForPurchaseShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_StockIssuedDuringPeriodSharesNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=txmd_StifelUnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=txmd_StifelUnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=txmd_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=txmd_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=txmd_GoldmanSachsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=txmd_GoldmanSachsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6789802112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">35 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May. 11, 2013</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,281,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,281,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Sharebased compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,381,690<span></span>
</td>
<td class="nump">$ 840,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ .24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember', window );">Outside Consultant Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Sharebased compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,465<span></span>
</td>
<td class="nump">9,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 21,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized noncash compensation associated with warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_ConsultantMember', window );">Consultant Agreement - Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Warrants granted to purchase common stock (shares)</a></td>
<td class="nump">283,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Sharebased compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,517<span></span>
</td>
<td class="nump">$ 38,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ExpectedToVestedWarrantsUponFdaApprovalShares', window );">Expected to vested warrants upon FDA approval (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized noncash compensation associated with warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock issued for excercised warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561,372<span></span>
</td>
<td class="nump">925,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Stock issued for excercised warrants, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,310,000<span></span>
</td>
<td class="nump">$ 358,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are expired in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ExpectedToVestedWarrantsUponFdaApprovalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares expected to vest upon receiving FDA apporval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ExpectedToVestedWarrantsUponFdaApprovalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item provides the weighted-average contractual remaining life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) that have been approved for issuance in the equity-based payment transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6770083952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">71.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">6 years 2 months 30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.78%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6777929552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1) - Stock Options [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOptionsAbstract', window );"><strong>Number Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning</a></td>
<td class="nump">20,725,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">185,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(340,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options Expired/Forfeited</a></td>
<td class="num">(1,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">20,569,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and exercisable</a></td>
<td class="nump">15,988,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested</a></td>
<td class="nump">4,581,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning</a></td>
<td class="nump">$ 3.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">7.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Expired/Forfeited</a></td>
<td class="nump">3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending</a></td>
<td class="nump">3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and exercisable</a></td>
<td class="nump">2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice', window );">Unvested</a></td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, ending</a></td>
<td class="text">6 years 3 months 19 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm', window );">Unvested</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, beginning</a></td>
<td class="nump">$ 146,864,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="nump">2,051,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, ending</a></td>
<td class="nump">71,940,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable</a></td>
<td class="nump">69,261,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Unvested</a></td>
<td class="nump">$ 2,679,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire unvested shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779155088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) - Catalent Inc.[Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Payable - related party</a></td>
<td class="nump">$ 59,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Manufacturing activities billed from related party</a></td>
<td class="nump">$ 1,464,858<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6778172544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">$ 4,930,091<span></span>
</td>
<td class="nump">$ 4,475,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member', window );">Customer A [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">$ 1,335,551<span></span>
</td>
<td class="nump">$ 1,416,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member', window );">Customer B [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">1,104,344<span></span>
</td>
<td class="nump">626,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member', window );">Customer C [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">$ 680,906<span></span>
</td>
<td class="nump">543,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member', window );">Customer D [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 386,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6779170912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CapitalLeaseObligationsTerm', window );">Non-cancelable operating lease term</a></td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental Expense</a></td>
<td class="nump">$ 118,550<span></span>
</td>
<td class="nump">$ 90,448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CapitalLeaseObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total term (in months) of the company's outstanding lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CapitalLeaseObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.4.0.3</span><table class="report" border="0" cellspacing="2" id="idp6775491312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract', window );"><strong>Future minimum rental payments, year ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2016 (9 months)</a></td>
<td class="nump">$ 418,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2017</a></td>
<td class="nump">507,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2018</a></td>
<td class="nump">388,976<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 1,314,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%H[; N 6CMP"Z!:.W0+P%H[>"O16CMX*]%;2MS;ZV.;HK4!OY>BM0&_EZ*U
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M$RSN/CY!XN6@3DB';0MMXX**%9VO(3K<G+2RM0OM,?4C.KM5U1=02P,$%
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M-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04    "  'A*5(SCB5]48"  !Z"@
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MI=ST&V8LB4D83TA*(PHG]@, ?3@%\<5L%J9?+8JSFYA=LRB,,Q)&4;*(,P9
M'P'HXRF(Q7=F'$D*D[@"(5>G(8E)/271(DVI[9)SLYK0K3Z4JW\:?\WNS=RW
M<>])3#,8W#$34=-,W#QD$T+OYS3F%(9"%UU$1F;F.[YAXRE]J7,HH8M8V,U\
MRL(QF[*,T4[Z4$ 7,=#T2:8)Y\1X:VHA3#M)0.M<1#N>)=&7VV0ZH2G_B]!_
M%BR#2^=" 5W$0!8;:2G)POONJ*%O+B)<2J=-R<S#]'G"T# 746R\X"RF)F%3
M>T;R+&VL[R"@<2ZBG!GSC&5MI=IJ,:2,Q3<TCKIC\:!['N(>7XRYF32[?-2*
MWPF&[GF(>V>+SO,@JO._B+IX*#MR8;X0A5#O8#3TT/NCAZW,* BZZ"$NGI0B
M2H%.>HB3SVH294 O/=1+K#A1%%350U1]L4I;&D1!=3U$W=-:14<$]?40?;&B
MQ4 ^U-=']#U;!^0"HJ#,_EME]J',/I39/R_S1.A<%MVD.I_V5]N,D:#._NMT
M/F!(G-<U1$&G?<3IEU&=$4&M?43KD]+ (%!H'Q'ZI=HXL" *"NVCG_LS*/\*
MHJ#4/B+U6530AULRJ'6 :'VF8BT-HJ#6 :(U5K'(G ?0Z0!Q&B_9WS9!%/0[
M0/P^BPH"B.IL7A'!SZ(Z^4&_@U?N(Y[R<R$*.AX@CC_;&G1K+M<0!4T/$--?
MV"H<D1 %30\0T\_^50;0] ":'KQU]S& I@^@Z8/^X>CV=%HS!U99BI4]RZJF
M&W,87-H#KOEI][#!P&Z&;'MF#KTCQYY,S2%T7Q21N9>4TRIOSF\M^7BD_?P_
M4$L#!!0    (  >$I4AL1?AG9@(  +\(   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&ULC5;=CJ,@%'X5X@.,@HIM8TVFG6QV+S:9S,7N-6UI-:/B *VS
M;[^ UD&6;+U1P.^'@QP.><_XNR@IE>"SJ5NQ#4HINTT8BF-)&R*>6$=;]>7,
M>$.DZO)+*#I.R<F0FCI$483#AE1M4.1F[)47.;O*NFKI*P?BVC2$_]G1FO7;
M  ;W@;?J4DH]$!9Y./%.54-;4;$6<'K>!L]PLX=80PSB5T5[8;6!GOR!L7?=
M^7':!I&> ZWI46H)HEXWNJ=UK964\\<H^N6IB7;[KO[-A*NF?R""[EG]NSK)
M4LTV"L")GLFUEF^L_T['&%(M>&2U,$]PO K)FCLE  WY'-Y5:][]\"6!(\U/
M0",!3024_)<0CX1X(D!#"(>9F;A>B"1%SED/1$?TWX8;!>=:1"D#%8PP7;-<
MP^BMB/+PIF5FB-V 0 8!)T2HM+T&:&ZP0Q8=^0SV-B)^;! [$<2&'AMZ\IB>
M./3$T!-#3[T+8"/P8X/4,4@M>C8W: ># 8&')4JS9,$B8,<$6R8K;Q0V8OW8
M(',,,HL._1ME!EFP4U:.Q<KF>[?*;@99L$QKQV)M\Q.OQ0R2/K: D9M1D:V
M_3DUPV0+7/[)6V@K^'_Y'+/$!;DNR%98^UUL#(H6N+@9#&-; ?I=9ABTP,5-
M=&CG,8I]F;@?,7B,%R,<9]&2D-RDAW;6(_].&S'IF/<+7-RLAW92(^P]7$;,
M>+I$T#W!0JM>-)1?3!T5X,BNK1P*PS0ZU>IG9.K-%[S(.W*A/PF_5*T !R95
MU3(%Z\R8I&H:T9,*ME2WB:E3T[/4S4RU^5!?AXYDW?VZ,-U9BK]02P,$%
M  @ !X2E2.&Q75S  P  \P\  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6R-E\N.VS@017]%\'XB5O'=<!N('00SBP!!%C-K=9MN"Y$L1U*WD[\?ZF&G
MQ%!M;:R';Y&GI.)5<7VIZN_-T;DV^5D6I^9Q=6S;\T.:-L]'5V;-A^KL3OZ?
M0U676>LOZY>T.=<NV_=!99$B8RHML_RTVJS[>U_KS;IZ;8O\Y+[62?-:EEG]
M:^N*ZO*X@M7UQK?\Y=AV-]+-.KW%[?/2G9J\.B6U.SRN/L+##E4GZ17_YN[2
MD/.D@W^JJN_=Q3_[QQ7K&%SAGMMNB,P?WMS.%44WDI_YQSCH[SF[0'I^'?US
MGZ['?\H:MZN*__)]>_2T;)7LW2%[+=IOU>5O-^8@NP&?JZ+I?Y/GUZ:MRFO(
M*BFSG\,Q/_7'R_"/86-8/ #' +P%@'@W@(\!/ A(![(^KT]9FVW6=75)FG/6
MO6UX\/*Z&\2/G/ADFOZR?US#W;<-ZG7ZUHTSD6P'"0Z2F&(W49B;)/7S1R$P
M@, ^G@_Q]GX\#^)Y'R_Z>,ZFB*<AB4&B>PD89%9S(6/*'54JH9GB4MY'$@&2
MH$@011HDJI=(/XW6/ I$=9P)JV$!CPQX).7!*(\D\UBI!1=1'"I3EH'D]VE4
M0*,H333KK2+3@ ;#E(WB4!TBY\;J^SPZX-&4)YKV5E,>8PU7"J/O=4>5OGP,
M V3WD4R 9"A2M%*WAJ;>EVJ4A\K &FGQ/HT-:"Q9H5S=CP<6^@RC^>AH/J-F
M)%562!'/*!""1 D+F/[P/J!,)LX$="HFM-51@]E-A<"L,0L6!H16"$B9HB6_
M'37C5"@9FT%Z1S=/%)HK4'<5<7<=-6,I&J4ES+RYJ5 R(,MMGBET5Z#V*N+V
M"F)2]VB5,2+NL!.IYAJ]<DF1AR8+DBP3L6"906B,0)TQ3KL%:GE<<*9$W!JG
M0D %>LG##LT1J#N*N#L"-3T%2FH5_WI,A%IR*W')DP[=$:@]QC_DVU&CQP^:
M50)F7C\5 E.>?M%*"4T2+(4*%L"UF9IHH@W7;DXSWT^%;HN,%N*2CBST1J3>
M&-;7F,M4$\]E3C-/\D=S2!U1QOUGU(QOT"J4\>J;ZK2VB[K5T!&1.J*,NP]2
MHQ/(+4?!XOT"3CT1M>\7]!*NT!61NJ*,-WE(K>XOSZ2E0HQWPH'6]PZHC%JP
M,C T1J3MIXS;&M+&$@SW-BSBS?QN(E7> #DL\6L,W1:IV\9+9CMJKJ7UWF=D
M(IWYC*1D>W;.7MR7K'[)3TWR5+5^I]=O\@Y5U3H_'OO@TSSZ'?CMHG"'MCO5
M_KP>]J3#15N=KUOLVSY_\S]02P,$%     @ !X2E2%A+.J4N @  D <  !@
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6R-E=V2VB 8AF\EDPM8(/]Q8F:J
MG4Y[T)F=/6B/4=%D-@DIH-G>??F)%AFBZX$!\KP?#S%"-5'VSAM"1/#1=P-?
MAXT0XPH OF](C_D+'<D@[QPIZ[&0778"?&0$'W2H[T $809ZW YA7>FQ5U97
M]"RZ=B"O+.#GOL?L[X9T=%J'*+P.O+6G1J@!4%?@ECNT/1EX2X> D>,Z_()6
M6P05HHE?+9FXU0Z4_([2=]7Y<5B'4#F0CNR%*H'EY4*VI.M4)3GSG[GH_SE5
MT&Y?JW_3RY7Z.\S)EG:_VX-HI"T,@P,YXG,GWNCTG<QK2%7!/>VX_@[V9RYH
M?XV$08\_S+4=]'4R=[)LCOD#T1R(;@&4/ S$<R!V L"8Z75]Q0+7%:-3P$>L
M?FVTDCA3163E0"Z&ZZY^7&;T4J=I!2ZJSAVR,4BDD<A';.^(XH8 .;]7(G(D
M(IV/C43V/!\[^5CG$Y//[Q4'LPB#Y!J)40$SY,.V-E:@$L'G,HDCD]@RA5?&
M((5&X N$?I=E:M$E=5Q2VZ7TNA@DTPB"YN/5>0@N&F6.46899=Z)-IDUD5_%
M3RPZY(Y#;CMXG_TF?^K@)Q8="L>AL!TBKT/QJ;=DF5IT*1V7TG:)O2ZEM=HX
M??2:/"87G1!T-R9H6R5>JYF9W\DRB](X7]"Z1_.\C J8N,\*6'OGB$_D)V:G
M=N#!C@JY#>L=^$BI(+(@?)'_AT8>C[=.1XY"-7/99N; ,!U!Q^OY=SN$ZW]0
M2P,$%     @ !X2E2(5L+?90 P  $0T  !@   !X;"]W;W)K<VAE971S+W-H
M965T-"YX;6R-E\V.FS 4A5\%9=_!U_\>92(UJ:IV4:GJHETSB9.@ DZ!3-JW
MK[%)QG@\"IN G7-]/V/[<%E>3/N[.VK=9W_KJNF>%L>^/SWF>;<]ZKKH'LQ)
M-_:?O6GKHK?-]I!WIU87.Q=45SE&B.=U43:+U=+U?6]72W/NJ[+1W]NL.]=U
MT?Y;Z\I<GA:PN';\* _'?NC(5\O\%K<K:]UTI6FR5N^?%A_A<8.=Q"E^EOK2
M!??9 /]LS.^A\77WM$ #@Z[TMA^&*.SE16]T50TCV<Q_QD%?<PZ!X?UU],]N
MNA;_N>CTQE2_REU_M+1HD>WTOCA7_0]S^:+'.;!AP*VI.O>;;<]=;^IKR"*K
MB[_^6C;N>O'_"#R&I0/P&(!O ;<\Z0 R!I#7 .IFZLG<O#X5?;%:MN:2=:=B
M6&UXM/)V&,2.G-G)=*[I'I?O?5EQMLQ?AG$FDK678">!FR*W@R<SX&F&-0["
M<2K!)E1P?C\#B>9 7#SQ\>)^/(WBJ8NG/EY.$1L_"2\13D(504A!2K>9Z*A@
MB*K[/"SB82&/2O)X"?=K DA22I(\$QVBA-,9*\@C'A[P")3DX4$>(C%PFGR.
MFXF.$J!(WN<1$8\(UEO,F(^,XF4X'YR<CPPX%1>2L:1N$^HX<,(!W^=1$8\*
M>9+KN%;A.C*D! *1!)H()0@N";M/!"BV!10RT233J!ES*:;21%,986+&$X(W
M-@4A#TOS0) (4Z$8!&XR09HJ":,(9IQ3P#$5#JF2N=:CQN?Z@.W2$0;IP_%&
MBC&'&?L;8D.$T!'%#$>$V!(A]$21]L11XW$I\'=VY$0&D@&9P1-;(H2>*-*>
M"*'984;>6?M0I22=LQMC0X30$67:$2&T.DJ!I0UZ(L/VL,XYK;$A@@AYDF^F
M]:@)-I<B\0O_RA1)I:*8S7@O0VRT$#JM3#OMJ!%SN"+I;*[8<$$%YT/.V(\X
M]D<<^J-,^^.H41X7/4"Z9'@CF\,3^R,._5&F_1'#Q*^I0L!X<O-NIE).*)5
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ME!N5PA&(\0@!'DU"AAB/X..1$OQ1" 'U#!& TS'4,:E%PK!"#$> P!+^2(2
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M'YMTI5+B<#@^D.655O\!4$L#!!0    (  >$I4COB2TOGP$  +$#   8
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&ULA5/;;J,P$/T5BP^H@9!L%1&DIJNJ
M?5BIZD/[[,  5FT/M4WH_OWZ0F@25=L7/#.<<^:,+^6$^MWT )9\2J',+NFM
M';:4FKH'R<P-#J#<GQ:U9-:ENJ-FT,":0)*"YFFZH9)QE51EJ#WKJL31"J[@
M61,S2LGTWST(G'9)EIP*+[SKK2_0JJ0+K^$2E.&HB(9VE]QEVWWA$0'PRF$R
M9S'QW@^([SYY:G9)ZBV @-IZ!>:6(]R#$%[(-?Z8-;]:>N)Y?%)_"-,Z]P=F
MX![%&V]L[\RF"6F@9:.P+S@]PCS"V@O6*$SXDGHT%N6)DA#)/N/*55BG^&=S
M.].^)^0S(5\(MVDP'AL%F[^9956I<2)F8/[LLJV#:R_BE(GS9D(:IH_58Y5E
M14F/7N@"LX^8/&(6!'7JW[;(+UOL\S-Z_C-]=>5P%>BKV>'Z9X'B2J ( L5_
M1[S$;*Z:T+,]E:"[<'4,J7%4-F[>4EUNYUT>SN0+7I4#Z^ /TQU7AAS0NI,-
MA]HB6G FTIMU0GKW?I9$0&M]^,O%.EZIF%@<3@]D>:75/U!+ P04    "  '
MA*5(6-BO8J !  "Q P  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;(53
MRV[;,!#\%8(?$$JRTJ2&+"!.4;2' D$.[9F65A(1DJN2E)7^??F0%=L(DHNX
MNYJ9G>6CFM&\V ' D5<EM=W1P;EQRYAM!E#<WN (VO_IT"CN?&IZ9D<#O(TD
M)5F195^8XD+3NHJU)U-7.#DI-#P98B>EN/FW!XGSCN;T5'@6_>!"@=456WFM
M4*"M0$T,=#OZD&_W94!$P&\!LSV+2?!^0'P)R<]V1[-@ 20T+BAPOQSA$:0,
M0K[QWT7SK64@GL<G]>]Q6N_^P"T\HOPC6C=XLQDE+71\DNX9YQ^PC' ;!!N4
M-GY),UF'ZD2A1/'7M H=USG]*3<+[7U"L1"*E7"?1>.I4;3YC3M>5P9G8D<>
MSB[?>K@)(EZ9>&\VIG'Z5#W6>7Y7L6,0NL#L$Z9(F!7!O/J[+8K+%OOBC%Y\
M3M]<.=Q$^F9Q>/^Y0'DE4$:!\L,1+S%?KYJPLSU58/IX=2QI<-(N;=Y:76_G
M0Q'/Y U>5R/OX1<WO="6'-#YDXV'VB$Z\":RFUM*!O]^UD1"YT)XYV.3KE1*
M'(ZG![*^TOH_4$L#!!0    (  >$I4A9K'X.G@$  +$#   8    >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&ULC5/+;MLP$/P5@A\0RK23%H8L($Y1)(< 00[M
MF996$A&2JY*4E?Y]^9 5VPC:7L3=U<SL+!_EA/;-]0">O&MEW([VW@];QES=
M@Q;N!@<PX4^+5@L?4MLQ-U@032)IQ7A1W#$MI*%5F6HOMBIQ]$H:>+'$C5H+
M^WL/"J<=7=%3X55VO8\%5I5LX352@W$2#;'0[NC]:KO?1$0"_) PN;.81.\'
MQ+>8/#4[6D0+H*#V44&$Y0@/H%04"HU_S9H?+2/Q/#ZI?T_3!O<'X> !U4_9
M^#Z8+2AIH!6C\J\X/<(\PFT4K%&Y]"7UZ#SJ$X42+=[S*DU:I_QGS6?:YP0^
M$_A"^%HDX[E1LOE->%&5%B?B!A'/;K4-<!M%@C()WEQ*T_2Y>JQ6O"C9,0I=
M8/89PS-F0;"@_FD+?MEBS\_H_-_T]97#=:*O9X?_T7]S);!) IN_CGB)N7;)
MSO94@^W2U7&DQM'XO'E+=;F=]^D0V0>\*@?1P;.PG32.'-"'DTV'VB)Z"":*
MFUM*^O!^ED1!ZV/X)<0V7ZF<>!Q.#V1YI=4?4$L#!!0    (  >$I4@M\@&W
MGP$  + #   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;(53RV[;,!#\
M%4(?$$J4DA:&+"!.4+2' D$.[9F65A(1DJN0E)7^??FP%=L(DHNXNYJ9G>6C
M7M"\V!' D3<EM=UFHW/3AE+;CJ"XO<$)M/_3HU'<^=0,U$X&>!=)2E*6YW=4
M<:&SIHZU)]/4.#LI-#P98F>EN/FW XG+-BNR4^%9#*,+!=K4=.5U0H&V C4Q
MT&^S^V*SJP(B OX(6.Q93(+W/>)+2'YUVRP/%D!"ZX("]\L!'D#*(.0;OQXU
MWUL&XGE\4O\1I_7N]]S" \J_HG.C-YMGI(.>S](]X_(3CB/<!L$6I8U?TL[6
MH3I1,J+X6UJ%CNN2_K#B2/N8P(X$MA*^Y]%X:A1M/G+'F]K@0NS$P]D5&P\W
M0<0K$^_-QC1.GZJ'IF!E30]!Z *S2QB6,"N">O4/6[#+%CMV1F=?T\LKAV6D
MEY%>WGW-KZ[X5>17GTYXB:FNFM"S+55@AGAS+&EQUB[MW5I=+^<]BT?R#F_J
MB0_PFYM!:$OVZ/S!QC/M$1UX$_G-;49&_WS61$+O0OC-QR;=J)0XG$[O8WVD
MS7]02P,$%     @ !X2E2$M>UI>@ 0  L0,  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&ULA5/+;MLP$/P5@A\02K*<%(8L($Y1M(<"00[MF996$A&2
MJY*4E?Y]^9 5VPB:B[B[FIF=Y:.:T;S: <"1-R6UW=/!N7''F&T&4-S>X0C:
M_^G0*.Y\:GIF1P.\C20E69%E]TQQH6E=Q=JSJ2N<G!0:G@VQDU+<_#V Q'E/
M<WHNO(A^<*' ZHJMO%8HT%:@)@:Z/7W,=X<R("+@EX#97L0D>#\BOH;D1[NG
M6;  $AH7%+A?3O $4@8AW_C/HOG>,A OX[/ZMSBM=W_D%IY0_A:M&[S9C)(6
M.CY)]X+S=UA&V ;!!J6-7]),UJ$Z4RA1_"VM0L=U3G_*?*%]3"@60K$2OF31
M>&H4;7[ECM>5P9G8D8>SRW<>;H*(5R;>FXUIG#Y53W5>;"MV"D)7F$/"% FS
M(IA7_[!%<=WB4%S0B\_IFQN'FTC?+ [O/Q<H;P3**%#^=\1KS,--$W:QIPI,
M'Z^.)0U.VJ7-6ZOK[7PLXIF\P^MJY#W\Y*87VI(C.G^R\5 [1 ?>1':WI63P
M[V=-)'0NA \^-NE*I<3A>'X@ZRNM_P%02P,$%     @ !X2E2/E.@Q6? 0
ML0,  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULA5/;3N,P$/T5RQ^
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MA?"SCTVZ4BEQ."X/9'VE]1]02P,$%     @ !X2E2 (L=5^? 0  L0,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&ULA5/;;J,P$/T5RQ]0$T*Z5420
MFJZJ[L-*51]VGQT8P*KM86T3NG]?7PA-HJI]P3/#.6?.^%).:%YM#^#(FY+:
M[FCOW+!ES-8]*&YO< #M_[1H%'<^-1VS@P'>1)*2+,^R6Z:XT+0J8^W95"6.
M3@H-SX;842EN_N]!XK2C*WHJO(BN=Z' JI(MO$8HT%:@)@;:';U?;?=%0$3
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M^9.-A]HB.O FLIL-);U_/TLBH74A_.%CDZY42AP.IP>RO-+J'5!+ P04
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M=',O<VAE970Q."YX;6R%4]MNHS 0_17+'U 30MHJ(DA-J]7NPTI5'W:?'1C
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MG+2&+"!.4;2' $$.[9F65A(1DJN2E)7\??B0%=L(FHNXNYJ9G>6CG-"\V![
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MZT;JA)MG[L(K6PJ=:%F'.%07Y]D_7U.-,(!?+8QBM4>Z]AMC[SKX45X<3Y<
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MO4!Q)5!$@6(>\?[FB)>8AZLF[&Q/%9@N7AU+:ARU2YNW5)?;^93',_F"5^7
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M>O]^ED1"ZT+XS<<F7:F4.!Q.#V1YI=5_4$L#!!0    (  >$I4BWE!@DK@$
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M\R<;#[5%=.!-9#>WE/3^_2R)A-:%\*>/3;I2*7$X'!_(\DJK3U!+ P04
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ME](<M.0DU#25<V;:M D$'6ZWSGSUE?\!4$L#!!0    (  >$I4CH>L#,U $
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M.+M9?(^13S=VO1U'=R<*)MNV 4\&?#>$\9>&:#)$*P-R9+:O[T21LA!\].1
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MA/N@HR>INYGJ<WM'VH%DX^W&O_]VJG]02P,$%     @ !X2E2$X&3V[) 0
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MA,&)G>FU42]\^,'&&K )//)&VM_@>)6*MS=+&+3TW;5U9]O!/8FST>8WH-&
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ML+,RW53WA3NGW4#Q_G;MW.^^\C]02P,$%     @ !X2E2-%%IL[7 0  U 0
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M.,W!:@YQ'.>[-$M5B+,L_X_=338TR6ISTEV:9-%U&,1IG@:[/"M=J'<GBS9
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MJG?X6N7-\!V]OC=M59Q-9E&1_1J/AW(XGL9?#'-F80-P!G QX/)+ ^$,!-5
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MNV_T*4,_*'FZ'9JFDUOV%U!+ P04    "  'A*5(;P+/E;(!  #= P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6R%4\MNJS 0_16+#ZC!@22-"%+3
MJZIW<:6JBW;MP/!0_>#:)K1_7S\()5&D;K!G."_#.!^E^M M@$&?G F]CUIC
M^AW&NFR!4WTG>Q#V32T5I\:6JL&Z5T K3^(,DSA>8TX[$16Y[[VH(I>#89V
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MKL/U)O=D)^47?JKBI<Q%XWLGL-&'-*N<X468/2AO.ILI> J>F>]:CW>2+I=
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MY<UX@Y(:_+X&'@NL#;\&9J]2( C067/&VT\A\$58]#S* 58 RG5;(Y3(\G(
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MSC5_$F-9J A/2810Q*T-"N\M>((X"CIW\&6A.<%A1_:8@4B;1PM"F3319U]
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M20>V$$' 3?Q@-'@!3(+NV!]/QK5 \7X=H "Y[,!7U,(TZ3BXRZS.AM@42TT
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M85<F]MSF"%]RPG9U (3!$'3=+G[J=0%Q.RTG3CG?YFNU]"(CRV,&)4"MZP5
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M>3&)%0MZ*HR<8;U/EWG\BHRK$J: 7+/;#V@:_=DF!+2X;C[2UQ@8\'A($ ]
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M@9K+"Z+3M-73'0IJ%_&[>>6]:G]FF*CPLEVDLRZW<7/#>^[J*##"7=Y58K)
MA\Z2%&7AS*5:D)35T_%M%$"T-)+R.\#M)3QS&\X -RE8!Q;0IKE.TB>5R"=I
M[<9=X'(QH*Q,2=1/RKB =%,",RM%TPEQ?"A\Z<K2[CK7& K$->0H6U$JP8-\
M&PP"?Q ,=C%GJKM8?IOSEN#Q@W&[.W YD"W22^%4>A?U,"/PBCVLLA^85M+A
M);T,\_\TP^0,9\PB>WC N#A.A@#*'75!?ANY.D<])FB%2,9&E4'W7I1XJSC6
M!9LES$]Q^L;&27<V "&\*AJL#H)>OPTB?!3'=+EP.;ZYTIW9"B Q6>4EX=(-
M?;,F2S.M$?AT<2]2ZWC=YB$IDI%:[ 869^_')T,0P W[(*=U^]T=",%D@C45
M)TZF]$MHY'8=+=!Z< F:;QQN+)D(46##9['U,Y&^VSP\J.1114NG0]&7$P^O
MX\MHJ.>/018.!OU&1K6;?$;M<>?7(Y^:';V"B@:@!$RZO;\+&NIUV]V_+Q)"
MS)?BG8,2_?2!?$!B&(V>(Q_3VP+NZ)?2D$%?ODZF#C(@<;WHDMF+3'C$+[MI
M0,,;=X"Q#!LQZ1DZZ;<[^UPS59@4":2ZEU?=,IW>"/X;_LTH9#_:&$S:P=\5
M;5BT'M72!^#Y$'[JCG??+Z<O* 7G&ZLV5A?\%,TW&&UN85Q0V@IGV^N#@-D?
M-/%M%'T/1J ;] <=3]HCOVAIV&"O9G%[K0UMEX-&&9:7YG<[8[LPH[W ,*:S
M=E'<WN4 ,YJIJ_"Z*RK3@*,D-4G:9#BN&BYT8AQ7+R[X#''<]D [7,GXJ]MA
M2PU++.E 2?A((*"P=/NX2KA%81V.><-V?B5-7Z]!E]\H#4L,)FA/1F5-6BK\
MPI;8>\PF]4VN$TND]TBKFO5-W2(U3,5G7%LYP9GBN:()O*::'UJ%\@92IS5T
M+$0-E0R<L@/Z'K!%"<1!7%^*P#A]$0(M>5GV^U+Z=3CTDX/$EA:Z.Q7!==I*
M);G&3:,*U^RTJ)PSHDJE[J;8&G*E9WD*R[UEK"FN[@1*53KPLVY/SR^&IG*I
M]0M\4SJ!4;\=#'[[#1=O(Z!GFMK:W?%OOQ%S(E6.G'O;2,54!*KS6VFA4YO!
M7#P<WAG<IL-.&=G-$Y_DE*G2D"1]!]UC.D2=M,"%X3ZIHF>HI?>O]8PNG7(W
M>"GCQ+C[:&ZC)<CTJ!?8.%CK&5_.DY- ?!!@Q-&0;ZB#"0AMI<A0DIC8D+4C
MASFJYC#NT3S%B8W@2@7.WNK9]"8Q\1P-.5J,OGJ<UAK#?Y#C%46&?G^"Q$0Q
M%-(+HE<C>Q8RQHSR1CR/(K,X:D/[%G5VJMO16X=Y@+R)9:*X!$&Q_3/MM=A8
MP=:"+NHXG*5%[:!0DI!\'TWMR.%YWP7&,1Z4&4>=;>.@VRZ:QLD*BAE4<C3H
M+\%<+"(+UXT7%&]=,V]WW/-[O9YA)2BY ;DG+",AU ,^UQY72Y0Z.+88[+G-
MDR/1\E(]>:<(.]?U#"P)\R6Y%8!UDDKJ=2FJAFY!'?"@0R%FX0H Z%C3,>M'
M5^W]_OOI-[:Q$NP-C8!K'<U3D+F=HUH_&@ZJZ9? QJ70_K !A.BQQM/[IM7=
M#W[Z&)+B^W6UDP_ZPZX?3(9?S,_+59?VY>=AB:/W!^UQOX&C]P/AZ&$]3]=<
MCAJ(OM1M76!UO;$_P+8/K^-G>W0.*,9Z.6QH1^R9E(L.'1E0YWOC2>*:.Y/F
MD74-S'WRTU^UJ6]:O9WX:0P^ECEP$BDIV3,5K=828Y%R<!^79$&:Y5BX,&8Q
MK42J-A=0\S1VEWB/*EY1M*)D- ,/IY!"=)I@;PU6<4.I=4@MIW0?-*#HV8SJ
M/"VP2XQQCW-_I%_GQF%5SXJ\NG@2L00L[BG;H+B1H.LU7% ]S!O!"^I52F"K
M7@FLE2L'&!8[VJ6)LJ(%3[$GY5DML$[^&%"I,RVAFOHMG(R:/;?&27?@]\>[
MS//44^B@-QC[?7>%5U:IK-<&J<T+MFMZLCUJ<3_XI7>!-1OND+^=)]@%!#E<
MH;X@YD<9585>X6^<"GUN?J2,0<M1MHX5YYQ3JU(J4J"TUN<*\K)GT_CI,25G
MJ_4K)AS @'])A244#BB#5?(N*."!Q57Z7JO>@I'2XF(K2Y>379;4<VLGX>]I
MG5CQQ&[/0&1*"^$;BC\[3=:LC&, YT:VE+S,,EE=C<%7E3 TP0'.5_)4>8<8
MT8$;E,)5=(-BF=-[9>KOF!VX9;<!9TO.NP:/(E\#!(]G+@IV$"?'NK3G3MO)
M" .E_& <-*F,KHVCYC3V6$N/#+U]:^AMZ*''HSLC<W>E;@W9 4O4E*E)KD1E
M\ 1_$Y9@@04EQ7F/-^J2V1#%'^J&C"(NF4%$(+(%5TUE7&HUK5> IT55E.E^
MMC.*$7&E*)KOH]JZ9)TN%L#CLA*!XQMB#"OHZ;I"29J5:=W%J5I?=H-#^/\
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M0"+)*+L]%6N?)$;>*\J$_)BD3TG5]JS8 G:C<QF??8#,CQB*3+8>:?RSDN
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M97-=+GAM;%!+ 0(4 Q0    (  >$I4A(=07NQ0   "L"   +
M  "  1D"  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  >$I4A&0=*,W0$  +,>
M   :              "  0<#  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<U!+ 0(4 Q0    (  >$I4@.<^.M&@,  )4,   0              "  1P%
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ !X2E2(M-5@$^ 0  :0,
M !$              ( !9 @  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ !X2E2)E<G",0!@  G"<  !,              ( !T0D  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  'A*5(SCB5]48"  !Z"@  #0
M        @ $2$   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  >$I4BOW0&^
M5P0  !L0   /              "  8,2  !X;"]W;W)K8F]O:RYX;6Q02P$"
M% ,4    "  'A*5(;$7X9V8"  "_"   &               @ $'%P  >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ !X2E2.&Q75S  P
M\P\  !@              ( !HQD  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    (  >$I4A82SJE+@(  ) '   8              "  9D=
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  'A*5(A6PM
M]E #   1#0  &               @ ']'P  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ !X2E2 :!2T0L!   #A(  !@
M ( !@R,  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  >$
MI4A+:<NBG0$  +$#   8              "  >4G  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    "  'A*5([XDM+Y\!  "Q P  &
M        @ &X*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ !X2E2%C8KV*@ 0  L0,  !@              ( !C2L  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (  >$I4A9K'X.G@$  +$#   8
M              "  6,M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    "  'A*5(+?(!MY\!  "P P  &0              @ $W+P  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  >$I4A+7M:7H $
M +$#   9              "  0TQ  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ !X2E2/E.@Q6? 0  L0,  !D              ( !
MY#(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  'A*5(
M!W7(*)X!  "Q P  &0              @ &Z-   >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    (  >$I4@"+'5?GP$  +$#   9
M      "  8\V  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ !X2E2%P[6BV= 0  L0,  !D              ( !93@  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  'A*5(T\L[:IX!  "P P
M&0              @ $Y.@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    (  >$I4@CH%(]GP$  +$#   9              "  0X\  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ !X2E2'"(_DR@
M 0  L0,  !D              ( !Y#T  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    "  'A*5(E@,&B: !  "Q P  &0
M@ &[/P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  >$
MI4C*8)5&GP$  +$#   9              "  9)!  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ !X2E2 UI@IJ@ 0  L0,  !D
M         ( !:$,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    "  'A*5(]D2(;]D!  !%!0  &0              @ $_10  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (  >$I4A4,G$!I $  +$#
M   9              "  4]'  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ !X2E2$ +B1:B 0  L ,  !D              ( !*DD
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  'A*5(Z&;_
M+*$!  "Q P  &0              @ $#2P  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    (  >$I4@5TN\WH@$  +$#   9
M  "  =M,  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M!X2E2-.+[%&M 0  %@0  !D              ( !M$X  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    "  'A*5(!B)JR*,!  "Q P  &0
M            @ &84   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    (  >$I4B#LGOZH@$  +$#   9              "  7)2  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ !X2E2+>4&"2N 0
M%@0  !D              ( !2U0  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    "  'A*5(2YIMT:(!  "Q P  &0              @ $P
M5@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  >$I4@3
MY^!&,@(   8'   9              "  0E8  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ !X2E2.AZP,S4 0  T 0  !D
M     ( !<EH  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  >$I4@NMJ3I2P(  %@(   9              "
M 49E  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ !X2E
M2"@.8?6# P  U!   !D              ( !R&<  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    "  'A*5( @IGO<8!  #;!   &0
M        @ &":P  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   (  >$I4C3N^ RC@(  ,D(   9              "  7]M  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ !X2E2!1)6U0F @  >@8
M !D              ( !1'   'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    "  'A*5(V8*U,EL$  !'%@  &0              @ &A<@
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  >$I4ASBHR,
M%@0  #$5   9              "  3-W  !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ !X2E2.Q*2M=" @  /0@  !D
M ( !@'L  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  '
MA*5(0A_464 #  #%#0  &0              @ 'Y?0  >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (  >$I4AO L^5L@$  -T#   9
M          "  7"!  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#
M%     @ !X2E2+V>0P+* @  M@L  !D              ( !68,  'AL+W=O
M<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  'A*5(LT1:NM@!  "K
M!   &0              @ %:A@  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM
M;%!+ 0(4 Q0    (  >$I4@1^(NCR0$  '<$   9              "  6F(
M  !X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ !X2E2/IY
M3PAL40  J2@! !0              ( !:8H  'AL+W-H87)E9%-T<FEN9W,N
9>&UL4$L%!@     [ #L #Q    ?<      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.4.0.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>86</ContextCount>
  <ElementCount>211</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Company</Role>
      <ShortName>THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BasisOfPresentationAndRecentlyIssuedAccountingPronouncements</Role>
      <ShortName>BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssets</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - FIXED ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNet</Role>
      <ShortName>FIXED ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PREPAID EXPENSE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpense</Role>
      <ShortName>PREPAID EXPENSE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - INTANGIBLE ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsNet</Role>
      <ShortName>INTANGIBLE ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrations</Role>
      <ShortName>BUSINESS CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Inventory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - FIXED ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetTables</Role>
      <ShortName>FIXED ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - PREPAID EXPENSE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpenseTables</Role>
      <ShortName>PREPAID EXPENSE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/PrepaidExpense</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - INTANGIBLE ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/NetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/InventoryTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsDetails</Role>
      <ShortName>OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - FIXED ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative</Role>
      <ShortName>FIXED ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNetTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - FIXED ASSETS, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetDetails</Role>
      <ShortName>FIXED ASSETS, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNetTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - PREPAID EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpenseDetails</Role>
      <ShortName>PREPAID EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/PrepaidExpenseTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - INTANGIBLE ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsNetDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - INTANGIBLE ASSETS, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsNetDetails</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - INTANGIBLE ASSETS, NET (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsNetDetails1</Role>
      <ShortName>INTANGIBLE ASSETS, NET (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/NetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/NetLossPerShareTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/RelatedParties</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/BusinessConcentrations</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="txmd-20160331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>txmd-20160331.xml</File>
    <File>txmd-20160331.xsd</File>
    <File>txmd-20160331_cal.xml</File>
    <File>txmd-20160331_def.xml</File>
    <File>txmd-20160331_lab.xml</File>
    <File>txmd-20160331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001387131-16-005278-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-16-005278-xbrl.zip
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M))5[<F\/8F@;:S%TO2=5TW(%:Z'!Y"^.^8SIDP[9-+C>T=6>KAAS(?_%\3<
MHY+;!KNM8VBUP<@]@7$F/" ?^JY-@A#=Y&BR-EK4#CB[^28A93,U 5FE4$M/
MZ1D FKH^: \D AE-["LS\!SO)9R)U@RPU^2Z:#M38)<J1M?(14_+9VL&OBK(
M.U,TJ:,;2KX30'WX^K;M8-C*=._I4>&%.78BT\VUPUG_F%_IR(J4KQ HGZP9
M\*H%QM6>"BB4-P$O]Q-->UP[&D7;(Q5V(Z+CKC-OM0UH*/D3B[)YFY/5LF2
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MXR2U/]IHARGG:AU<-KK4F4 NP_W=@)G'B<M9+:A8>/*.]5[+!]YHZK4#1,6
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ME>#.S5H.YMS=DHWDCDC:C'PHG;01*&LCLR?W9DNJ-H:2\DIV;MF<J:_HZDI
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MX6DK=80E_!H/3"N* SQ:KE"'PI,C"J;J=551+ZOAYHDL+:&5)/:Z+>FFTN+
MPB[CJTU4X_,87--GEIJHE57X\T/J(R*XK'3%;J_;-HJWTE3;9_BUR,_GX;B=
M%<=)6D?L=4K.QWD,]KB(+DL]L=L]GLNEFXQ)EE3,50RSEC0&9I5UM[Z7=-]M
M4WB61QYYY+%5=BN///+((X\\GD8TBT<>#X=6//+((X\\$,4CCYS@//+((X\\
M",4CCYSH//*XM<ACW5#B\A#DC1>9WHL#ZV,O]SW[%]^WWQS7;=TE94_YB*/
M8GVTC=? #Z(A#4B"Z@I#P3*#8(+/F"/L+4%-7S-7Z01?@RK[T\1*)PQE^G$@
M.!DBTN9@)@USSD9_Z% +T1 >_6Q?]'/'=;6[#/S)>IN"G\MM24[Z0X[Y_H*B
ME&JD0/B 7P@7B5B=^;)/1>Q)8BA?/-O/J9231,8MB4Z9%WXC:-D2^TSH@]@S
M7XCP0$:FXZ$5DN<-X1Z&\6WA_20(SVN69!ZX/$W0@!A9,+8^KF::K?-'T;GI
M ?1]X"OA*VEI-"\?MDM\#<W8SL$K H OK$7/N_NKASZ.$,;C/*JO/@D4M\G7
MH3^(WLR "&-0]XF.PWDRS_QT3@RE)FX3E<6>S@]W#X%4[S6QURN)TC6WL))^
M))Q"!5,I!FRFDC,FOIF:F[$)FLGJ.<^7J&([;,%>N)S/@L XK^4'8S\ Y2Z\
MD><0EKE+F[' 3FQQ_[:>+':T?;9OXV2@BGD'="A1QZ>,_FF'$JT="SII8FSB
M GH?S!K^7&N4\5Y<^6W$!<?CP'\EMC#T@Y'O$3S(#<SQ1+"#^$6P3,]V;-3+
MS//FEP(LG:?3Z8F=3LD]9UP8;5\Q&Y*H=[9[*< A*N;M,K_<$^6R3$O._-N_
M$<,X[Y1XMJW1H,?ASOZUFMK,L/9^3#R$ZQ!%R*XT:;<CRF6)^ER8<!_KE(C!
M-T4[Z)"ZJ^W7KWNI\MV"AKWUO3.S+=DKA\6L+5O.(</.2=$:V#DI6@/[49#B
M])S6K[$;.6/0H%%@VF1D!G_0,A[AU8G,D>.%F'<%/X_*([Z\9KGIFF5#%A5M
M#S?4M*C@XK0H7MW-YF0_(K+SC7YPQHJ[P3$WJNN!XZ6I3=5.NWEOBO+>%.JV
MC*0G/S+=>O3A;0DVE(EB5X?_&36E(N]%<<A$?R_K'5$M[FJX;9K7O("3DWK3
M_6WT-%'7^$V#!V;Y;(:Z-O:+V00"WOCC%+L_[++QQX8M?SGU&Z=^*WI_G'*/
M!][O@_?[X/T^JN?UMR5C@O>6X"LYII6T,D+*^WW,^E<'4/?.^WUP4BU.]5X3
M-=[O8TL4ZC71[J,C:KS=Q\Y6U 3)9+6T*(JW^]B6'\+;??!V'RV G;?[.&CT
M\U*T-A%C$P^0M_O8JSKF[3X:V@0=21<[NM**M9PR'=YK/;&K;;?G 5?,2^<Q
M=%WL2;SKS;[I(.^3!*?GU5;K^B'P9A_E>K2CB;*QSYXUG [<PVH9,?BF: <=
MN*=[N DPO&W(85?E<U*T<#F'##LG16M@/PI2G)[7R]N&M+>;@-X1.PKO)G Z
M%.=M0TZ2['RC'YRQLDD0@;<-6=\:XFU#ELFCHVLKT#%D455+3N-/IZW *1#]
MO:P9HM3=2ZL8WC9DQ_O;D'51*2MA.9W]?2B6S_&U#<G#]*\XC)S!9 USD'40
M^?%#')Z]F.;XXZ,U)';LDKO!379,T:>G%'W/_L7W[3?'=9\0P">8_[/K6W_\
M_)__(< _/\X/X0^NJ;GXQ7DE]OQHUW$4!R1?(7WU?4R\D,R.+5BP(/CC@0Q^
M>G<=^"-P,HTS28;_CWSV63U3Y7<_;P]+5_#2B-;ZF_EZ;L+ I5&G:$@$#R82
M!K!484+,(!2<4# Q)N6Z_EMRPC/>!4W+^\/0\7]ZEQ2QUVP78QQ:MYBL+%?9
M<E. 3$O]#O07KFBVC9#OGK)W9W4?_1&RW8,P9%U$RKIFM,J)2SB_HS=0DK6)
M X[B3GC?$T;PTC#\H887SJL E\]8K5Y3::3X614[4DN*GUMT9+3A.F%;\*3?
M-;E[4X[6-+&G:@=R\KEU1;$Y(_-K*SDC'X$\YG?#<38^!GFL2)R1.2/7"<K5
M]@:?"T!Y+@O.-1%9FX_:W6$!T1?'?'9<)W)(>.F$ENN',%1SP;@UL0,?8OQP
M>_=T)?2$:;J)^DFX>_KKU8-P\>WAX>KV2?ART_]\\^7FZ>;JD>(OSC YA]-]
M1N&V,R6EGV#%08#]3=PI(9%JH1-&V.T$ Y4L).EX+T5!2=Y!NOEC^!:EJ^PC
M OC5#*QAVCVZ9KO](T'!ACVT6U(9DYX :-OIYMBWK" F0" 7=!LL28@"!_Y-
M.S6=5K!1GL?P6L%&4=(4L:>7[#@>&FX)M3J*+JJ=DDCF"4:'=]6D.I$^8W,2
M@#DB OQ>',)+IH<Z8S1RPA"/?2N(HS:Z:SMK_B"J/4-4]NJZ<4K0Z(4H2UU1
MWFO#OM:;--LT8_P1>MTL<>0Y))Y%N-Q8.H^AJ&*/'W_LG0ZZH8A2K\1F;(W,
M."[3PR4OX.^@O6%:%EZH@@E$29H9Y]BED6)9%16-!^KW30=%ED15VN?)WRE:
M&RSJ:R82)!$6W,Y8[F?+BJ@J_'QZWW30-? 2C38=\)V G8'G/B;X(31G_6WH
MNR0T72+83A@%SG,<P;<#PJ7'\GDZABC)O-'NOLF@*J*A<TMC/UY*X$],%\^5
M.7\NY4]=['3X11G[)@.8&-VR0LW6B(EC-#$L/Q[['CM""4@4!QX7&LM/3KJZ
MJ&G[9%=.!QK'4#11E?893VJE=3&3D;-KDX.TX'+IK>8*M:ZW4Z<G=@W>VNET
M"-Y515TIR3YI=S.G'5E0*ULY;:W?Y=/=4_]+2;)S*_J!G$(3& ,[XHN=LO#E
MZ32!.06B=T1=[8&,K)G!?-P-9 K*'*;5*A4J2@J+4"Y8#4/NS=;UA.'%%FV-
M0+3(@.3%%KS88NVMP8LM#BM]GQ=;'!*U>+%%*\X2>;$%+[9H!>R\V.*P!0DO
MMN#%%H='!UYLP8LM#HMC>;%%.^C BRWV(3MXL04OMCA$.O!BBWUG0O)B"UYL
M<:!DX,46O-BBU?S)BRW:0 9>;,&++0Z'6WFQ13OHH/!B"UYL<?*Y][S8XL0(
MSHLM>+$%S[OGQ1:<Z+S88EVPBHHMRBHGEMW4>S?H>Y%C.VX<.:_DD5AQ0-^^
M^FZYL4UL++*X\$?C.#+Q/I&[P949>(#X\)X$CT.SR2M"-L?3TY (K++BF8"#
M+(P#$@)20EJ/,?8C^.R8KCL1TO4*8;9@>,:,A#<_=FUA:+[B$,03'(^A 3X(
M?@RNMNE:L4M1@74>=!SXU2.1X/IA*(P):$Y$BP#S^!:%)?)I8B.\$4: IZ'O
MPAX*!8>6B4R$-P)/>WX$[ON4$$)ZMS ,Z/AVF"Z%V.=3%EC)=1LS&*]5V:++
MU2+[.RO4Z.RN4.-I&!"2W&8K$,"C7<\JY=1OG/J\4FEO*.!E2@50/**N%/PQ
MJMJCJ4NJ.V,3)2^*).I&3S3T0C9KP2HYW8H/*L 3ZH(+7);K=\*U2OL(EO]F
M!@%8ZB4BB<=-&XZ;RHJH=&51*LM'X<'R8R*Z*DJ2(FIJZTY(6FF=K0R9[\*9
MR3X)-(Y^2H'3O4,RW36J(G9U2>S(/&Y^DN0'>[_;%?6R6IT#BJ W&"QO/NZ]
M/+).G_MLAL2^-R<C$+#]-S.PJ6-[Q_S:7TTWIN/WPS >L>]:U_$(H^KF%#XA
M#ED\',/3E('/8,F8Y"Y\]6WBTM!UXK<++V@KP^,VH-=[H:]$"[$_838@1//8
M,"PB8!P])!&.& W3*7,!_JJQ\.V<P,P%R.GX/[U+@CPUX^5='BX_$ M\']%"
M%B[_RK;,51HN?PZ$#_BKP..IM3#$PZT%4#PXX1]G T2B@T@E820$9E12#\T#
M>"L#>.>=$A.LN?7]-R?4)H32=M8/JI!0+0RM;EFA_^IC$H7K1)/5B#_E#/F.
M?*YLMPBR1&J<,O)Q-'QA+5SHW?-.]\P CYI%J_'E=-#=$K/U9LTV<GA),!+>
M@[<X(680_L!Y?-D\QKE2<B;,ZZ!:+FC.E<Y91L:=B)F#.R3>LK2Y=%X=>-L6
M)@YQ"]/8.)_CD-+YEHO]N#'3,MSO.-A?,>S?1%"^2LC_(NU+":_G1^];$4B,
M:-)PF+]>P:< "X.7)YC#;B8 "2":"4LZ5R2IET;A%>'>-;/B<I?VV72\@1^,
MZ-($=LU!6'3)P=Y"\3Q7G0??&PLMW\;T2@'8*71SA\(WW"?N!,^S6)+J794D
MU2/%SF\$]=%<N+T/'&^^D)GOKKZ3P'+"V2_O \<JB3$?.=Y27 D/9&0Z>,(L
M7,#8 4CEV'2%+\X (_+"[^C*GB2B^B\O 7E)CB(RQKD!%#E>Z%@SWZ+F+F2G
MUH=!$E6D;>ETY[/ITFXQ9B14NB/E%$X.I&9RZ^E]$F5Q%)Y;OWS&BK=_-$$N
M]5PI:7W."=6N#6:<\YUU"#M+QB9PAB;*W9*DTQ.N5MERZY)?6*H=CX(MY=&N
M+NI[[3C6;CJ4B(N-C[//]]I+MMVXW]EI4[N6<\BP'P4I6NP8;TU1II$HKBJ7
MSO->U211TK:;'7" F1E;5I'*>5FE(Y?+IR&7VTV*;6\#4=)ET9 /Y>J!_7<[
MV**N'#L!L3]<^\& .*7N):^ ;[@"_KTLRF7!Y6U4OY?HYMW1N=V22BWU:4^C
M'\61J79.-$ZT0W6>]],$)'? O$DU*F\"T5 3B*I-WTZG!TC;#0F5=VLY++UD
MG)=</<8IUHZ]U9'%GB:)2EDXLPT-<5H09MAVY2\),>T1T\F30#SKGE+/<&@C
M&^_L'%L7>]C@J5.2R\0#E-N+T\LE#0-.&/>[V@9Z66K8"=-@R_P/GH5BR*+<
MW>?EJZWTOK>L/+]YKXGZY.JRZCR:J&/CX Z7V'M+_-+X7>[[W@6]<TZ#O1UG
M&YV>*!G[)$!+KR[;O'!ZOA3[QK/\$7DROU\ZH>7Z8=SD#67U5@Z#/*<?8OQP
M>_=T)<B*D. $9E0_"3>W%W=?KX2G_M^3ZR7C])T/V=L[O>YK.WQP208D"&CM
M.!)(B,SOV%261*RRW)W>6T>[OMHD(L'(\>"%9V0* 6\X%VQG *,0SX*GGDGT
MAC>T8;WZP/%,SW),5PC(V <+SWNAH^(D\+H3TCKW);/!WSCCB)C(+#!3F':J
M)9YIH;&%PV SQ.1E\RV]+,YQ78 #ZS/!N"06?#-,(,I#BJ.3[V/"QO(!1K!"
M0W(N_ ;/^?3J-_8S_C@V)S#+1 @!U\X 3%4O$@;$)@$LSD<+%^#(XQ";[;*F
MN3 1#!W&;H2K?>_\0 '!6^D AH!8>.A0KQ&O"*/ ,&C:X@X$")+1LM6DM]0%
MM'C59F72[%5 U0?X%4: (?!^/'\,BZ"DH3?E66803'  ;+\0"@/8CL(X<. 5
MVK;I7.A;%ICP] 58M6?3QP+R[]@)")T4=G/HV'10=AN?*;RFK1OH]7MO]$@*
M8;13[LNQG3,0G$@ WIANQXM/(Q\&=YT_B#M!&GM(G>GOEY\8X4/$/I  >!),
M>:0+3(<0(%C/Q",#)Z(\5S0OY1HD^C/B#3;5G\2&U=+GY_'_!O0!Q$;P/UC=
M((8WERT1(2B8[ER@0E7P*5^&),4@=KZ #>H!QP7^JQ-2% 8I\'3$*9<!R8=F
MR&Y$3#GI7'@:XLV%R?6%4PZ+/?P(W/MG DB&$, <VU9VBJOI=F7W')X7*8E5
M(GU>_(/R&#D175S?L[&2&@:';0@[O;4*09]5"* .OMX\?;VZ?7H4^K>7\/?M
MT\WM+U>W%S='K2% &KH@@PG(&Q#\3ACAQGXEP"H@!HF _3NHJ/WL6Z;P8$8^
M#'(-WKUCF\(X#L(8125(4%,PU#,JU8 MO3,+=XA+8\PY"40GHGL9K^9$.4VW
MR/_$L._9[E,I@R=/$IH&%^(CCV0<)074$GVP2[4"[%1Z:RB(#-;['$$!G""S
M1]DXJ-38;DT8'C?" %>9"+T[3[@FST&,O5GD+BO0IF* %L13]8E+A,W_ L(;
M^1SD":P4IPC-$<X3AGX0XNPI-C/I78+8Z1B 87Q%G,6KAV/!>N(1_AG&(*GH
M%(@H$*/9CV\@*I@^=.@UJL BM*]!'\2[FV!79TA#4<AP.UT&4!3>0&4S15DA
MWEO2_7U[3??Q0E^3(@CL89)UWP'DTZMHV8V_"9K6:["/I/J+#(RFZQ+]]B\]
M2=0T8#S@]C&CH#LY:D07*]Y!',5H%,)^&0%+)Y08LXY1S*0#U-7L?=0<*AJX
M<< XM*9'6?,19<O-1[)\'MIT!;O)X\[*]\VH=XZ\FT8LB^U3CC?:GK!P1V^@
MBMS=H/TF%:;O>XFL93G3.$!FE>V]#/YXVQ8H3;0MT$#UR>K.NO0?3"[(ANN$
M?<%/6_8=\=>ECBAU]TF'5NF,S5FZ)-WF-(H&3J3N2NUVQ5YGG;N46K.CCB-=
M<"/[[,E'KRUUXIBCG/IP-8RUTTGDW7Z-1(EQMX/2"%E494V4>RW,WM[_]9CU
MXN?+^V!?T_C)5[;S'FCT)&FW'5[[P5T:B/V"6[)]-U[RF!"/"?&8T&'9]SPF
MQ&-"/";$8T(\)L1C0CPFQ&-"/";$8T(\)L1C0CPFM&E,J)&H3AHJBKZ/[(_%
MR?[](#"]%YK4]GE2?$U;4@K RN#NXH@F!L.,Z6TZR64Z:8=7>KW03#RI']X-
MIC&D?R9+_.?5:.SZ$T)R]09?J6?_3H@]A[WZ[?'RGMT ]4ZPB>6,3#?\Z=W-
M[?6[G['"Z<</NU]:BE2;.!^OO,B))AB_2\HF&*RYD98@0C^3E-PRERQ1[AF*
MH78DZ<</U6:;CPW>!2^FY_Q)T7$!"T6=S'#CV??P*G(3_@E<EF;S/V*R.^6N
M;>3N-I"MYA8G],[F\S[]]0IS>N_[M[_3W;5>]FZ3T,[N]MU"@4GCYIC$8'^$
M7R]%X<:SSD7!A'=>3=L$H@9CGV7TBYB//ONXD)0;X-8RO8E(L])9NN/;T'?=
MB>"_8<E(&#^'CNV8@8.3OSJ1^978.-N7+Q<XV25QS3>39OJ/L*EE5A RH5G]
M=&B8ZE?VXB>:<OP+S.)5@#A[]A--J,0Q+G JY'$K<%AN,.#C%?9O.!TMS62>
M'RY]_USXYF%N;UKY@)00?/@C>'.F6?TPX#R"DT6(4\#$6< P:)MF>M(@-E8W
M1)20059/X&-H.U\H03-0$US-%$CD'WHCRW^# 69_A,7F?X_#\_S/N]LFNT]!
MG8H/DYXP^ /A,U8A ;GG),:1(N WPDY/A#=@/6]*]MZG4!@2TXV&6"Y$L%3%
MCJTH93R8Q(J3XA8K(&96]T5S^@-4(<Z?M+B$O0>;!Z FN.')=\L%%%.>QWQ\
M.G%:A4,+N+#.BGV&[15[9FQ326%EJ@O+G[*ZLS!3531;'X'- ^=[.'^:H&VY
M8$&!^R5$ ;P;"AX!41":K!P*-MU+[)J1#W^:8RS.P<S]N469:<D3;D/3?C5I
M </0#T =T^(H$ $380PZ>61:5!;@256"!5;88 <Q6 2HJVU:VD9A=3R66CX'
M(*O(PY*T1!: Q'AU$$.T9F R&H,YS(KLZ"VQ, W[*2%>X(1_A$EQ&B*!%GL!
MMORQ"=.>I8GM*?PV&3B6PTX=12Q#<F-JOPS]2!BX9CC$K_TP(CZ(2C]T0B;1
M7DU6-V"#L>"/ )41+;%CP .E_7%" "#H/*KFL"&BIVP-J:#%VBN"11.VXS-*
M ")?L U#@".8+OZ;EDLAB9X!!":\LX(&TQFQ6C"8D15? !@HKX&RF,"?89M@
M089I3;!0RO7?2 #^38C ()3D>8(%B<\N8W+X/&14QQJXM/X0(!LX+JM-,U%P
M4R#P+Q+E-\*Y< =DGF<!J@UP'R%K(XE,80R4P;M^<0$9SH@U]'S7?YFP"AH*
M%6&:*5]BPC@T>2MDH S!F!6>'=]\-1TWU;E+4'@.RC$K7TEJX;QX@#=CHK
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M.>#9I;IQM1J@NH-"L<2"CJK$B(I"0XNJ9)7&8AEADMPIU(+4Z'!8+F!QJ'%
MDSY-X$2;R7[<5RX0?C!)C7.7:@6V=S(7A"Z";?-$J>&U##'HCA>:E9GG&! >
MTXAF]X?\J<G<T0S@) E"#NA::&Y]S+)O84V8[8BK+.9R9O3-<CHVSD>/+14S
M&46F$,G2#VO[*#M2J]4+]%;KL!-7J[\Q%DG,J6?B.L 5B6'^1I.KIAD\A1;4
MZG2C)>=>=B[?(<B?P;,=R$ZY$* )B:920LQOC>D-'@RVV2.O-/R>OP1BD3#3
MM-N%M-C%6X!@OA<')'^?WH)Q4/5CW?D+@I[ZM[_<?/YR!0+_\>KI411NKY[H
MNX'P(4/1WLK*]M,;G[79HL*-*GAZM0KF_#.CZ"7([IBA6H=9!%2?6U8\BEG!
M 7P->FJVFL+)6">[,:B@&Q@=:B$3KVK3KRUC/0D3UFK])4N'UOMKQST'VM-U
M(VOT)>M;[GJ6=)%# ,IO&UW>AX*3?HL]WK9.^5]0E.;5C7"1B-69+_M4Q)XD
MAOHYE=+/J9231 :>B)TP+Z3M&LZ$I&&#\$#OQJ,7(.7-C7N6=/9^$H3G/YR4
M/$W00$]\YXVMCZN99NO\L>6.F7PE?"4GTH]U5I@H5$PDOH9F%+;-W&]?L+O[
MJX<^CA#&XSRJKSX)%+?)UZ$_B&CKD#&H^T3'5>L8=FS-5N4FFJV"0]'3Y5TM
M[%3[XC9"JO>:V"MKD-;<P@I-(DZAU?U(#=A,)1U)^69J;L8F:":KYWH[UM?:
M/J+*MAR12]859L2.^[*D2M: "V^V?@YAF;NT&0^KFW1/%CM:B4;@3;VW3H;W
M.Z!#B3H^9?1/#^NT=BSHI(FQB0OH?3!K^'.M4<9[<>6W$1=,<Z!6-V=+/.^0
M;X)E\W0Z/;'3X;=M[)L.[PU)U#L]KI@79?06F5_NB7*OQ OFS+]UYI>-\TZ)
M9]L:#7H<[NQ?JZG-#&OOQZPJY1!%R*XT:;<CRMIV)3@7)MS'.BAB\$W1#CJD
M[FK[]>N./=2M9:[<^MZ9V9;LE<-BUI8MYY!AYZ1H#>R<%*V!_2A(<7I.ZU>\
M$@3KK/&"#8*]8U@I:7KM N9=)?6;)1%??M]IP_>=RH8L*EI)<A:_X?:(*%[=
MS>9D/R*R\XU^<,:*N\$Q-ZKK@>.EJ4W53KO;?:_US@(,<S?_SAI)ZK:,)'IG
M=3WZ\!NA-Y2)8E>'_QDUI2*_!OR0B?Y>UCNB*I<<6VZ'YB6G<)S43>]OHZ>)
MNE98RGZ*^_M0+)_-4+=3B^4#;<0Q\]7F=\WPQA^[/?-ID8^RE\8?"TUNZMGJ
MG/J-4[\5O3].N<<#[_?!^WWP?A_5\_K;DC'!>TOPE1S32EH9(>7]/F;]JP.H
M>^?]/CBI%J=ZKXD:[_>Q)0KUFFCWT1$UWNYC9RMJ@F2R6EH4Q=M];,L/X>T^
M>+N/%L#.VWT<-/IY*5J;B+&)!\C;?>Q5'?-V'PUM@HZDBQU=:<5:3ID.[[6>
MV-6VV_. *^:E\QBZ+O8DWO5FWW20]TF"T_-JJW7]$'BSCW(]VM%$V=AGSQI.
M!^YAM8P8?%.T@P[<TSW<!!C>-N2PJ_(Y*5JXG$.&G9.B-; ?!2E.S^OE;4/:
MVTU [X@=A7<3.!V*\[8A)TEVOM$/SEC9)(C VX:L;PWQMB'+Y-'1M17H&+*H
MJB6G\:?35N 4B/Y>U@Q1ZNZE50QO&[+C_6W(NJB4E;"<SOX^%,OG^-J&Y&'Z
M5QQ&SF"R&5CC'4SY&Q$L<^R 7>+\2008C@2>Z;)T?!'^XX4.#.N]"./ @8D=
M=X))^BYYF3X4$%9Y'_E"2*PXP*?].,@R'4S/SD6%SH4[SR*"F?PL.*'P$I@>
M#" *;_ ].Y:AZ1."62\C48A#G!O?#&%"Y,HSUX'71B0:^K8 0P7T5P)+&E&8
MXY ,8E=PG0'!==$)O]/?8*&*)$R(&< 2WX:.-410\>WT80> =EUB13'@ MX;
M@\TZ26$Y%VX&].GI,CT_FEGJ6P"F^YD_@&F]28X*=OH.JXDP(Q@'_P6D.Q>>
MIN$U6@1)@C&A ""6\1N<)46B?2[T:5'%5S, ^).&(89( 0NRLGBZH!P5627F
MM/PR >?-#.<0)&L,08S$*\=<AYP%$W;8A.<[VQ][V)(WGH!"CS8I ,QY\8B
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M2<-Z>)+KCT:^!Y !?8>^:Y,@G[CXEEY?8R:WUW@Q#4WY S96TB-Y.H0HC,U
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MQX;'+.>8]' AF3ZWU)V<HA9^N2* < 7+A#PN?L>W/#^"V\3,8>69)C<:!(9
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MS(/[0[W<^"(BPT=9JOK)+,RKU ))P'$H6(,UF$U86/B=,6Q7 DCS-,@?CC,
M%W$Z(6P0WZ@!CJ:8AAE.^BN*W#<ISGA*R@+'_XG=7 D$TXN1',B)M"72O+^D
M>[?X*+=5/>9NLX[=D?8I@J3[X@RJ5("B[Q(G[-X49@+HL5!?Y8I*=-50)QYT
MCJ:VQZR%[-(6I2K$I)$%"PG,5E.-I(\6ZK'9963/_=.!?B'N:#8GWH=K%[+
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MC'^51,RLM"GGE5WB9*UB.4S@(C)H.:^-1Z>/K.,EU./S2,=PI: -,E61&,>
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M2=<_<U85=[5:&AI'5%5BAZJ:U>3E"D!P>V[@94'.8!__7I! CRD*IVBZKH<
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MZ/&V0&OM8L(*[F?7RRT!)8DJK]JW[T021^OZQV=F$$0/9,6X%\6_W6$U$S=
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MYQ+[-Z*14BL\E&%V474MHQQ!\LEB2N^-G#\W,XV@,*G,[5CU;%SR?%O[.O=
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MXC/KIS]CSX'25T#SA6I$HS0J:B-%#%-<BJL*;AE 9&ML%E?HW9JCZ@*Y!<!
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M&W1I7LJX-[C4!QW658)7\A61F$G9Z6$QRI;T+$5)_T/O2Y'?_#]02P,$%
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MT,R9'1J;R!&JUT1+BP ,0D1:=5'!:.!-89_#.%QM5DJWTJ&Q"0BA>DU M C
M $*D51<0)0TP!S$G*JJ<0^-WFSC@U&IBH/X13/]W->KV/?L=EA_PGO5^H$UC
MU0^(U&OY@28!&!R(M.+\0$$#S ^8+CD=+S6-EIAPEY9#EI3@@.+EF.[/Z48]
MW]*CP"2FAVR*243#8Q= !NJWP:1@  0LO9:BZ%^^13O: TU0]#SUO#I=9=AA
M)ZP++_;#*$S(CIU^THNW/WEIZI'O"AV.(8\-[/12GV+'B,$Y=OIHR3FH\0R=
MHXH4F(L:1UZ672]+[:[3>7C_D"O<DX+>IFO2JMUT2U)BY[ RU; +*4:/DF6%
M*I2DB/$<URV-DSC;1+DG.8B2T%AS.S+U:C?3)7#>_RJMN#ZOR=#H/L5L!CN&
M7Y'T_542_WGC1>$RQ 'Y]1U;=LU(A\1Y^(CIF80<$^:\UK#2UYP:0Z:,,+#5
M4]LNYB@+*A;8-1,[?P(VBU&5:"Z9ZK2S16+U6%.@7.O\LO&[<]0HE.).)"D.
M* VH8,UBLUY'(4['"0-LRC+LYF'VBWJKKN.RNN\R,Z&U\U*S@(&5F9[<"KKD
M0BTV1/F .2+.+FT6AI+#ZI):KWIK42TG!X,VO8Z"15878 <\EI(LK29XB=,4
M!W/\B.,--O-<O3BM+:OZF5(OJLS8G..JOZY=?%7,*"VX@;FO29ABG\A6SI5=
M(IM.2JQ@TR^U*9Q#1JD6YWV\W(OHMHXLMK^#A8PYCEC2N)?FVUNRX<P\G^5P
M?-PV?U$=CO808/7TM+=AK>-58VXP2.RM,G= 6Y A1@=J[4^CLIL<IXMDF3]Y
M*9[%.5$\O(OP*,NP.GO:D-?NBJR'.>VUF0$C&$#VT;:+Q>N;Z7R$LI(3K0DP
MP65H7X1QF./+\!$''=/(F/OL_7>2LG"NPG?VDF U5[:_::WD67-V,&CMKS.7
M7LLDG#,1:"<#%4+0W18Q,:@(\D/RKT19G,8XGR0K+V3A(75*MX+>)DJU:C<Q
M*24&@T"=AOR>XQ%'27%WQ4\R K$E09>?I.N$[%HP>L)W&0'DL0\0?DS251+C
MXGKQ=I)N[L=>'(0!4>&&N6W%V;8YK[6=;E]SZKVN*:-SO W1MHN]DAWE!3\*
MB #D5Q+*^3I#Y^C5&L?T'OZWP";O61S@Y=X3>&\I=MWC(!/;3K.7".?0WD_O
M+LAW4LXCR:1^U/CAYTV4A^L(D]U<@%=>^DMVD:1?P]Q;A7'&8N?LL%CA7_M*
ML.9EAYE6^]I^[,YA.5QG+G&V%(+R6@J;]1]+.:^SG2!@'G<4YV$01AMZUKS
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M2PDF6X8I^6J^G<7+A,S,; 5W1W>P?BXRVXS/WIM$/<S8O4ADP 0#9#TTY1+
M2U:6UEDPHP;W(6?)#/O?W2>/KP,<T@GR>_H/"KGO&_,B^=/?"RWF^#ZDFL<Y
MO7W5L5I.9@-2.B4I@F0TS@&C48Q[];R Q(Z6789S!XLQNV0>T7K+SW_"6ZEQ
M')U=8$C4;".C0P0(&F+-)-@HB1&C1H3<!3HJ/T;79 *SVC_;PH)(J0H"S=]
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MNKKIL,("@0='RAX9>&2#QTI<72\OPMB+_9",@"0+%1DN_5BMYN;U,*:5J&?
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MQ20O ,O1]O[7.[A1*+W[M1)^;S_\YNS=K]^?_;8D?_O;WYY]>/>[LS??OY4
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M8H$%G8[L_/C/G<0H-&RT8TR$W6^]N/E08J!^6JP8#SHK2@[&?_*H77DF>9)
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MU\M9EFUHP12VCN1[3T0%K*L4*G+]4FQER0(G9-1H79 [Z0%:VS,,:&PE(TZ
M[)0E(TA"!ZL7U$IR14H+:N37Y"XZH,2*[$2Y_3.LYA;JQK^'338-&74V$;XG
M6P&6B('N:5!F%^*]IP&9F(5J\Z3(!7R*BS'"HLKL0_0G_+R.$K+B(&XKC!^I
M%Z,)?&FQE_!QEK&,0*^QB<C#%4;9&ON%&R0?C+PG)T/M)L5K+PQ*=-+UER1K
M5$8(K/?56DKS0<M]I2XA=!,3PC0/_XF#(FN<_M&O/T;_R6[BDGWITT/H/R"Z
M]21;1N0_>.D]K6MZ[Y&E2XZPE]+*]!E*O=R[B[:(!?\:AQ5A7$KP=W>!Z7'
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M#4AO8]<^ !"*/@A<&CCPVUV-Q[ZW4'-(\CW,W1 I R5C&P<X?;)FTT28*1,
M''X/<Q='RN#(V,8!#AR4^F!H.W2 @P$ X2#]P=VJ4CS03-X0M>7('PMBN4Q"
MZK"6\Y_DWB%\!'/W4,U15Y43CNDT1S7X3%W4!XJ@MC,191BX**(^8M\<@-Y8
M+^ST$WST6VP/Q4O;@0E X-5'O]6<XT G6>?+G$DVT%4=H/AH.^Q0QD?".PZ
M5+!I HNVPXW6I[EC<5< %>XJKB1%G< WE4BQ!M?\,VV4=7S+%KS)"VW;O8;
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M[*!8&RXMU_(69/9 V'7'(I6ET&SX/9#@ [$;/A.YE#9DL,@L1]0'!S0R90.
MA,IX"B\ =#V['.0O<P%4QC"=QB?7RE((MJJ </@2NW1OR/7LU[!8**#5?8U?
M<?&.&H3XB>2  [=<!'-/AE-56]-['C P?$9Q +&K. FUZK93ZF9Z?U33;CCL
MXT JN6A,G\[MQP$[126!X]O)K60X)D_)GX1'D;#^IDL)@+%3$TA3$#DWDE,2
MQ8&7?GFRO/5"NO)2;Y:]?+P(G.1:^";P[7@154'#AE :P;1C(0='F26M\% /
MR%V.G"5)'Z,&0B+M!83A1[,P )E'<W_YFAJ?WA]6WTR*RC)D'4]U&=IF9DP
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M-;V0F?E&DT)VAQ)6Q1JR_O#NI@.,ZAF4JGAP61.5"MB0\FU-Q_PTMJ$RXSB
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ME2DQ7(W3H,+6!.U 5/9(?%N51]<U%?I$[]V>SB?5CL+,*'Q3N@P7'S5G!>T
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MB5#V%_8/5NR!_N;_ U!+ 0(4 Q0    (  >$I4BN-G:/"8L  /J9!@ 1
M          "  0    !T>&UD+3(P,38P,S,Q+GAM;%!+ 0(4 Q0    (  >$
MI4A:]?["^PT  &J(   1              "  3B+  !T>&UD+3(P,38P,S,Q
M+GAS9%!+ 0(4 Q0    (  >$I4CHM<]/ZQ   "'9   5              "
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8;6Q02P4&      8 !@"* 0  ;$4!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
